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Abstract  
 
Iron-oxide nanoparticles have been widely investigated as both diagnostic and 
therapeutic agents. Yet, as therapeutic agents, very limited research has been conducted to 
explore the potential of iron-oxide nanoparticles in vaccinology. Notably, there are no iron-oxide 
nanoparticle-based vaccines for cancer immunotherapy or infectious disease currently on the 
market. This reality is confounding because of the seemingly dynamic potential of iron-oxide 
nanoparticles in these applications. More specifically, iron-oxide nanoparticles possess 
numerous material characteristics that would make them highly attractive as carriers of vaccine 
components to immunologically relevant sites, such as the lymph nodes. These material 
characteristics include biodegradability, magnetic susceptibility, particle size control and surface 
composition diversity, among others. Accordingly, here we proposed to investigate the ability to 
leverage iron-oxide nanoparticles for lymph node targeting and lymphocyte activation toward 
design of efficacious vaccines. 
In part one of this thesis, we explored how iron-oxide nanoparticles could be leveraged 
for the activation of humoral immunity. Activation of humoral immunity can be exploited to 
stimulate the production of antigen-specific antibodies with variable effector functionality that 
could be employed in both diagnostic and therapeutic applications (e.g. vaccines). Specifically, 
for engagement with the humoral immunity system, we developed an inorganic Au@Fe hybrid 
nanoparticle platform, coined inorganic virus-like nanoparticle (IVLN). As compared to traditional 
nanoparticle technologies, the IVLN mimics viral structure through the incorporation spherical 
geometry, topographical spiky antigenic clusters, optimal spatial distribution of antigenic clusters 
and extremely high local density of antigen with those clusters. We demonstrate that IVLNs 
dramatically improve B-cell activation, germinal center formation and production of antigen-
specific antibodies with functional efficacy against HER2+ breast cancer in mice. Notably, as 
compared to traditional nanoparticle technologies, IVLNs increase the population of antigen-
specific B-cells by 6-fold resulting in a 4 to 18-fold improvement in antigen-specific IgG 
production in-vivo.  
xii 
 
In part two of this thesis, we investigated how iron-oxide nanoparticles could be 
leveraged for the activation of cellular immunity. Activation of cellular immunity facilitates the 
production of cytotoxic T lymphocytes with potential efficacy in the treatment of infectious 
diseases, as well as cancer. Specifically, for engagement with the cellular immunity branch, we 
developed a novel method to engineer lipid-coated iron-oxide nanoparticles (IONP-ML) using 
the phenomenon of lipid-stitching. This method allowed fabrication of IONP-ML with precise 
control of particle size, ultra high-density of biomolecule loading, and high MRI visibility. These 
characteristics translated to unprecedented in-vivo performance. Remarkably, the IONP-ML 
facilitated up to 200-fold increase in biomolecular loading and 9 to 40-fold increase in lymph 
node targeting efficiency as compared to previously reported technologies. As such, these 
materials could be broadly applicable in the efficient and tailored presentation of biomolecules in 
the lymph nodes toward induction of cellular immunity.  
Overall, the work presented herein reaffirms the robust potential of iron-oxide based 
nanoplatforms as drug delivery vehicles, imaging modalities and immunomodulatory agents for 
both humoral and cellular immunity, thereby providing justification for the continued research, 
development and clinical translation of iron-oxide based nanoplatforms.  
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Preface 
 
The content herein describes two unique approaches to the activation of lymphocytes 
utilizing iron-oxide nanoplatforms with virally inspired material design.  
In Part 1 of this dissertation, iron-oxide nanoparticles are combined with gold 
nanoparticles to yield an inorganic virus-like nanoparticle (IVLN) system with a core-satellite 
morphology. The focus of this work was to develop virus mimicking nanoparticles for B 
lymphocyte activation. Traditional viral-like particles are the most efficacious vehicles in the 
activation of humoral immunity for antigen-specific antibody production. However, numerous 
manufacturing issues (e.g. scalability, post-translation modifications) and the potential for 
adverse immune events limit the robustness of their performance. To overcome these 
limitations, we sought to develop alternative virus-mimicking materials using inorganic 
nanoparticles. We hypothesized that the unique advantages in fabrication of inorganic materials 
could be leveraged to recapitulate the unique geometry and patterns of viral-like particles that 
are essential for efficacy, while minimizing potential complications. Herein, we explore the 
potential of the IVLN technology for antigen-specific antibody production against the human 
HER2/neu oncogenic protein.  
In Part 2 of this dissertation, we report on the development of a novel method to 
fabricate iron-oxide nanoparticles coated with ultra-stable lipid shells. The focus of this work was 
to develop iron-oxide nanoparticles for image-monitored lymph node delivery and activation of 
CD8+ T lymphocytes. Although this application has been explored previously, to date, limited 
success has been achieved. The failures of established materials are most often attributed to 
poorly stable surface coatings that do not permit the high-density biomolecule loading and 
particle size control required for in-vivo applications. To address these limitations, we developed 
a novel method that utilizes the phenomenon of lipid stitching. We hypothesized that lipid 
stitching could be employed to produce stable iron-oxide nanoparticles well-defined lipid films 
on a particle’s surface. Herein, we explore how to best leverage this method to control 
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nanoparticle size and support surface conjugation of biomolecules at ultra-high densities. In the 
context of cellular immunity, we propose that moving forward these materials would be ideally 
suited for the efficient delivery of subunit and conjugate vaccines, such as the model DNA-
based covalent conjugate vaccine ovalbumin-CpG, to the lymph nodes.  
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CHAPTER 1 
Nanoparticles for Antigen-Specific Antibody Production:  
The Potential of Viral Mimicry  
 
 
1.1 Introduction: 
 
An antibody, or immunoglobulin, is a specialized glycoprotein produced by the immune 
system to neutralize pathogens, such as bacteria and viruses, in a highly specific manner1. The 
specificity of an antibody is not limited to these pathogens, however. In fact, antibodies have 
been developed against innumerable proteins, peptides, carbohydrates, nucleic acids and small 
molecules both synthetic and naturally occurring. Today, whether it be for protection against a 
wide-range of communicable diseases and cancer, or to provide valuable diagnostic and 
experimental research tools, antibodies are a critical part of both the healthcare and 
biotechnology fields2, 3. 
With the exception of recombinant antibodies that are solely produced using genetic 
manipulations of antibody coding genes in-vitro, antibodies are the result of animal 
immunizations to stimulate humoral immunity4. The B-cell, or B lymphocyte, is a type of immune 
cell that serves as both a lymphocyte and as an antigen-presenting cell in the humoral immunity 
branch of the adaptive immune response1. The major functional contribution of B-cells to the 
immune system is the production of antibodies. These antibodies are polyclonal in nature and 
will be the main focus of this review; the production of monoclonal antibodies following animal 
immunizations has been previously extensively reviewed elsewhere5-7.  
Antibody production is the result of B-cell activation and maturation in response to an 
antigen1, 8. For simplicity, in this review the term antigen will be used to describe any compound 
(small molecule), biomolecule (protein, peptide, carbohydrate) or pathogen (virus, bacteria, 
parasite) for which an antibody is being produced. B-cell activation most frequently occurs within 
the lymph nodes and happens in either a T-cell independent (TI) or T-cell dependent (TD) 
fashion8-10. T-cell independent B-cell activation is caused by two unique classes of antigens, 
known as TI-1 antigens and TI-2 antigens11-13. TI-1 antigens have intrinsic B-cell activating 
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properties regardless of B-cell receptor specificity (e.g. Lipopolysaccharide or CpG 
oligonucleotides)12, 14. TI-2 antigens are characterized by highly repetitive structures, most often 
associated with carbohydrates or synthetic polymers, which facilitate strong direct engagement 
and crosslinking of B-cell receptors11, 13, 15. Traditionally, T-cell independent B-cell activation 
results most significantly in the production of IgM antibodies with modest affinity and failure to 
stimulate an antigen-specific memory response. The only known exception to this rule is a viral 
infection, which has been shown to stimulate the production of high titer, antigen-specific IgM 
and IgG with memory in a T-cell independent manner9, 16-18.  
Those antigens that do not intrinsically stimulate B-cells or do not strongly crosslink B-
cell receptors are considered T-cell dependent (TD) antigens19. TD antigens compromise the 
majority of antigens. As the name would suggest, T-cell dependent B-cell activation relies not 
only on the activation of B-cells through the B-cell receptor, but also necessitates CD4+ T-cell 
help. T-cell dependent B-cell activation can be described in a three-step process19, 20. First, B-
cell receptors weakly associate with TD antigens promoting receptor-mediated endocytosis, 
degradation of the antigen and the subsequent presentation of the antigen on B-cell receptors in 
the context of Major Histocompatibility Complex II (MHC-II). Second, simultaneous to B-cell 
antigen presentation, CD4+ helper T-cells (commonly follicular T helper cells) are activated in 
an antigen-specific fashion by dendritic cells. Third, once active, these CD4+ T-cells cells 
interact with B-cells through two signals: T-cell receptor coupling to MHC-II on B-cell surfaces 
(signal 1) and CD40/CD40L co-stimulation (signal 2). Upon engagement of these two signals, B-
cells are fully activated and B-cell proliferation is stimulated. Traditionally, it is this process that 
promotes germinal center formation and the maturation of antibody-secreting plasma cells that 
are responsible for the antibody class switching and somatic hypermutation necessary to 
produce high specificity and high avidity antibodies21-23.  
As a result of this complex mechanism however, the production of antibodies is not 
practical for many antigens, especially low molecular weight antigens, such as peptides or small 
molecules24. The failure to produce antibodies against these antigens is most of the result of 
inefficient delivery to the lymph nodes, as well as poor inherent immunogenicity. For this reason, 
particle-based delivery vehicles and adjuvants are most often a necessity for the production of 
high avidity, high specificity and high titer antibodies in-vivo25, 26. While the appropriate 
commercial adjuvant choices for efficacious B-cell activation and antibody production have been 
reviewed extensively elsewhere, the focus of this review is on the current status and future 
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prospective of nanoparticles as both adjuvants and delivery vehicles in vaccine development 
and antibody production research25, 27-30.  
 
1.2 Traditional Nanoparticles for B-cell Activation and Antibody Production:  
 
The search for a universal scientific definition of the term nanoparticle is elusive, 
however, for most, nanoparticles are considered colloidal-based systems with particle sizes 
ranging from 1 to 1000 nanometers that have defined interfaces and behave in solution 
according to the principles of Brownian motion.  Regardless of the definition, nanoparticles are 
classified based upon their physiochemical properties including composition, size, shape, 
surface properties, crystallinity, dispersion state and surface-to-volume ratio31, 32. The 
manipulation of these physiochemical properties across the variable nanoparticle types not only 
informs their uniqueness as materials, but also provides incredible opportunity for functional 
diversity. As a result, nanoparticles have been successively applied in far ranging applications 
including medicine, manufacturing and electronics33, 34. In the field of medicine, nanoparticles 
are widely researched and developed as drug delivery vehicles and immunostimulatory 
agents35-37.   
As drug delivery vehicles, nanoparticles are capable of achieving both active and 
passively mediated site-specific delivery in the body38, 39. For the specific application of antibody 
production, the most relevant delivery site is the lymph nodes40. The lymph nodes are 
secondary lymphoid organs, which serve as immunological filters for the body. More specifically, 
the lymph nodes are known to serve as critical sites for immune activation due to their high local 
density and spatial organization of antigen-presenting cells and lymphocytes41, 42. This proximity 
and organization facilitates efficient immune activation by dramatically improving the probability 
for coordinated cellular collisions.  
The nanoparticle material properties for effective lymph node delivery including particle 
size, shape, surface charge, and stability have been studied extensively43-46. The most 
commonly cited material property for efficient lymph node delivery is particle size. According to 
the literature, nanoparticles with less than 200 nm diameter are capable of achieving passive 
lymph node delivery, while those nanoparticles with sizes in 200-500 nm range must be 
delivered to the lymph nodes actively44. This mechanistic difference is the result of lymphatic 
vessel physiology. While lymphatic vessel can range in diameter from 10-60 microns, the 
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lymphatic endothelial cell junctions that allow for entry of nanoparticles from the interstitial space 
are size-limiting41, 47. Due to the size of these junctions, nanoparticles greater than 200 nm in 
diameter do not efficiently enter lymphatic vessels. Conversely, nanoparticles or 
macromolecules with less than a 20 nm diameter more freely diffuse in and out of the lymphatic 
vessels and suffer from inefficient delivery as a result of leakage45. For these reasons, it has 
been demonstrated previously that nanoparticles with 10-100 nm particle sizes are delivered to 
lymph nodes with the greatest efficiency48. More narrowly, a particle size between 30-50 nm has 
been reported as being ideal for lymph node delivery49-52.  
Passive delivery indicates that nanoparticles are free and stable within the lymphatic 
fluid, while active delivery indicates that lymphatic transport is only possible in the context of 
migrating peripheral antigen-presenting cells that have up taken nanoparticles at the injection 
site44. These mechanistic differences in delivery would theoretically manifest in immunologically 
more efficacious outcomes for passive delivery as compared to active, especially in the context 
of B-cell activation and antibody production. This variance in efficacy is due to the fact that B-
cells activation is significantly improved by direct presentation of antigen in its’ native 
confirmation at high density on nanoparticle surfaces to facilitate B-cell receptor crosslinking for 
B-cell activation53-55.  Based our current understanding of lymphatic transport of nanoparticles, 
this phenomenon would only be truly feasible in the context of passive delivery. 
As immunostimulatory agents, nanoparticles have been shown on innumerable 
occasions to heighten the immune response acting both as adjuvants and as promoters of 
cellular uptake and antigen-presentation37, 56-60. Although the function of all nanoparticles as 
adjuvants is commonly debated in the literature, it is clear that some nanoparticles are 
composed of materials with inherently immunostimulatory components either synthetic or 
biologically derived. For example, inorganic nanoparticles such as carbon nanotubes, synthetic 
polymeric nanoparticles such as polyanhydride nanoparticles and biologically-derived polymeric 
nanoparticle such as chitosan nanoparticles have been shown previously to induce an 
inflammatory response that promotes the appropriate cytokine environment for immune 
stimulation based on their chemical composition57, 61, 62. On the other hand, materials such as 
liposomes and gold nanoparticles are most often considered chemically inert and do not 
contribute to the immune response based on chemical composition alone.  
Taken together, it becomes evident that nanoparticles are capable as both delivery 
vehicles and as immunostimulatory agents for robust activation of the immune system, which 
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can be utilized to facilitate the production of high avidity, specificity and titer antibodies in-vivo. 
However, the choice of what nanoparticle to use for what application remains a critical decision.  
 
1.2.1 Lipid Nanoparticles (Liposomes)  
 
First described in the 1960’s, liposomes are small artificial spherical vesicles that are 
composed of natural or synthetic phospholipids, which undergo self-assembly into one or more 
bilayers engulfing an aqueous core63. The popularity of liposomes is due to their simplicity in 
formulation, wide diversity and availability of the phospholipid components, as well as their 
profile as being highly biocompatible and highly biodegradable64. In fact, liposomes were the 
first nanoparticle-based drug delivery strategy to be successfully translated from research to 
clinical used, and represents the nanoparticle technology most widely approved as drug 
products by the FDA65, 66.  
Liposomes can be formulated as unilamellar or multilamellar vesicles with particle sizes 
ranging from 25-2500 nm having anionic or cationic surface character, depending upon their 
phospholipid composition and formulation scheme63. Liposomes are capable of carrying cargo 
in three separate compartments: the aqueous core, the hydrophobic acyl chain layer and the 
surface67. For the purposes of B-cell activation and antibody production, the most relevant 
loading mechanism is surface presentation due to direct contact with B-cells that promotes 
bivalent B-cell receptor engagement46, 68. Importantly, with the clinical acceptance of and 
commercialization of PEGylated phospholipids with diverse categories of functional moieties 
such as maleimide, azide, nitrilotriacetic acid and biotin, surface modification of liposomes with 
antigen has never been easier.  
Based on literature review, liposomes have been previously utilized for antigen-specific 
antibody production in greater than twenty different publications (Table 1.1)68-88. The average 
serum antibody titer achieved across these publications is approximately 32,800. Despite this 
relatively modest average titer, liposomes have been used previously with great success. More 
specifically, two examples of the efficacious application of liposomes for antibody production in 
terms of antigen-specific IgG serum titers were reported by Moon et al and Yan et al70, 86. Moon 
et al was able to achieve a malaria antigen specific IgG titer of approximately 200,000 with a 
very low dose of 1 µg by incorporating the lipid adjuvant MPLA into the formulation86. Yan et al 
demonstrated serum titers between 105-106 for 1.5 µg HIV tat protein utilizing nickel-chelating 
methodology for liposomes surface modifications70.  
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Despite the successful application of liposomes for antibody production in over thirty-five 
publications, several challenges for this technology remain. One such challenge is that 
liposomes are the subject of a significant anti-carrier response as the result of antibody 
production against the lipid and polymer components of the lipid formulation67. Due to this anti-
carrier response, liposomes are exposed to rapid antibody-mediated blood clearance, which 
reduces their therapeutic efficacy during re-dosing. Another such challenge to the application of 
liposomes for antibody production is that, in the majority of cases, the use of high doses and 
adjuvants are still required to produce high titer antigen-specific antibodies68, 74, 75, 81, 88. 
 
1.2.2 Inorganic Nanoparticles 
 
1.2.2.1 Gold Nanoparticles 
 
The potentially most widely utilized inorganic nanoparticles in biotechnology today are 
gold nanoparticles89-91. As the name would imply, gold nanoparticles are gold metallic colloids 
that can be easily synthesized with controlled size, shape and surface properties92, 93. As such, 
gold nanoparticles can be engineered with a unique range of physiochemical properties, which 
make them valuable and adaptable in many fields including drug delivery, imaging, diagnostics 
and electronics.  
As drug delivery vehicles, gold nanoparticles display ideal particle size, tunable surface 
properties and low toxicity94. Additionally, the intrinsic ability of gold nanoparticles to coordinate 
the commonly exploited gold-thiol (Au-S) bond facilitates surface functionalization with a wide-
range of antigens containing naturally occurring or synthetically modified thiol moieties95. Gold 
nanoparticles have been previously employed as vehicles for antigen-specific antibody 
production in greater than twelve unique publications (Table 1.2)60, 92, 96-102. Notably, the average 
antigen-specific IgG serum titer observed in these publications was approximately 73,400. 
Notable applications of gold nanoparticles for antibody production in terms of titer and 
application diversity were published by Kumar et al and Dykman et al60, 101. Kumar et al 
demonstrated the ability to formulate gold nanoparticles as a vaccine against malaria using the 
Pfs230 protein, which resulted in the stimulation of antigen-specific IgG titers of approximately 
640,000 using a 10 µg dose and the FDA-approved adjuvant alum101. This titer is significantly 
higher than the majority of literature published for gold nanoparticles by nearly an order of 
magnitude. In this vein, while Dykman et al produced modest titers of approximately 15,360 
10 
 
using bovine serum albumin as a model protein, the success of this group is in their incredible 
diversity of applications for gold nanoparticles including antibody production against influenza, 
foot-and-mouth disease virus, tuberculosis and small molecule drugs60, 96, 97, 103, 104.  
While gold nanoparticles have many advantages as nanoparticles for immune activation, 
several disadvantages of their use do exist. The most commonly considered disadvantages of 
using gold nanoparticles include lack of biodegradability, poor clearance, the potential for long-
term toxicity associated with coatings and capping ligands, as well as the cost to manufacture 
gold nanoparticles at industrial scales105, 106. 
 
1.2.2.2  Silica Nanoparticles   
 
Silica nanoparticles are nanoparticles composed of silicon dioxide that have 
demonstrated promise in a wide-range of biological application including drug delivery, imaging 
and tumor ablation107, 108. This promise is the result of the simplicity and precision of the 
synthetic process, which readily allows for manipulation of such material properties including 
particle size, shape, crystallinity, porosity and biodegradability109, 110. In this way, silica 
nanoparticles can be precisely engineered for specific applications without necessitating a one-
size fits all philosophy. The most commonly utilized silica nanoparticle for drug delivery 
applications are known as mesoporous silica nanoparticles. Mesoporous silica nanoparticles 
have honeycomb-like structural features with high surface area and high reactivity, which 
facilitate high antigen payloads. In addition to their potential as delivery vehicles, silica 
nanoparticles are considered by many to be viable adjuvants for vaccines based on improved 
cellular uptake mechanisms111-113.  
Silica nanoparticles have been utilized previously for antigen-specific antibody 
production in at least seven applications (Table 1.2; three publications report titers)114-120. 
However, silica nanoparticles have been shown to only achieve modest antigen-specific IgG 
titers. Specifically, the highest antibody titer obtained with silica nanoparticles systems was 
6,400 by Mahony et al against ovalbumin as a model protein antigen114. Beyond the modest 
stimulation antibody production, the main disadvantage associated with the use of silica 
nanoparticles is the potential for toxicity121.  Toxicity of silica is most commonly linked to 
crystallinity and particle size. While it is now well established in healthcare and manufacturing 
that crystalline silica is toxic, traditionally amorphous silica is considered safe. However, recent 
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research utilizing silica nanoparticles suggests that the silanol groups that form on the 
nanoparticles surface interact with phospholipids in red blood cells leading to hemolysis122, 123. 
Additionally, there have been connections made between silica nanoparticles usage and the 
onset of melanoma124.  
 
1.2.2.3  Carbon Nanotubes 
 
Carbon nanotubes are allotropes of carbon, which form highly stable hollow cylindrical 
nanostructures that can be synthesized as single, double or multi-walled structures125. The 
number of walls increases the surface area and tensile strength of the material. Due to their 
distinctive structure, carbon nanotubes are known to have unique mechanical, electrical, optical 
and thermal properties125. As such, carbon nanotubes have been utilized in applications ranging 
from scaffolds in tissue engineering to sensors for environmental toxins126, 127.  
As drug delivery vehicles, carbon nanotubes combine extraordinarily high surface to 
volume ratios and extensive diversity of potential biomolecule conjugation schemes128, 129. As 
immunostimulatory agents, carbon nanotubes have been shown to be able to stimulate a 
dramatic pro-inflammatory response, in addition to facilitating rapid and efficient cell entry61, 130, 
131. Taken together, these characteristics make carbon nanotubes versatile delivery vehicles. 
Accordingly, carbon nanotubes have been evaluated as potential vehicles for antigen-specific 
antibody production in at least three previous applications (Table 1.2)61, 131, 132. The results of 
these applications demonstrate that while carbon nanotubes can be utilized for antibody 
production, the modest antigen-specific serum IgG titers between 1,000-10,000 achieved do not 
distinguish them as unique for this specific application.  
Despite the continued application of carbon nanotubes as drug delivery vehicles and 
immunostimulatory agents, they suffer from several glaring drawbacks. Chief among these 
drawbacks includes a lack of biodegradability and high in-vivo toxicity133, 134. More specifically, 
carbon nanotubes have been connected in animal models to behave in an asbestos-like manner 
in the lungs leading to the spontaneous induction of lung cancer135. 
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1.2.2.4  Iron-Oxide Nanoparticles 
 
Iron-oxide nanoparticles (IONPs) are clinically accepted biomaterials with intrinsic 
physico-chemical properties including biocompatibility, biodegradation and magnetic 
susceptibility that make them versatile and safe nanoparticle candidates in biomedical 
applications136-138. Clinically, IONPs are utilized as FDA-approved biomaterials for diagnostic 
MRI imaging as T2-weighted contrast agents139, 140. IONPs can be synthesized by established 
techniq ues such as thermal decomposition with extreme precision of particle size and shape 
(spheres, rods, cubes)137, 141. Beyond the choice of size and shape, the most significant choice 
that must be made during IONP synthesis is surface coating material and formulation scheme. 
The potential surface coatings of IONPs for biomedical applications include synthetic polymers, 
sugars or lipids142-144. The choice of surface coating determines the capacity of an IONP to 
facilitate antigen surface conjugation while maintaining colloidal stability, and therefore governs 
the nanoparticles ultimate application scope both in-vitro and in-vivo.   
Despite the extensive utilization of IONPs for biomedical research and medical 
diagnostics, few therapeutic applications have been successfully adapted. In fact, to date, only 
one publication reports the utilization of IONP nanoparticles for antigen-specific antibody 
production (Table 1.2). Interestingly, this publication by Pusic et al was able to stimulate the 
production of antigen-specific serum IgG titers between 10,000-100,000145. One potential 
explanation for the lack of translational therapeutics based on IONPs in literature could be that 
contradictory reports of the immunostimulatory potential of IONPs have been reported. For 
example, although Pusic et al reported on the successful application of IONPs for the treatment 
of malaria, other reports suggest that IONP administration can actually attenuate the production 
of antigen-specific IgG in animal models146. These conflicting reports may be linked to variability 
IONP surface coating materials and formulation methodologies. More specifically, although 
IONPs traditionally exhibit excellent biocompatibility and biodegradability, these features can be 
dramatically reduced by surface coatings that require harsh cross-linking procedures to facilitate 
antigen conjugation and high colloidal stability in-vivo (e.g. dextran)147-149.  
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1.2.3 Polymeric Nanoparticles 
 
1.2.3.1 PLGA Nanoparticles 
 
Poly (lactic-co-glycolic) acid or PLGA is a biodegradable, controlled release block co-
polymer. The biodegradation of PLGA is the result of the hydrolysis of ester linkages, the rate of 
which is determined by the relative hydrophobicity of the lactic and glycolic acid monomer units 
150. PLGA systems have received extensive attention in both research and clinical applications 
over the last three decades, and are considered to be the best-defined biomaterials for drug 
delivery 151. Accordingly, PLGA has been widely explored in the fabrication of nanoparticles, 
microparticles, implants and injectables 151-154. PLGA nanoparticles facilitate both antigen 
encapsulation and surface presentation via a myriad of chemistries. Inside, PLGA has been 
previously demonstrated to be able to encapsulate proteins, peptides, and small molecule drugs 
while sustaining controlled release integrity155-157. Outside, PLGA nanoparticles can either be 
formulated with specifically modified polymers to coordinate direct polymer modification or can 
be surface coated with functional PEGylated phospholipids to allow for conjugation based on 
thiols, click chemistry or biotin-avidin associations158-162.  
PLGA nanoparticles have been previously applied as drug delivery vehicles for antigen-
specific antibody production in a number of applications including, but not limited to: ovalbumin, 
anthrax, malaria, bovine parainfluenza and clenbuterol (Table 1.3)158, 163-167. Interestingly, 
despite limited utilization of PLGA nanoparticles for antibody production to date, the average 
antigen specific serum IgG titer based on literature review is approximately 100,000. Of the 
applications listed above, the work by Manish et al stands out as being noteworthy163. With a 
single 100 µg dose of anthrax protective antigen domain protein, Manish et al were able to 
stimulate an antigen-specific IgG serum titer of approximately 310,000163. The implication of this 
data set is that, based on the depot-forming and controlled release nature of PLGA, it may be 
feasible to produce high titer, antigen-specific IgG with a single immunization. With alternative 
systems, this phenomenon would only be observed after multiple booster doses.  
The drawback associated with the use of PLGA nanoparticles for antigen delivery is the 
potential to damage the antigen during both loading and release168-170. More specifically, many 
formulation methods for PLGA nanoparticles require exposure of sensitive antigens to organic 
solvents170. Additionally, as a result of the bulk-eroding nature of PLGA, the hydrolysis and 
reveal of oligomer units in the core produces a harsh acidic environment168, 169. Beyond these 
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potential complications, another drawback of PLGA is that the formulation of PLGA 
nanoparticles below 100 nanometers with high yield can be difficult and tedious in terms of size 
control and formulation stability171. Often, to achieve such particle size extensive and laborious 
filtration techniques are required. As a result, PLGA nanoparticles are not ideal vehicles for 
lymphatic transit.  
 
1.2.3.2 Polyanhydride Nanoparticles  
 
Polyanhydrides are a lesser-known class of biodegradable co-polymers with translation 
potential that can also be readily formulated into nanoparticles172. Clinically relevant 
polyanhydrides are based on the three diacids monomer units, sebacic acid or SA, 1,6-bis-(p-
carboxyphenoxy)hexane or CPH, and 1,9-bis-(p-carboxyphenoxy)-3,6-dioxaoctane or CPTEG 
173-175. Polyanhydride nanoparticles have been shown previously to be non-inflammatory, non-
toxic, and non-mutagenic 176. Significantly as compared to PLGA nanoparticles, polyanhydride 
nanoparticles are more readily applicable to the stable encapsulation and delivery of protein 
based antigens due to their nature as surface eroding polymers and inclusion of amphiphilic 
units 177.  
 In addition to their delivery potential, polyanhydride nanoparticles have also been 
implicated to have inherent immunostimulatory or adjuvant-like properties based upon their 
composition57, 178. More specifically, polyanhydride polymer systems have been shown to 
stimulate a Th1 type immune response through TLR receptor pathways57. This 
immunostimulatory response has been demonstrated to be applicable to both the cellular and 
humoral branches of the adaptive immune response. As such, polyanhydride nanoparticles 
have been utilized for antigen-specific antibody production in at least eight publications with an 
average antigen-specific IgG titer of approximately 95,000 (Table 1.3)164, 179-184. Of these 
examples, the two most noteworthy applications were by Petersen et al and Ulery et al181, 185. 
Petersen et al produced titers between 105-106 using a 10 µg dose of anthrax protective antigen 
administered subcutaneously without additional adjuvant181. Ulery et al demonstrated that 
polyanhydride nanoparticles could be administered intranasally to produce titers between 104-
105 against a 50 µg dose plague relevant surface antigens185. 
The potential drawbacks associated with the use of polyanhydride nanoparticles are 
complications in polymer reproducibility and toxicity associated with non-ideal organic solvent 
usage during formulation (e.g. chloroform, dichloromethane)186-188. As compared to PLGA that is 
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widely commercially available at highly characterized and defined compositions, polyanhydrides 
must be synthesized in house186. The requirement of in house synthesis can lead to dramatic 
batch-to-batch variability and lab-to-lab variability that can dramatically affect reproducibility and 
the transfer of information.  
 
1.2.3.3 Chitosan Nanoparticles  
 
Chitosan is a biologically derived, glucosamine-based, linear co-polymer that is 
produced by deacetylation of chitin189, 190. Chitin is a type of polysaccharide that is a primary 
component of the exoskeletons of crustaceans. The physiochemical properties of chitosan 
including degree of deacetylation and molecular weight alter the materials’ solubility, 
encapsulation efficiency, degradation rate and formulation flexibility, and thereby determines 
chitosan’s ultimate functionality190. Much like the synthetic polymers PLGA and polyanhydride, 
the biologically derived polmer chitosan behaves with controlled release character191. As a drug 
delivery vehicle, chitosan nanoparticles primarily deliver antigen via encapsulation, or more 
appropriately electrostatically mediated complexation62, 192, 193. Notably, chitosan is traditionally 
utilized in mucoadhesive applications due to its highly basic and cationic properties, including 
being FDA approved for wound dressing194. Thus, chitosan is more of a depot-forming material 
than a classical lymphatic trafficking agent. As an immunostimulatory agent, chitosan has been 
shown previously to stimulate the production of cytokines in a pro-inflammatory manner, to 
activate macrophages, dendritic cells and natural killer cells, as well as being connected to both 
anti-tumor immunity and anti-viral immunity62, 195-198.  
Chitosan nanoparticles have been utilized in a variety of applications for antigen specific 
antibody production including, but not limited to: ovalbumin, hepatitis B, H1N1 influenza, 
pneumococcal infection, E. coli, anthrax and snake venom (Table 1.4)192, 193, 196-203. Based on 
literature review, the average antigen-specific serum IgG titer produced while utilizing chitosan 
nanoparticles as the delivery vehicle and adjuvant was approximately 60,000. Two particular 
examples that stand out from this group are from Pawar et al and Malik et al192, 196. Utilizing 
glycol-chitosan nanoparticles for intranasal vaccination against Hepatitis B surface antigen, 
Pawar et al was able to stimulate antigen-specific IgG titers of approximately 100,000 using only 
a 10 µg dose and no additional adjuvant by changing the molecular weight of the chitosan 
polymer196. Alternatively, Malik et al demonstrated the potential to combine chitosan 
nanoparticles with additional adjuvant, such as CpG or poly I:C, to promote a more robust 
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immune response against anthrax192. More specifically, Malik et al showed a 2-fold 
enhancement of antigen-specific IgG titers from 100,000 (without CpG) to 200,000 (with CpG) 
by encapsulating the anthrax protective antigen into trimethyl chitosan nanoparticles and using 
CpG oligonucleotides as adjuvant192.  
 Despite the promise of chitosan nanoparticle for both their delivery and 
immunostimulatory potential, several drawbacks of their use do exist. Chief among these 
drawbacks is that chitosan has poor solubility at physiological pH and is highly soluble at acidic 
pH, which dramatically effects degradation timing and informs antigen bioavailability204. In the 
specific context of B-cell activation and antibody production, chitosan nanoparticles rely on 
encapsulation for antigen loading and in-vivo depot formation for antigen delivery, which 
simultaneously limits lymph node delivery and B-cell receptor surface interactions with 
particulate antigens. Lastly, although chitosan is generally considered non-toxic and 
biocompatibility, recent studies have implicated chitosan in mutagenic genotoxicity205.  
 
1.2.4 Virus-Like Nanoparticles  
 
Virus-like nanoparticles (VLPs) are self-assembled protein nanoparticles that are 
composed of viral-derived structural proteins206-208. VLPs do not contain the genetic material 
necessary to facilitate viral-induced host cell transformation and replication. As a result, VLPs 
are considered to be safe for human application. To date, VLP-based vaccines have been 
employed in at least 16 FDA approved and licensed products, including the FDA-approval of 
vaccines for Hepatitis B Virus (Recombivax) and Human Papillomavirus (Gardasil)207. 
Additionally, VLPs have been evaluated in more than 30 clinical trials for applications including 
Alzheimer’s disease, breast cancer, nicotine addiction and rabies207. Based on the collective 
lessons learned from the development and clinical translation of virus-like nanoparticles it is 
clear that the unique functional efficacy of VLPs can be attributed to their unique structural 
features. 
Structurally, VLPs are defined as having a rigid geometry with multivalent and high-
density antigen display with particle sizes ranging between 30-500 nm59, 207, 209, 210. In other 
words, viruses are highly organized and repetitive structures by design that coalesce to display 
epitopes in high density with defined shape and patterns. Interestingly, this level of geometric 
patternization is unseen in any other biological system. As a result, it is now thought that the 
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immune system is capable of recognizing the structural features of viruses as pathogen 
associated molecular patterns, or PAMPs210, 211. Traditionally, PAMPs are molecules associated 
with groups of pathogens that are recognized by cells of the innate immune system via 
pathogen recognition receptors212. Examples of PAMPs would include materials such as 
lipopolysaccharide, flagellin or CpG oligonucleotides212. Nanoparticles would not traditionally be 
characterized as PAMPs, but virus-like particles are now considered by many to be. In this way, 
viral geometry in and of itself has been proven to be immunostimulatory in nature. More 
specifically, in the context of B-cell activation antibody production these unique structural 
features manifest in two different ways.  
The first is highly efficient B-cell receptor engagement and cross-linking. Based upon 
experiments performed with synthetic polymers with antigens are defined spacing intervals, it is 
now better understood that B-cell activation is the result of B-cell receptor crosslinking or forced 
aggregation and that the optimal spatial resolution of antigens for this phenomenon to occur is 
15-20 antigens within a 5-10 nm diameter211, 213. Viruses are known to frequently have surface 
antigens geometrically orientated with defined spacing and density that would satisfy these 
requirements214, 215. Notably, based on a biological recognition of this phenomenon, many 
viruses have evolved to reduce the extent of antigen surface density and controlled display to 
facilitate immune evasion (e.g. Human Immunodeficiency Virus)216.  
The second manner in which the structural features of VLPs are manifested is in the 
ability to stimulate the production of autoantibodies against self-antigens in addition to high titer 
antibody production against foreign antigens – an ability truly unique to VLPs55. Autoantibodies 
are antibodies formed against self-antigens and are most commonly associated with the onset 
of autoimmune diseases. As such, the immune system is regulated in such a way that 
autoantibody producing B-cells, which are frequently made by chance, should be weeded out 
and eliminated through a process known as tolerance217. Tolerance can either result in the 
clonal deletion of autoantibody producing B-cells, receptor editing to fix the recognition patterns 
or through the induction of B-cell anergy. However, in the case of viruses, B-cells are activated 
so strongly that they are influenced to escape tolerance regardless of the antigen’s origin.  
 As a result of the intrinsic immunostimulatory nature of VLPs combined with the 
appropriate material properties for efficient lymphatic trafficking and retention, VLPs are ideal 
candidates as nanoparticles for antigen-specific antibody production against a wide-range of 
antigens. For example, VLPs have been utilized for antibody production in application including, 
but not limited to: influenza, human immunodeficiency virus, hepatitis B, respiratory syncytial 
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virus, middle eat respiratory syndrome, severe acute respiratory syndrome, hand foot and 
mouth disease virus, Alzheimer’s disease, TNF-alpha, estriol, nicotine and tumor-associated 
carbohydrate antigen (Table 1.5)55, 111, 215, 218-232. Significantly, VLPs exhibit the highest average 
antigen-specific serum IgG titer at 120,000. Multiple examples of the successful application of 
VLPs for antibody production stand out in the literature. Skrastina et al confirmed the ability of 
VLPs to achieve dramatically high titers (titer = 300,000) against viral components when they 
employed the hepatitis B virus-like particle to stimulate an anti-hepatitis B surface antigen 
response111. Chackerian et al harnessed the autoantibody production capabilities of VLPs to 
produce high titer response against the self-antigen peptide TNF-alpha224. Lastly, Maurer et al 
demonstrate the dynamic range of VLPs by stimulating a strong humoral immune response 
against nicotine, a small molecule, which is a class of antigen that is traditionally difficult to 
stimulate a specific and high-titer antibody response against220.  
 While the tremendously diverse and robust potential of VLPs is evident, this technology 
still has a number of disadvantages233. The first noteworthy drawback of VLPs is the unwanted 
level of non-specific immunogenicity toward the capsid structural components234. This 
immunogenicity often results in the off-target production of antibodies against the capsid itself, 
which leads to a high level anti-carrier response. This response can dramatically reduce 
therapeutic efficacy upon re-dosing. An additional disadvantage of VLP technology is if VLPs 
must be surface modified for antigen loading the protein can be denatured or the colloidal 
stability of the particle can be compromised235. Moreover, traditional bioconjugation schemes for 
antigen surface loading would dramatically reduce the pattern and density controls that are 
significant in VLP efficacy214. In terms of manufacturing, VLP formulations can be challenging233. 
More specifically, unlike other traditional nanoparticles that are chemically synthesized, VLPs 
must be genetically engineered, self-assembled and secondarily modified within a host cell. 
Different host cell types can include e. coli, yeast, insect cells, plant cells or other mammalian 
cells, each with its own unique advantages and disadvantages236, 237. Beyond the requirement of 
highly specialized technology to produce these materials, this formulation process lends itself to 
potentially poor reproducibility and can limit application scope. As a result of the potential 
formulation complications, alternative methodologies are currently being pursued to formulate 
viral-like nanoparticles in an attempt to capitalize on their class-leading efficacy while reducing 
technical difficulties. Accordingly, a new descriptor for nanoparticle regardless of class has been 
introduced in recent years – viral-mimicry.  
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1.3 The Potential of Virus-Mimicking Nanoparticles for Antibody Production 
 
1.3.1 What is Viral Mimicry?  
 
Viral mimicry is a derivative of molecular mimicry. Molecular mimicry is a biological 
phenomenon that can be evolutionarily developed or artificially engineered based on a 
fundamental understanding of the immune systems ability to recognize biomolecules or 
infectious agents with specific compositions, shapes, patterns, densities, topographies, etc238, 
239. For example, researchers now believe that the human immunodeficiency virus employs 
molecular mimicry for immune evasion by limiting antigen surface density and patternization. As 
a result, HIV often fails to facilitate dual B-cell receptor engagement and crosslinking leading to 
B-cell anergy and failure to stimulate the humoral immune response216. Traditionally, molecular 
mimicry is discussed in the context of autoimmune diseases wherein self-antigen escapes 
immunological self-tolerance. However, in the context of viruses, molecular mimicry can be 
harnessed for beneficial immune stimulation.  
 As previously introduced, viruses have rigid geometries with multivalent and high-density 
antigen displays that are completely unique in biological systems. In response to these 
distinctive characteristics, the immune system has evolved to recognize geometric 
patternization and high-density antigen display as a sort of PAMP210, 211. Traditionally, PAMPs 
are recognized by the innate immune system through pathogen recognition receptors (PRR), 
such as toll-like receptors212. PRR engagement results in the induction of a pro-inflammatory 
cytokine response that adjuvants host immunity, both humoral and cellular212. In this way, viral 
structural properties could be considered self-adjuvanting and intrinsically immunostimulatory.  
Therefore, the ability to mimic these unique structural characteristics would be of the upmost 
interest to researchers attempting to develop the next generation of preventative and 
therapeutic nanoparticle-based vaccines.  
 
1.3.2 Viral-Mimicking Nanoparticles for Antibody Production - Current Status  
 
Viral-mimicking nanoparticles are those nanoparticles that are rationally designed and 
engineered based on the knowledge gained from studying how viral physiochemical properties 
either circumvent or foster the host immune response240-242. While protein-based virus-like 
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particles are most frequently discussed as viral-mimicking nanoparticles, recently research in 
this area has broadened to incorporate lipid, polymeric and inorganic nanoparticles243-246. While 
currently no comprehensive nanoparticle platform has been reported to replace true virus-like 
particles, significant advancements have been made in the imitation and application of the 
unique individual components of viruses. A few examples of the individual components that 
been adapted from viruses and engineered into viral-mimicking nanoparticles include: particle 
size, particle shape, surface topography, antigen display, antigen density and antigen 
organization (Table 1.6).  
The role of nanoparticle size and shape was recently evaluated by Dykman et al and 
Niikura et al utilizing gold nanoparticles as a delivery platform with bovine serum albumin and 
West Nile Virus envelope protein as a model antigen system, respectively60, 92. Both Dykman 
and Niikura identified spherical nanoparticles between 40-50 nanometers as being the most 
effective at inducing antigen-specific antibody responses, and rod-shaped gold nanoparticles as 
being the least effective. Interestingly, both Dykman and Niikura also identified a particle-size 
dependent response in addition to the particle shape response. Larger nanoparticles (40-50 nm) 
were more approximately 2-fold more efficacious in stimulating antibody production as 
compared to their smaller counterparts (15-20 nm). Mechanistically, Niikura connected the 
variability in the immune response to different sized and shaped nanoparticles to the type and 
extent of the cytokine environment, and to a lesser extent cell uptake. More specifically, 
spherical nanoparticles of 40 nm diameter combined induction of a pro-inflammatory cytokine 
response with high cell uptake, while rod-shaped nanoparticles induced an inflammasome type 
response and cubes showed exceptionally low cellular uptake92. 
Beyond particle size and shape, one material property that has been connected to 
cellular uptake and could be used to influence the immune response is nanoparticle surface 
roughness, or topography. The significance of nanoparticle surface topography for cellular 
uptake was recently explored by Niu et al employing silica nanoparticles247, 248. Niu suggests 
that in addition to the receptor-mediated mechanisms for cellular uptake, the “nano-ecology” of 
viruses may contribute significantly and in part explain their unparalleled cellular delivery 
efficiencies and infectivity. While not specifically for the application of antibody production, Niu 
demonstrated in two separate publications that the surface roughness of nanoparticles could be 
manipulated to improve cellular uptake and delivery efficiency of genetic material or protein247, 
248. Beyond the obvious improvement in biological relevance of the nanoparticle surfaces, this 
phenomenon could be applied for improved antigen-presenting cell activation that would be vital 
21 
 
in T-cell dependent B-cell activation.  Additionally, surface roughness is known to contribute to 
improved antigen loading capacity on nanoparticle surfaces247. 
Nanoparticle surface loading of antigen is significant for the robust induction of the 
humoral immune response. While both surface presentation and encapsulation have been 
demonstrated to be viable strategies for the stimulation of antibody production, publications by 
researchers such as Kirby et al and Guan et al indicate the loading mechanism can be used to 
skew the balance of the immune response68, 249. More specifically, using a microparticle 
platform, Kirby et al determined that the immune response of surface presented antigen is 
skewed towards the humoral immune response, as compared to the cellular immune response 
for encapsulated antigen249. Similarly, using a liposomal system, Guan et al demonstrated that 
surface exposed peptide could stimulate an antigen-specific antibody response, while 
encapsulated peptide could not68. Despite the significance of the results reported by Kirby et al 
and Guan et al, no connection between antigen surface display and viral mimicry was ever 
addressed. Two publications that do make this connection and exploit this phenomenon for 
antigen-specific antibody production come from Riitho et al and Moon et al, who both produce 
viral-mimicking lipid-coated PLGA nanoparticles with surface antigen display as potential 
vaccine platforms for bovine virus diarrhea virus and malaria, respectively158, 250. But, surface 
antigen display alone is not sufficient to achieve true viral mimicry. The manner in which the 
antigen is displayed, in terms of density and organization, is of the upmost importance.  
As previously introduced, antigen density and organization are known to influence the 
immunostimulatory potential of viral-like particles and therefore affect the dose response 
relationship, as well as the ability to stimulate autoantibodies55, 211, 214, 215. While the role of 
antigen density has been broadly explored and obtained design parameter in numerous 
publications, the ability to have any degree of control over antigen organization or patternization 
on nanoparticle surfaces has been elusive. One such publication that combines the significance 
of antigen density and organization is the work of Ingale et al, who developed a liposomal 
formulation using HIV envelope glycoprotein trimer251. Utilizing histidine tagged native HIV 
trimers and a liposomal formulation with nickel-NTA functionalized lipids at defined molar ratios, 
Ingale et al were able to produce 80 nm liposomes with native HIV envelope protein trimers with 
homogenous distribution and regular 13-15 nanometer spacing intervals251. These materials 
demonstrated the capacity to stimulate an effective antigen-specific antibody response, as well 
as the neutralizing antibody response required for protective vaccination.  
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1.3.3 Viral-Mimicking Nanoparticles for Antibody Production – Future Prospective   
 
While many advances have been made in the design, engineering and application of 
viral-mimicking nanoparticles for antibody production, no single truly universal nanoparticle 
system has been developed that can compete with the combined delivery efficiency and 
immunostimulatory potential of viruses or viral-like particles. At present, many researchers are 
taking a selective view of material properties to be mimicked and have achieved a certain level 
of success in their intended application, but it may be time to take a more holistic approach to 
viral-mimicking nanoparticle design.  
The ability to define an exact material design criterion for a holistic viral-mimicking 
nanoparticle platform is elusive.  However, based on literature review, a suitable design for the 
next-generation of viral-mimicking nanoparticle for antigen-specific antibody production should 
include:  
 
1. Spherical nanoparticle with particle size of approximately 40-50 nanometers.  
2. Negatively charged surfaces with rough surface topography  
3. Antigen surface presentation with defined spatial intervals and >10,000 molecules 
per µm2.  
 
At present, there is no one specific type of nanoparticle that stands out as being able to 
accomplish this feat. For this reason, the future of viral-mimicking nanoparticles for antibody 
production may be in hybrid systems. For example, the so-called core-satellite nanoparticles 
originally developed be Chen et al 252, 253. This core-satellite nanoparticle is composed of a 
larger poly(siloxane) coated iron-oxide nanoparticle core complexed with numerous smaller gold 
nanoparticle satellites. This material has the ideal shape, size and surface charge. Moreover, 
the gold nanoparticle satellite density can be modified to simultaneous offer variable roughness 
as well as densely packed, thiol-reactive surfaces for biomolecule conjugation. While the 
potential of this system has yet to be explored for antibody production, this hybrid methodology 
in viral-mimicking nanoparticle material design is the way forward.  
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1.4 Conclusion  
 
In modern scientific research and medicine, antibodies are critical research tools and 
therapeutic agents. In order to continue to advance their wide spread applicability, new 
technology must be developed to facilitate the production of high specificity and high avidity 
antibodies. Beyond advancing the in-vitro systems to improve the efficiency and accuracy of the 
monoclonal antibody production process, the best hope the industry has is to modernize in-vivo 
B-cell activation and antigen-specific antibody production. The old school methodology for 
antibody production relies on high doses, toxic adjuvants and the use of inefficient, poorly stable 
and weakly immunostimulatory carrier proteins. A modern approach to B-cell activation and 
antibody production is the utilization of nanoparticles. Nanoparticles can be engineered with 
ideal material properties to facilitate efficient delivery as well as immune activation. Numerous 
types of nanoparticles have been previously investigated to this end including: liposomes, 
inorganic nanoparticles, polymeric nanoparticles and viral-like nanoparticles. Of these systems, 
viral-like nanoparticles have been shown to be the most efficacious as a result of their unique 
structural properties. However, viral-like nanoparticles can be difficult to produce, while having 
poor reproducibility and have high anti-carrier responses that limit the effectiveness of future 
doses. As a result of these drawbacks, researchers have tried to find alternatives. The answer is 
viral-mimicry. To be considered a viral-mimicking system, the nanoparticles must be designed 
with some combination of viral inspired particle size, particle shape, surface properties, antigen 
density, antigen display, antigen organization, or surface topography. An ideal viral-mimicking 
nanoparticle would incorporate all of these things. However, while significant progress has been 
made in this research area, a nanoparticle with this holistic potential is not yet a reality. The 
development of a universal viral-mimicking nanoparticle platform remains elusive, but given the 
significance of antibodies in research and medicine, the pursuit is worthwhile.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 
 
1.5 Tables  
 
Table 1.1: Lipid Nanoparticles for Antibody Production 
 
Nanoparticle 
Type: 
Application - 
Antigen 
Immunization Scheme 
(Dose, Interval, Route) Adjuvant Isotype 
Antibody Production: 
Absolute Amount, Titer, 
OD/D.F. 
Author 
Lipoplex 
Ovalbumin (OVA) 
 
Primary – 50 µg, IP 
Secondary (10 days) -50 µg, IP 
Tertiary (20 days) - 50 µg, IP 
CpG IgG Anti-OVA IgG Titer – 10,000 Kim69 
Liposome Ovalbumin (OVA) 
Primary –  100 µg, SC 
Secondary (14 days) – 100 µg, 
SC 
α-
galactosylceramide 
IgG1 
IgG2b 
Anti-OVA IgG1 Titer – 100,000 
Anti-OVA IgG2b Titer – 200 
Okazaki81 
Liposome Conalbumin (ConA) 
Primary –  20 µg, IV 
Secondary (21 days) – 20 µg, 
IV 
n/a 
IgG1 
IgG2a 
 (IV) Anti-ConA IgG1 Titer - 
131,072 
(IV) Anti-ConA IgG2a Titer - 
1024 
Shahum82 
Lipoplex 
Hen Egg Lysozyme 
(HEL) 
Primary – 50 µg, IP 
Secondary (10 days) - 50 µg, IP 
Tertiary (20 days) - 50 µg, IP 
CpG IgG Anti-HEL IgG Titer – 20,000 Kim69 
Liposome 
Human Serum 
Albumin (HSA)  
Primary – 240 ug, IV (Rabbits)  n/a IgG Anti-HSA IgG Titer ~ 65,536 
Van 
Rooijen83 
Merck Lipid 
Nanoparticles 
Hepatitis B Surface 
Antigen (HBsAg) 
Primary –  0.2 µg, IM 
Secondary (14 days) – 0.2 µg, 
IM 
n/a IgG Anti-HBsAg IgG Titer ~ 200 Thoryk84 
Multilamellar 
Vesicles 
Hepatitis B Surface 
Antigen (HBsAg) 
Primary – 0.25 µg, SC 
Secondary (10 days) - 0.25 µg, 
SC 
Tertiary (20 days) – 0.25 µg, SC 
Incomplete 
Freund’s Adjuvant  
IgG  
Anti-HBsAg IgG Titer - 10,000-
100,000 
Vangala85 
Liposome  
Recombinant  
Plasmodium vivax 
Circumsporozoite 
antigen 
Primary – 1 µg, SC 
Secondary (21 days) - 1 µg, SC 
MPLA IgG Anti-VMP IgG Titer – 200,000 Moon86 
pH-sensitive 
Liposome 
 HIV gp120 
V3 loop peptide 
(R15K) 
V3 loop peptide 
(T26K) 
Primary – 10-50 µg, IM 
Secondary (7 days) – 5-25 µg, 
IM 
n/a IgG 
Anti R15K IgG Titer – 800  
Anti T26K IgG Titer – 6,400 
Chang87 
Liposome 
HIV gp41 
MPER peptides  
Primary – 30 µg, ID 
Secondary (21 days) –  30 µg, 
ID 
Tertiary (42 days) –  30 µg, ID  
MPLA  IgG 
Anti-MPER-NH2 IgG Titer – 
75,000 
Anti-MPER-COOH IgG Titer – 
20,000 
Donius88  
Liposome 
Leishmania 
mexicana  
Surface Antigen 
(gp63)  
Lipophosphoglycan 
(LPG) 
Primary – 5 µg, SC, IP 
Secondary (4 weeks) – 5 µg, 
SC, IP 
Complete Freund’s 
Adjuvant  
IgG 
(SC) Anti-Leishmania IgG Titer 
– 323 
(IP) Anti-Leishmania IgG Titer – 
1080 
Russell80 
Liposome 
Mycobacterium 
Tuberculosis  
Mycobacterial 
fusion protein 
(Ag85B-ESAT-6)  
Primary – 2 µg, SC 
Secondary (14 days) – 2 µg, SC 
Tertiary (28 days) –  2 µg, SC 
Trehalose 6,6’-
dibehenate (TBD) 
IgG1 
IgG2b 
Anti-Ag85b-ESAT-6 IgG1 Titer –
15625 
Anti-Ag85b-ESAT-6 IgG2b Titer 
–3125 
Davidsen79 
Liposome 
Tetanus Toxoid 
(Ttd) 
Primary – 2 µg, IP 
Secondary (4 weeks) – 2 µg, IP 
n/a 
IgG  
IgE 
Anti-Ttd-IgG Titer - 4096 
Anti-Ttd-IgE Titer - 64 
Naito78 
Outer 
Membrane 
Vesicles 
Meningococcal B 
Neisseria 
meningitides 
Membrane Protein 
(PorA) 
Primary – 1.5 µg, SC 
Secondary (14 days) – 1.5 µg, 
SC 
Tertiary (28 days) – 1.5 µg, SC 
n/a 
IgG 
IgG1 
IgG2a 
IgG2b 
IgG3 
Anti-PorA IgG Titer - 2512 
Anti-PorA IgG1 Titer - 1445 
Anti-PorA IgG2a Titer - 1622 
Anti-PorA IgG2b Titer - 3311 
Anti-PorA IgG3 Titer - 741 
Arigita77 
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Liposome 
Meningococcal B 
Neisseria 
meningitides 
Membrane Protein 
(P1) 
Primary – 20 µg, SC 
Secondary (42 days) – 20 µg, 
SC 
n/a  
IgG + 
IgM 
Anti-P1 IgG + IgM Titer – 
100,000 
Muttilainen76 
Virus Mimetic 
Nanovesicles 
Avian Influenza  
H1N1, 
Hemagglutinin 
Primary – 100 µg, IM 
Secondary (14 days) – 100 µg, 
IM 
Tertiary (28 days) – 100 µg, IM 
Alum  IgG Anti-HA IgG Titer – 1,000 Zhang75 
Virus Mimetic 
Nanovesicles 
Human 
Papillomavirus 
L2 Capsid, peptide  
Primary – 1.33 ug, IM 
Secondary (14 days) – 1.33 µg, 
IM 
Tertiary (28 days) – 1.33 µg, 
IM 
Alum  IgG Anti-L2 IgG Titer – 10,000 Zhang254 
Liposome 
Histone H3 
C-terminal peptide 
Primary – 60 µg, IP 
Secondary (21 days) – 60 µg, 
IP 
Tertiary (42 days) – 60 µg, IP 
MPLA IgG Anti-H3 IgG Titer - 1600 Friede74 
Liposome 
Human Synthetic 
Mucin MUC1 
Peptide (BP25) 
Primary – 5 µg, FP 
Secondary (14 days) – 5 µg, IP 
MPLA 
IgG 
IgM 
Anti-MUC1 IgG Titer - 6400 
Anti-MUC1 IgM Titer - 1600 
Guan68 
Liposome Dextran 
Primary – 125 µg, SC 
Secondary (21 days) – 125 µg, 
SC 
n/a IgG Anti-Dextran IgG Titer - 512 Sarkar73 
Liposome 
Lipopolysaccharide 
(LPS) 
Primary – 50 µg, IP n/a IgG 
Anti-LPS IgG Titer – 30,000-
35,000 
Nakhla72 
Lipid  
Nickel  
Nanocapsule 
HIV, Gag p41 
protein 
Primary – 1 µg, SC 
Secondary (14 days) – 1 µg, SC 
n/a IgG 
Anti-Gag p41 IgG Titer – 5,000-
10,000 
Wadhwa71 
Nickel-  
Lipid 
Nanoparticle 
HIV, Tat protein 
Primary – 1.5 µg, SC 
Secondary (14 days) – 1.5 µg, 
SC 
n/a 
IgG 
IgG1 
IgG2a 
Anti-Tat IgG Titer – 105-106 
Anti-Tat IgG1 Titer – 105-106 
Anti-Tat IgG2a Titer – 105 
Yan70 
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Table 1.2: Inorganic Nanoparticles for Antibody Production  
 
Nanoparticle 
Type: Application - Antigen 
Immunization Scheme 
(Dose, Interval, Route) Adjuvant Isotype 
Antibody Production: 
Absolute Amount, Titer, 
OD/D.F. 
Author 
Gold  
Bovine Serum 
Albumin (BSA) 
Primary – 1.2 µg, IP 
Secondary (14 days) – 1.2 µg, IP 
Tertiary (28 days) – 1.2 µg, IP 
Quaternary (42 days) –1.2 µg, IP 
CpG IgG Anti-BSA IgG Titer – 15,360 Dykman60 
Gold 
West Nile Virus  
Envelope Protein 
(WNVE) 
Primary – 0.1 µg, IP 
Secondary (21 days) – 0.1 µg, IP 
Tertiary (42 days) – 0.1 µg, IP 
n/a IgG Anti-WNVE IgG Titer – 1200 Niikura92 
Gold 
Foot and Mouth 
Disease Virus Peptide 
(FMD) 
Primary – 6.25 µg, SC 
Secondary (10 days) – 6.25 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG Anti-FMD IgG Titer – 16,384 Dykman96 
Gold 
Foot and Mouth 
Disease Virus Peptide 
(FMD) 
Dose: unknown 
Schedule: 7 injections over 9 weeks  
Route: IP or SC  
Complete 
Freund’s 
Adjuvant  
IgG Anti-FND IgG Titer – 60,000 Chen255 
Gold 
Malaria  
Plasmodium 
falciparum (Pfs230) 
Primary – 10 µg, IM 
Secondary (21 days) – 10 µg, IM 
Tertiary (42 days) – 10 µg, IM 
Alum IgG Anti-Pfs230 IgG Titer – 640,000 Kumar101 
Gold 
Streptococcus 
pneumonia type 14 
capsular 
polysaccharide 
(Pn14PS) 
Primary – 3 µg, SC 
Secondary (5 weeks) – 3 µg, SC 
Tertiary (10 weeks) – 3 µg, SC 
MPLA 
Quil-a 
IgG 
IgG1 
IgG2a 
IgG2b 
IgG3 
Anti-Pn14PS IgG Titer - 50 
Anti-Pn14PS IgG1 Titer - 100 
Anti-Pn14PS IgG2a Titer – 0  
Anti-Pn14PS IgG2b Titer - 10 
Anti-Pn14PS IgG3 Titer - 50 
Dodi Safari100 
Gold 
Pseudomonas 
aeruginosa 
Flagellin  
Primary – 10 µg, SC 
Secondary (14 days) – 10 µg, SC 
Tertiary (28 days) – 10 µg, SC 
n/a IgG Anti-Flagellin IgG Titer - 1000 Dakterzada99 
Gold Diminazene (DMZ) 
Primary – 100 µL, SC 
Secondary (14 days) – 100 µL, SC 
Tertiary (28 days) – 100 µL, SC 
Quaternary (42 days) –100 µL, SC 
Complete 
Freund’s 
Adjuvant  
IgG Anti-DMZ IgG Titer - 512 Staroverov98 
Gold Clenbuterol (CBL) 
Primary – 12.5 µg, SC 
Secondary (14 days) – 12.5 µg, SC 
Tertiary (28 days) – 12.5 µg, SC 
Quaternary (42 days) –12.5 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG Anti-CBL IgG Titer – 256 Vasilenko97 
Mesoporous 
Silica 
Ovalbumin (OVA) 
Primary – 10 µg, SC 
Secondary (14 days) – 10 µg, SC 
Tertiary (28 days) – 10 µg, SC 
n/a IgG Anti-OVA IgG Titer - 6400 Mahony114 
Silica  
H1N1 Influenza 
Hemagglutinin 
Antigen (HAC1) 
Primary – 10 µg, IT 
Secondary (21 days) – 10 µg, IT 
c-di-GMP 
IgG 
IgA 
Anti-HAC1 IgG Titer – 100-1000 
Anti-HAC1 IgA Titer – 100-1000 
Neuhaus119 
Mesoporous 
Silica 
Micrurus ibiboboca 
Snake Venom  
Primary – 10 µg, SC n/a IgG Anti-Venom IgG Titer - 588 Mercuri120 
Iron-Oxide 
Malaria  
Merozoite Surface 
Protein  
(rMSP1) 
Primary – 16 µg, IM, SC, IP 
Secondary (21 days) – 16 µg, IM, SC, 
IP 
Tertiary (42 days) – 16 µg, IM, SC, IP 
n/a IgG 
(IM) Anti-rMSP1 IgG Titer – 104-
105 
(SC) Anti-rMSP1 IgG Titer – 102-
103 
(IP) Anti-rMSP1 IgG Titer – 103-
104 
Pusic145 
Carbon 
Nanotubes 
Foot and Mouth 
Disease Viral Peptide 
(FMDV) 
Primary – 100 µg, IP 
Secondary (14 days) – 100 µg, IP 
Complete 
Freund’s 
Adjuvant  
IgG Anti-FMDV IgG Titer – 10,000 Pantarotto132 
Carbon 
Nanotube 
Azoxystrobin (AZc6) 
Primary – 5 µg, SC 
Secondary (21 days) – 5 µg, SC 
Tertiary (42 days) – 5 µg, SC 
Quaternary (63 days) –5 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG 
Anti-AZc6 IgG Titer – 1000-
10,000 
Parra61 
Multi-walled 
Carbon 
Nanotube 
Ovalbumin (OVA) 
Primary – 100 µg, IV 
Secondary (7 days) – 100 µg, IV 
Complete 
Freund’s 
Adjuvant  
IgG 
IgG1 
Anti-OVA IgG Titer - 2000 
Anti-OVA IgG1 Titer - 2000 
Grecco131 
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Table 1.3: Synthetic Polymeric Nanoparticles for Antibody Production  
 
Nanoparticle 
Type: 
Application - 
Antigen 
Immunization Scheme 
(Dose, Interval, Route) Adjuvant Isotype 
Antibody Production: 
Absolute Amount, Titer, 
OD/D.F. 
Author 
PLGA Ovalbumin (OVA) 
Primary – 25 µg, IM 
Secondary (14 days) – 25 µg, IM 
Tertiary (28 days) – 25 µg, IM 
n/a IgG Anti-OVA IgG Titer – 50,000 Zhang167 
PLGA Ovalbumin (OVA) 
Primary – 25 µg, IM 
Secondary – 25 µg, IM 
MPLA + 
R837 
IgG1 
IgG2a 
IgG2b 
Anti-OVA IgG1 Titer – 95,000  
Anti-OVA IgG2a Titer – 
110,000  
Anti-OVA IgG2b Titer – 
110,000 
Kasturi166 
PLGA 
Anthrax 
Protective Antigen 
Domain (PAD4) 
Primary – 100 µg, route not reported n/a IgG Anti-PAD4 IgG Titer – 310,000 Manish163 
Lipid-Coated 
PLGA 
Malaria antigen 
(VMP001) 
Primary – 2.5 µg, SC 
Secondary (21 days) – 2.5 µg, SC 
MPLA IgG Anti-VMP IgG Titer – 105-106 Moon158 
PLGA 
PMMA 
Clenbuterol (CBL) Primary – 25 µg, SC n/a IgG 
(PLGA) Anti-CBL IgG Titer - 
1414 
(PMMA) Anti-CBL IgG Titer - 
1682 
Rodgers165 
Polyanhydride Ovalbumin (OVA) Primary – 100 µg, SC, PO Flagellin 
IgG1 
IgG2a 
(SC) Anti-OVA IgG1 Titer – 512 
(SC) Anti-OVA IgG2a Titer – 
512 
(PO) Anti-OVA IgG1 Titer – 128  
(PO) Anti-OVA IgG2a Titer – 
128  
Salman164 
Polyanhydride 
Anthrax,  
Protective Antigen 
(PA) 
Primary – 10 µg, SC 
Secondary (15 days) – 10 µg, SC 
n/a IgG Anti-PA IgG Titer – 105-106 Petersen181 
Polyanhydride HIV, gp41 protein 
Primary – 500 µg, SC 
Secondary (7 days) – 500 µg, SC 
Tertiary (14 days) – 500 µg, SC 
n/a IgG 
Anti-gp41 IgG Titer – 100 -
1,000 
Vela-
Rameriz182 
Polyanhydride 
H5N1 Avian 
Influenza 
H5 Hemagglutinin 
trimer 
Primary – 10 µg, SC 
Secondary (21 days) – 10 µg, SC 
Tertiary (42 days) – 10 µg, SC 
Poly I:C IgG Anti-H5 IgG Titer - 100-1,000 Ross183 
Polyanhydride 
Yersinia pestis  
F1-V protein 
Primary – 50 µg, IN n/a IgG Anti-F1-V IgG Titer – 104-105 Ulery185 
Polyanhydride 
Pneumococcal 
Surface Protein A 
(PspA) 
Primary – 25 µg, SC n/a IgG 
Anti-PspA IgG Titer – 15,000-
20,000 
Haughney256 
Polypropylene 
Sulfide 
Ovalbumin (OVA) 
Primary – 10 µg, IN 
Secondary (7 days) – 10 µg, IN 
Tertiary (21 days) – 10 µg, IN 
Flagellin 
IgG 
IgA 
Anti-OVA IgG Titer – 105-107  
Anti-OVA IgA Titer – 1000 
Stano257 
Guanidinylated 
Cationic  
Polymer 
Ovalbumin (OVA) 
Primary – 80 µg, ID 
Secondary (7 days) – 80 µg, ID 
Tertiary (14 days) – 80 µg, ID 
n/a 
IgG 
IgG1 
IgG2a 
Anti-OVA IgG Titer – 800,000  
Anti-OVA IgG1 Titer – 3,750  
Anti-OVA IgG2a Titer – 
900,000 
Li258 
pH-responsive 
Block Co-
Polymer 
Ovalbumin (OVA) 
Primary – 25 µg, ID 
Secondary (21 days) – 25 µg, ID 
CpG 
IgG1 
IgG2c 
Anti-OVA IgG1 Titer – 106-107 
Anti-OVA IgG2c Titer – 104-105 
Wilson259 
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 Table 1.4: Biologically-Derived Polymeric Nanoparticles for Antibody Production  
 
Nanoparticle 
Type: Application - Antigen 
Immunization Scheme 
(Dose, Interval, Route) Adjuvant Isotype 
Antibody Production: 
Absolute Amount, Titer, 
OD/D.F. 
Author 
Chitosan-
Polylysine 
Ovalbumin (OVA) 
Primary – 25 µg, SC 
Secondary (7 days) – 25 µg, SC 
Tertiary (14 days) – 25 µg, SC 
CpG IgG Anti-OVA IgG Titer – 65,536 Han199 
Chitosan Ovalbumin (OVA) 
Primary – 20 µg, IN 
Secondary (7 days) – 20 µg, IN 
Tertiary (14 days) – 20 µg, IN 
CpG IgG Anti-OVA IgG Titer – 10,000 Slutter193 
Alginate-
coated 
Chitosan 
Hepatitis B Surface Antigen 
(HBsAg) 
Primary – 10 µg, SC 
Secondary (21 days) – 10 µg, SC 
CpG 
IgG 
IgG1 
IgG2a 
Anti-HBsAg IgG Titer – 3293 
Anti-HBsAg IgG1 Titer – 2953 
Anti-HBsAg IgG2a Titer - 1992 
Borges198 
Glycol 
Chitosan 
Hepatitis B Surface Antigen 
(HBsAg) 
Primary – 10 µg, IN 
Secondary (21 days) – 10 µg, IN 
n/a 
IgG 
IgA 
Anti- HBsAg IgG Titer – 100,000 
Anti- HBsAg IgA Titer – 10,000 
Pawar196 
Chitosan H1NI Avian Influenza 
Primary – 0.375 µg, SC 
Secondary (20 days) – 0.375 µg, SC 
n/a n/a HI Titer – 4,000 Dzung202 
Chitosan 
Pneumococcal Type 12 
Polysaccharide (Pn14PS) 
Primary – dose unknown, ID 
Secondary (35 days) – dose 
unknown, ID 
n/a 
IgG 
IgG1 
IgG2a 
IgG2b 
IgG3 
Anti-Pn14PS IgG Titer - 100 
Anti- Pn14PS IgG1 Titer – 500-
5000 
Anti- Pn14PS IgG2a Titer – 500-
1000 
Anti- Pn14PS Ig2b Titer – 100-
1000 
Anti- Pn14PS IgG3 Titer - 100 
Haryono197 
Chitosan 
Escherichia coli 
Recombinant protein (EIT)  
Primary – 20 µg, IN 
Secondary (28 days) – 20 µg, IN 
Tertiary (42 days) – 20 µg, IN 
n/a 
IgG 
IgA 
Anti-EIT IgG Titer – 20,480 
Anti-EIT IgA Titer – 20,480 
Doavi201 
Chitosan 
Anthrax,  
Protective Antigen (PA) 
Primary – 20 µg, SC, IM, IP 
Secondary (7 days) – 20 µg, SC, IM, 
IP 
Tertiary (15 days) – 20 µg, SC, IM, 
IP 
CpG IgG 
(SC) Anti-PA IgG Titer – 200,000 
(IM) Anti-PA IgG Titer – 175,000 
(IP) Anti-PA IgG Titer – 150,000 
Malik192 
Chitosan 
Borthops jaraca (BJV) 
Borthops erythromelas 
(BEV) 
Snake venom 
Primary x 6 (1 per week) – 100 µL, 
SC 
n/a IgG 
Anti-BJV IgG Titer – 102,400 
Anti-BEV IgG Titer – 102,400 
Rocha 
Soares200, 
260 
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Table 1.5: Virus-Like Nanoparticles for Antibody Production 
 
Nanoparticle 
Type: 
Application - 
Antigen 
Immunization Scheme 
(Dose, Interval, Route) Adjuvant Isotype 
Antibody Production: 
Absolute Amount, Titer, 
OD/D.F. 
Author 
T7 
Bacteriophage 
Influenza A Virus 
M2 Protein (M2e)  
Primary – 100 µg, SC 
Secondary (14 days) – 100 µg, SC 
Tertiary (28 days) – 100 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG 
IgG1 
IgG2a 
Anti-M2e IgG Titer -100,000 
Anti-M2e IgG1 Titer -100-1000 
Anti-M2e IgG2a Titer -100,000 
Hashemi218 
Papaya 
Mosaic Virus 
Influenza A Virus 
M2 Peptide (M2e) 
Primary – 90 µg, IM 
Secondary (14 days) – 90 µg, IM 
n/a 
IgG 
IgG2a 
Anti-M2e IgG Titer -51,200 
Anti-M2e IgG2a Titer -
51,200 
Therien232 
Influenza 
Virus-Like 
Particle 
Influenza 
Hemagglutinin (HA) 
Primary – 1 µg, IM, IN 
Secondary (14 days) – 1 µg, IM, IN 
IL-12 n/a 
(IM) Anti-HA Titer - 3250 
(IN) Anti-HA Titer - 6000 
Galarza231 
Influenza 
Virus-Like 
Particle 
H9N2 Influenza  
Hemagglutinin (HA) 
Primary – 15 µg, IM 
Secondary (21 days) – 15 µg, IM 
Novasome n/a Anti-HA Titer - 1338 Pushko230 
Influenza 
Virus-Like 
Particle 
H7N9 Influenza  
Hemagglutinin (HA) 
Primary – 2 µg, IM 
Secondary (14 days) – 2 µg, IM 
Iscomatrix n/a Anti-HA Titer – 100-1000 Smith261 
Plant Virus 
HIV-1 
gp41 peptide 
Primary – 100 µg, SC 
Secondary (35 days) – 100 µg, SC 
Alum IgG 
Anti-gp41 IgG Titer – 30,000-
50,000 
McLain228 
Papaya 
Mosaic Virus 
HIV-1  
T20 peptide 
Primary – 90 µg, IM 
Secondary (14 days) – 90 µg, IM 
n/a 
IgG 
IgG2a 
Anti-T20 IgG Titer -25,600 
Anti-T20 IgG2a Titer -25,600 
Therien232 
Hepatitis B 
Virus 
Hepatitis B Surface 
Antigen (HBsAg) 
Peptide 
Primary – 20 µg, IV n/a 
IgG 
IgM 
Anti-HBsAg IgG Titer – 10,240 
Anti-HBsAg IgM Titer - 160 
Jegerlehner215 
Hepatitis B 
Virus 
Hepatitis B Virus 
Core Protein (HBc) 
Primary – 25 µg, IP, SC 
Secondary (14 days) – 25 µg, IP, SC 
Tertiary (28 days) – 25 µg, IP, SC 
Complete 
Freund’s 
Adjuvant  
IgG 
(IP) Anti-HBc IgG Titer – 
350,000 
(SC) Anti-HBc IgG Titer – 
350,000 
Skrastina111 
Glycoprotein 
Virus-Like 
Nanoparticles 
Respiratory 
Syncytial Virus 
(RSV) 
Primary – 10 µg, IM 
Secondary (28 days) – 10 µg, IM 
n/a 
IgG 
IgG1 
IgG2a 
Anti-RSV IgG Titer –25,600 
Anti-RSV IgG1 Titer –6,400 
Anti-RSV IgG2a Titer -25,600 
Lee227 
Coronavirus 
Middle East 
Respiratory 
Syndrome (MERS)  
Primary – 3 µg, IM 
Secondary (21 days) – 3 µg, IM 
Matrix M1 n/a Anti-MERS Titer - 1689 Coleman226 
Coronavirus 
Severe Acute 
Respiratory 
Syndrome (SARS)  
Primary – 3 µg, IM 
Secondary (21 days) – 3 µg, IM 
Matrix M1 n/a Anti-SARS Titer - 3152 Coleman226 
Enterovirus 71 
Hand Foot and 
Mouth Disease 
Virus (HFMDV) 
Primary – 10 µg, SC 
Secondary (14 days) – 10 µg, SC 
Tertiary (28 days) – 10 µg, SC 
Alum IgG 
Anti-HFMDV IgG Titer – 
32,768 
Li225 
Bacteriophage 
Qb 
Alzheimer’s 
Disease 
Human β-Amyloid 
Peptide (AB) 
Primary – 11.2 µg, IM 
Secondary (14 days) – 11.2 µg, IM 
Tertiary (28 days) – 11.2 µg, IM 
Complete 
Freund’s 
Adjuvant  
IgG Anti-AB IgG Titer - 105-106 Chackerian223 
Human 
Papillomavirus 
TNF-alpha peptide 
Primary – 15 µg, ID 
Secondary (14 days) – 15 µg, ID 
Tertiary (28 days) – 15 µg, ID 
Complete 
Freund’s 
Adjuvant  
IgG 
Anti-TNF-alpha IgG Titer – 54-
105 
Chackerian224 
Tobacco 
Mosaic Virus 
(Steroid) Estriol 
(E3)  
Primary – 1 µg, SC 
Secondary (14 days) – 1 µg, SC 
Tertiary (28 days) – 1 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG 
Anti-E3 IgG Titer – 250,000-
300,000 
Zhao222 
Tobacco 
Mosaic Virus 
(Steroid) Estriol 
(E3)  
Primary – 50 µg, SC 
Secondary (14 days) – 50 µg, SC 
Tertiary (28 days) – 50 µg, SC 
Complete 
Freund’s 
Adjuvant  
IgG 
Anti-E3 IgG Titer – 100,000-
150,000 
Wei219 
Bacteriophage 
Qb 
Nicotine 
Primary – 60 µg, SC 
Secondary (14 days) – 60 µg, SC 
Alum IgG 
Anti-Nicotine IgG Titer – 
300,000-400,000 
Maurer220 
Bacteriophage 
Qb 
Tumor-associated 
Carbohydrate 
Antigen (TACA) 
Primary – 20 µg, SC 
Secondary (14 days) – 20 µg, SC 
Tertiary (28 days) – 20 µg, SC 
n/a 
IgG 
IgM 
Anti-TACA IgG Titer – 5000 
Anti-TACA IgM Titer - 1600 
Yin221 
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Table 1.6: Viral Mimic Material Properties and Functional Role 
 
Material Property Parameter or Descriptor Functional Role 
Particle Size 20-300 nm Lymph node delivery 
Particle Shape (aspect ratio) Spheres and rods  Biodistribution, cellular uptake 
Surface Properties Negative charge, hydrophilic Lymph node delivery 
Antigen Density >150 molecules/µm2 B-cell receptor crosslinking 
Antigen Display Surface presentation B-cell receptor engagement 
Antigen Organization Geometric pattern with defined spacing intervals PAMP 
Surface Topography Rough Cellular uptake 
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CHAPTER 2 
 
Engineering Inorganic Virus-Like Nanoparticles with Viral 
Structural and Functional Mimicry for Lymph Node Homing, 
B-cell Activation and Enhanced Antigen-Specific Antibody 
Production 
 
2.1 Abstract:  
 
Virus-like nanoparticles (VLN) are an alternative to viruses as a delivery strategy. 
However, engineering of VLNs is limited by the difficulty of incorporating viral mimicry. Here, we 
generated inorganic VLNs (IVLN), which mimic viral structure and function for lymph node 
homing, B-cell activation, and antigen-specific antibody production. The IVLNs were 
synthesized with viral-like spiky topography using Au@Fe hybrid nanoparticle technology. Hubs 
of antigen were controlled at viral-like densities of 20,000-25,000 molecules/um2 with display 
organization in a 3D patch pattern at ~6 nm intervals critical for B cell receptor crosslinking. 
IVLNs have unique viral-like functions to improve lymph node homing and distribution into 
subcapsular sinus macrophages and B-cells by 3-fold, facilitate 6-fold enhanced of B cell 
activation, and 4 to 18-fold antigen specific IgG production with prophylactic anti-cancer efficacy 
against HER2+ breast cancer in mice. The IVLN with viral-like structure and function may have 
broad applications to modulate immune responses. 
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2.2 Introduction:  
 
Viruses are known to be the most efficient delivery vehicles to generate efficacious 
immunological responses1,2. Therefore, it has become desirable to utilize viruses in a wide 
variety of application such as vaccines, antibody production and gene delivery3-5. However, the 
use of traditional live attenuated or heat-killed viruses as a delivery tool is challenging due to 
their safety profiles, difficulty in manufacturing and associated non-specific immune responses6-
8. Accordingly, alternative approaches have been developed to exploit the structural feature of 
viruses while minimizing these concerns.   
To replace traditional viruses, virus-like particles (VLP) have emerged as delivery 
vehicles for many applications9. VLPs are protein-based nanoparticles that are composed of 
viral capsid proteins that self-assemble into geometrically rigid three-dimensional nanospheres 
that directly resemble viral structure and confirmation without the viral genome10,11. Thus, VLPs 
are considered a viable and safe alternative to traditional viruses12. VLPs are especially 
advantageous as B-cell vaccine for viral vaccines13,14. For instance, clinically human 
papillomavirus (HPV) VLP vaccines using HPV L1 capsid proteins widely used to prevent HPV 
infection15-17. Several other VLP vaccines have been made to prevent infections including an 
FDA-approved vaccine for hepatitis B virus, as well as vaccines for influenza, norovirus and 
chikungunya virus currently undergoing clinical trials18-21.  However, numerous obvious 
disadvantages of VLPs formulation and usage remain. First, it is very difficult to reproducibly 
and controllably synthesize and manufacture VLPs due to a reliance on viral capsid protein self-
assembly within an expression host for particle formation22,23. Second, VLPs are known to 
strongly activate B-cells to generate antibodies against capsid proteins, which is the very 
purpose VLPs as vaccines to prevent viral infections, However, if the immunity is intended to be 
directed against other proteins or peptides conjugated to the VLP carrier, this anti-carrier 
response dramatically limits the specificity and strength of the intended immune response24,25.  
As a result of the challenges associated with the use of VLPs, there has been increasing 
interest in the development of novel nanoparticle systems that mimic viral-like structure and 
function1,26-28. To date, the most traditional approaches in the development of viral mimicry 
nanoparticles for the delivery of antigens include the use of liposomes, polymeric nanoparticles 
and inorganic nanoparticles29-32. Indeed, these nanoparticles have been extensively evaluated in 
both the context of drug delivery and vaccine development and have been found to more 
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efficaciously stimulate B-cell and T-cell immunity as compared to soluble antigens. However, 
these traditional nanoparticle systems do not ideally represent viral-like structure and material 
properties, nor do they exhibit any viral-like function to stimulate the immune response.  
To engineer an authentic viral mimicking nanoparticle system, which is not only 
representative of viral-like structure, but also function, a more holistic design approach needs to 
be considered.  This viral mimicking nanoparticle system needs to have viral-like surface 
topography, antigen density and antigen display organization, which is very difficult to achieve 
with traditional nanoparticle technologies. In addition to complex design elements, the viral 
mimicking nanoparticle system must also have appropriate particle size, surface charge and 
antigen immunogenicity which is rather easy to achieve with any nanoparticle system. 
In this study, we surmised a holistic approach to viral mimicking nanoparticle design 
through the development of an inorganic virus-like nanoparticle (IVLN) technology that mimics 
viral structure and function. This technology is based on a hybrid Fe@Au core/satellite 
nanoparticle technology, which is composed of ultra-small gold nanosatellites (AuNP, 2-3 nm) 
anchored to an iron-oxide nanoparticle core (IONP, 15-20 nm). These nanosatellites provide 
viral-like spiky and rough surface topography. The overall size of the IVLN is 20-30 nm under 
transmission electron microscopy (TEM) with a hydrodynamic size of 60-70 nm by dynamic light 
scattering (DLS). The antigen display density was controlled to be greater than 10,000 
molecules per micron squared (2,000 peptides per IVLN). Antigen display organization and 
surface topography were controlled in a patch pattern with ~6 nm distance between clusters, 
which may be critical for B-cell receptor crosslinking and robust activation33. Based on these 
material design parameters, our IVLN incorporates unique structural features including spiky 
surface topography, high antigen density and patterned antigen display that are more virally 
relevant and significantly distinctive from any other current inorganic nanoparticle technology34-
38. Additionally, we tested IVLN viral-like function in terms of lymph node homing, lymph node 
immune cell uptake and specific distribution39, as well as the ability to facilitate robust 
stimulation of B-cell immunity in an antigen-specific fashion. As compared to a traditional 
nanoparticle system, our IVLN proved to have the viral-like functional to improve lymph node 
homing (3-fold), increase B-cell specific interactions (3-fold), to promote antigen-specific B-cell 
proliferation (6-fold) and germinal center formation (3-fold), and to enhance antigen-specific IgG 
antibody production (4 to 18-fold) that function to prevent cancer growth in a mouse model of 
HER2+ breast cancer. Taken together, these data suggest that the IVLN both effectively mimics 
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viral-like structure and exhibits viral-like function, which may have broad applications as a 
delivery technology to boost antigen-specific immunity.  
 
2.3 Experimental Section:  
 
Materials. All reagents were used as obtained from commercial sources without further 
purification, except for γ-Methacryl oxypropyltrimethoxysilane (98%) that was purified by 
distillation under reduced pressure and 2,2-Azobis(isobutyronitrile) (98%) that was purified by 
recrystallization in ethanol. Iron oxide (III) (FeO(OH), hydrated, catalyst grade, 30−50 mesh), 
oleic acid (technical grade, 90%), ammonium iron (II) sulfate hexahydrate (ACS reagent, 99%), 
1-octadecene (technical grade, 90%), anhydrous tetrahydrofuran (THF, 99.8%), carbon disulfide 
(99.9%), magnesium turnings (>99.5%), 2-chloro-2-phenylacetyl chloride (CPAC, 90%), 
poly(ethylene oxide) monomethyl ether (PEO), anhydrous dioxane (99.8%), dimethylformamide 
(DMF, 99.9%), dimethyl sulfoxide (DMSO, 99.9%), o-phenanthroline monohydrate (ACS 
reagent, 99%), hydroquinone (ACS reagent, 99%, sodium sulfide, chloroauric acid, nitric acid 
(ACS reagent, 70%), and hydrochloric acid (ACS reagent, 37%) were purchased from Sigma-
Aldrich. Mouse uncoated IgG and IgM Total ELISA Ready-SET-Go! Kits, 1-Step Ultra TMB-
ELISA substrate solution, HRP-conjugated goat anti-mouse IgG1 secondary antibody, HRP-
conjugated goat anti-mouse IgG2a secondary antibody, Nunc Immobilizer Amino 96-well ELISA 
plates, BupH carbonate bicarbonate buffer packs (coating buffer), Pierce protein free PBS 
tween blocking buffer, 20x PBS-tween wash buffer, Geneticin (G418) selective antibiotic, 
Invitrogen eBioscience fixable viability dye eFluor 780, and Molecular Probes streptavidin Alexa 
Fluor 647 conjugate were obtained from Thermo Fisher Scientific.  HRP conjugated goat anti-
mouse IgG secondary antibody, Zombie UV fixable viability kit, FITC anti-mouse CD19, 
PE/Dazzle 594 anti-mouse IgD, Alexa Fluor 647 anti-mouse/house GL7 antigen, Brilliant Violet 
421 and PE/Dazzle 594 anti-mouse/human CD45R/B220, FITC anti-mouse CD95, Brilliant 
Violet 421 anti-mouse/human CD11b, FITC anti-mouse CD169 and PE goat anti-mouse IgG 
secondary antibody were purchased from BioLegend. HER2 peptides 
(CDDDPESFDGDPASNTAPLQPEQLQ, Biotin-PESFDGDPASNTAPLQPEQLQ, 
CDDDPESFDGDPASNTAPLQPEQLQGGGK) were custom synthesized by LifeTein. 30 nm 
iron-oxide nanoparticles cores stabilized by oleic acid in chloroform were purchased from Ocean 
Nanotech. DSPE-PEG(2000) and DSPE-PEG(2000)maleimide were obtained from Avanti Polar 
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Lipids. 2’3’-cGAMP was acquired from InvivoGen. Fluorescamine was purchased from MP 
Biomedicals. Sulfo-Cy5.5 NHS ester was acquired from Lumiprobe. Microvette 500 Z-Gel serum 
collection vials with clotting factor were obtained from Sarstedt. Matrigel Basement Membrane 
Matrix was purchased from Corning. Gold and iron ICP standards were purchased from Fluka 
Analytical.  
Mice. All animal experiments were conducted according to the protocols approved by the 
University of Michigan Committee on Use and Care of Animals (UCUCA). BALB/c mice ages 5-
7 weeks were purchased from Charles River Labs. 
Cells. All cells were maintained at 37C, 5% CO2/95% air atmosphere and approximately 85% 
relative humidity. D2F2/E2 cells (provided by Dr. Wei-Zen Wei40) were cultured in complete 
DMEM high glucose supplemented with 10% NCTC 109 media, 1% L-glutamine, 1% MEMs 
non-essential amino acids, 0.5% sodium pyruvate, 2.5% sodium bicarbonate, 1% pen/strep, 5% 
cosmic calf serum, 5% fetal bovine serum, 500 µg/mL Geneticin and 50 µM 2-mercaptoethanol. 
RAW264.7 macrophages were cultured in complete RPMI-1640 media supplemented with 10% 
fetal bovine serum, 1% L-glutamine, 1% MEMs non-essential amino acids, 1% sodium pyruvate 
and 1% pen/strep. Primary B-cells were cultured in RPMI-1640 media supplemented with 10% 
heat-inactivated fetal bovine serum.  
Formulation and Characterization of Inorganic Virus-Like Nanoparticles (IVLN). The IVLN 
was formulated based on previously reported protocols by our group with minor modifications41. 
The final Au to Fe ratio of the formulated IVLN was quantified by inductively coupled plasma 
mass spectrometry (ICP-MS) using a Perkin-Elmer Nexion 2000 based on previously reported 
protocols modified from analysis by ICP-OES42. IVLN formulations were imaged by transmission 
electron microscopy (TEM) using the JEOL 3011 High Resolution Electron Microscope. The true 
particle size of AuNPs, IONPs and IVLNs was quantified using ImageJ software. The volume-
weighted hydrodynamic particle size, polydispersity index and zeta-potential of all formulations 
in milliQ water at 25°C was evaluated with the Malvern Zetasizer Nano-ZS using dynamic light 
scattering and phase analysis light scattering, respectively.  
Lipid-Coated Iron-Oxide Nanoparticle Formulations (IONP). Lipid-coated iron-oxide 
nanoparticles were prepared based on previously reported methods for thin-film hydration with 
minor modifications43,44. 10 mg of DSPE-PEG(2000)-maleimide was added to 1 mg of 30-nm 
iron-oxide nanoparticle cores stabilized by oleic acid in chloroform as gently mixed. The 
resulting solution was subjected to solvent rotary evaporation to remove all chloroform and form 
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a thin film. Simultaneously, this film and 100 mM PBS, pH 7.4 were heated to 75°C in an oven. 
Upon reaching temperature, hot PBS was rapidly added to the film and mixed immediately and 
vigorously to facilitate thin film hydration. The resulting nanoparticle solution was stored at 4°C 
to promote lipid self-assembly. Free phospholipid was removed by magnetic separation 
overnight at 4°C using the EasySep magnetic separator device (StemCell).  
IONP-HER2 and IVLN-HER2 Formulations. HER2 peptides were conjugated to both IONP 
and IVLN through thiol-mediated chemistries. Specifically, IONP-HER2 was formulated via 
maleimide chemistry and IVLN-HER2 was formulated via the gold-thiol linkage. HER2 peptide 
was added to IONP at 1.5x weight ratio excess in milliQ and incubated overnight at 4°C. HER2 
peptide was added to IVLN-HER2 at 5x weight ratio excess in milliQ and incubated overnight at 
4°C. Both materials were purified either by magnetic separation overnight at 4°C using magnetic 
separation, or by centrifugal separation at 10,000 x g for 30 minutes at 4°C. Peptide loading was 
determined using fluorescent quantification using a modified fluorescamine peptide 
quantification assay in the presence of nanoparticles (Ex/Em: 390/465 nm, Biotek Cytation 5)45. 
Quantification was performed using a standard curve with increasing peptide concentration with 
standardized concentration of nanoparticles (IONP or IVLN) to account for quenching effects.  
Immunizations and Serum Collection. At day 0, mice were immunized with the equivalent of 
50 µg or 5 µg of HER2 peptide plus 10 µg of cGAMP regardless of formulation type. 
Subsequently, at day 14, mice were boosted twice at two-week intervals with 50% of the original 
dosage for both antigen and adjuvant (day 14 and 28). To evaluate serum antibody titers, blood 
was collected by submandibular puncture 10 days after each immunization (day 10, 24 and 38). 
Serum was separated from whole blood by centrifugal separation at 10,000 x g for 5 minutes at 
25°C using the Microvette 500 Ser-Gel collection vessels with clotting activator.  
Enzyme-Linked Immunosorbent Assay (ELISA). Absolution quantification of total IgG and 
total IgM antibody analysis was performed using the mouse uncoated total IgG and total IgM 
ELISA kits based on manufacturer recommended protocols (Thermo Fisher). Antigen-specific 
IgG, IgG1 and IgG2a antibody titers were quantified based on previously established protocols 
for indirect ELISA with minor modifications46. Specifically, HER2 peptides (200 µL, 100 ug/mL in 
100 mM carbonate buffer, pH 9.4) were chemically conjugated to ELISA plates through the 
terminal amine group utilizing Nunc Immobilizer Amino immunoassay plates by overnight 
incubation with exposure to light at room temperature. Following overnight incubation, ELISA 
plates were washed three times with 100 mM PBS, pH 7.4 with 2% Tween-20. Subsequently, 
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ELISA plates were blocked overnight at 4°C with 300 µL of ELISA blocker (Pierce Protein-Free 
PBS Blocking Buffer). Following blocking, the ELISA plates were washed 3x. Serum samples 
containing primary antibodies were serially diluted (101-108 fold) using 100 mM PBS, pH 7.4 
containing 10% ELISA blocker reagent and added to each well at 200 µL total for 2 hour 
incubation at room temperature. Following sample addition, the ELISA plates were washed 3x. 
500-fold diluted A\anti-IgG-HRP, anti-IgG1-HRP, or anti-IgG2a-HRP was added at 100 µL to 
each well and incubated for 1 hour at room temperature. After 1 hour, the ELISA plates were 
washed 5x. Next, 100 µL of 1-Step Ultra TMB Substrate Solution was added to each well and 
allowed to incubate and develop color for 15-20 minutes at room temperature with gentle 
agitation. After 15-20 minutes, color development was stopped by the addition of 100 µL of 100 
mM sulfuric acid. Colorimetric development was quantified by absorbance spectroscopy at 450 
nm using the BioTek Cytation 5 plate reader. Antibody titers were determined by any 
absorbance signal at a given dilution factor that was greater than the PBS control absorbance 
signal plus three standard deviations47.  
Quantification of Nanoparticle Delivery to Lymph Nodes in-vivo. Mice were injected 
subcutaneously in the left hock with either IONP or IVLN at 200 µg total Fe per mouse. At the 
designated time intervals, mice were sacrificed and lymph nodes of interest were dissected for 
ex-vivo analysis. The extent of nanoparticle delivery to the lymph nodes was quantified using 
ICP-MS based on previously reported protocols modified from analysis by ICP-OES48. 
Quantification of Peptide Delivery to Lymph Nodes in-vivo. To facilitate quantification of 
peptide delivery to lymph nodes, lysine terminally modified HER2 peptides were chemically 
conjugated to sulfo-Cy5.5 NHS Ester. This conjugation was carried out at a 5-fold molar excess 
of sulfo-Cy5.5 NHS Ester to HER2 peptide. IONP-HER2-Cy5.5 and IVLN-HER2-Cy5.5 were 
subjected to Cy5.5 functionalization after initial peptide conjugation was completed in order to 
enable facile purification of excess fluorescent dye by magnetic separation. Subsequent to 
Cy5.5 functionalization, mice were injected as previously stated. After 3 hours, mice were 
sacrificed and lymph nodes of interest were dissected for ex-vivo analysis by IVIS imaging. IVIS 
imaging was utilized for semi-quantification of peptide delivery in terms of radiant efficiency. 
In-vitro Cell Uptake. IVLN-HER2 and IONP-HER2 cellular uptakes was evaluated in 
RAW264.7 macrophages and primary B-cells isolated from murine spleens using an EasySep 
Mouse B-cell isolation kit. Nanoparticle samples were incubated at 50 µg/mL Fe with cells for 18 
hours in blank RPMI media at 37C, 5% CO2/95% air atmosphere and approximately 85% 
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relative humidity. After 18 hours, cells were lifted by cell scraping and washed thrice with 
phosphate-buffered saline (PBS).  Following the wash steps, resulting cell pellets were re-
suspended in 1 mL of PBS, cell counted and then digested in 1 mL aqua regia (1:3 molar ratio 
nitric acid: hydrochloric acid) for analysis by ICP-MS.  
In-vivo Cell Uptake. IVLN-HER-Cy5.5 and IONP-HER2-Cy5.5 were injected subcutaneously in 
the left hock with either Lipid-IONP or IVLN at 200 µg total Fe per mouse. At 3 hours and 24 
hours, mice were sacrificed and lymph nodes of interest were dissected for ex-vivo analysis by 
flow cytometry. Lymph nodes were dissociated by mechanical methods to prepare single cell 
suspensions. Single cell suspensions of lymph node cells were stained for analysis by flow 
cytometry using the MoFlo Astrios flow cytometer. Viable cells (Zombie UV) were identified as 
either B-cells (B220+) or subcapsular sinus macrophages (CD169highCD11b+) and evaluated for 
positive nanoparticle interactions (Cy5.5). Flow cytometry data was analyzed by FCS express. 
Antigen-Specific B-cell and Germinal Center Flow Cytometry.  Mice were immunized as 
previously introduced. At day 10, mice were sacrificed and lymph nodes were dissected for ex-
vivo analysis by flow cytometry. Antigen-specific B-cell analysis was accomplished using 
tetramer staining based on previously established protocols with minor modifications49. 
HER2/neu peptide tetramers were prepared by mixture of biotin-labeled HER2 peptide with 
Alexa Fluor 647 labeled streptavidin at a 4:1 molar ratio at room temperature for 1 hour without 
further purification. Antigen-specific B-cell population were identified using CD19, and the 
HER2-peptide tetramer using flow cytometry. Germinal center B-cell populations were identified 
using the following markers B220, IgD, GL7 and CD95 (B220+IgDlowGL7+CD95+).  
Tumor Studies.  Forty-nine days after the primary immunization, mice were inoculated with 
250,000 D2F2/E2 cells subcutaneously in the right flank. D2F2/E2 cells were prepared at 2.5e6 
cells/mL in 100 µL and mixed at equal volume with Matrigel matrix. Tumor size was quantified 
by caliper measurements every 7 days. Tumor volumes were calculated using the following 
equation:  
𝑇𝑢𝑚𝑜𝑟	𝑉𝑜𝑙𝑢𝑚𝑒 = 𝑥𝑦- 2/  
 
End points were determined by using the End-Stage Illness Scoring System; mice receiving an 
End-Stage Illness Score greater than 6 were euthanized by CO2 asphyxiation.  
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Statistics.   
Data are expressed as mean ± standard deviation (SD), unless otherwise specified. 
Comparisons between two groups were made using the unpaired Student’s t-test. Means of 
multiple groups were compared with the one-way analysis of variance (ANOVA), followed by 
post hoc Tukey’s pairwise comparisons. All probability values are two-sided, and values of p < 
0.05 were considered statistically significant. Statistical analyses were carried out using the 
GraphPad Prism 7 software package. 
 
2.4 Results:  
Generation of Inorganic Virus-Like Nanoparticles (IVLN) that Mimic Viral-like Properties  
 
 To achieve viral-like spiky and rough surface topography, we attached ultra-small gold 
nanoparticles (AuNP, 2-3 nm), termed satellites, onto the surface of an iron-oxide nanoparticle 
core (IONP, 15 nm) to produce the Au@Fe hybrid nanoparticle platform coined inorganic virus-
like nanoparticle (IVLN) (Figure 2.1A). AuNP attachment to IONP is achieved by the interaction 
between reactive AuNP surfaces and free siloxane moieties present in the polymer used to coat 
the IONP. The IONP of the IVLN was synthesized by thermal decomposition to produce a 15-
nm spherical core stabilized by oleic acid in chloroform based on established techniques (Figure 
S1A). To achieve aqueous stabilization, the IONP was coated with a poly(siloxane) and 
poly(ethylene glycol) containing di-block co-polymer based on procedures previously reported 
by our group41. Separately, ultra-small gold nanoparticles or satellites (AuNP) with ~3 nm sizes 
were prepared using a modified precipitation method by reduction of chloroauric acid in aged 
sodium sulfide50 (Figure S1B). The resulting AuNP solution is added to an IONP solution at 
defined weight ratios and incubated overnight at 4°C to allow for self-assembly.  
 To control the density of viral-like spiky structures and therefore the extent of 
biologically relevant roughness on IVLN surfaces, we adjusted the ratios of AuNPs to IONPs 
within the initial formulation. The number of AuNPs on the surface of IONPs was initially 
quantified by the amount of gold (Au) and iron (Fe) present after magnetic purification (Figure 
2.2A) and was subsequently validated by TEM (Figure 2.2B). To quantify the amount of Au 
loading per Fe, inductively coupled plasma mass spectrometry (ICP-MS) was performed. With 
ICP-MS, it was determined that the average loading efficiency on a per weight basis was 73 ± 
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7% with linear dependence (R2 = 0.997) (Figure 2.2A). Notably, above an initial loading ratio of 
60% weight Au to Fe, destabilization of nanoparticles in solution was observed (data not shown) 
and was therefore not the focus of further research. Based on known crystalline structure and 
quantified particle size and weight of Au and Fe respectively51,52, it was possible to quantify the 
number of AuNP satellites per IONP as theoretically ranging from 1 to 14 (Figure 2.2A).  
 To provide visual confirmation of AuNP and IONP-polymer self-assembly to form the 
IVLN, transmission electron microscopy (TEM) was performed (Figure 2.2B). TEM imaging 
confirmed that by controlling the initial loading ratio of Au to Fe on a per weight basis it is 
possible to yield IVLNs with variable AuNP surface density and qualitatively intriguing viral-like 
character (Figure 2.2B-insert). From the TEM images in Figure 2.2B, IONP-polymer core and 
AuNP diameters were quantified to be 15.9 ± 1.3 nm and 2.3 ± 0.4 nm, respectively. TEM 
visualization of AuNPs per IONP revealed that the 10%, 20% and 30% Au to Fe weight loading 
conditions yielded IVLNs with 4 ± 2, 9 ± 3 and 13 ± 5 AuNPs per IONP-polymer core, 
respectively. These report values agree with the theoretically calculated number of AuNP on the 
IVLN surfaces discussed previously.  
 To control the distance between viral-like spiky structures with optimal distance of 5-10 
nm, which is an ideal distance for B-cell receptor activation33, we adjusted the number of AuNP 
on the IVLN surfaces. Under optimal formulation conditions, IVLNs can be produced with a 
minimum average distance between 5.1-6.3 nm between AuNPs, based on rudimentary models 
(Figure 2.2C, Supporting Information). In addition to average inter-particle distance, the number 
of AuNPs per unit area was determined to be approximately 20,000-25,000 AuNPs per square 
micron, which is a value that compares favorably to the antigen density reported for viral-like 
particles53 (e.g. Hepatitis B Virus, ~ 20,000 antigens per µ2) (Figure 2.2D).  
 To further evaluate the viral mimicking nature of the IVLN, we next evaluated the 
capacity for and mechanism of peptide loading in this system. We choose a non-viral and non-
capsid oncogenic human HER2/neu-specific peptide. Based on previously published works, this 
HER2 peptide contains a B-cell epitope with an overlapping CD4 helper T-cell epitope54-56. In 
order to effectively control antigen density, display and organization, we developed the IVLN to 
facilitate peptide conjugations specifically to the viral-like spiky structures (AuNPs) and not to 
the surrounding polymeric surfaces (IONP). Therefore, a cysteine containing terminal flank was 
added to the HER2 peptide antigen to facilitate facile loading to the IVLN via the Au-S linkage 
(CDDD-PESFDGDPASNTAPLQPEQLQ). During conjugation trials, polymer-coated IONP alone 
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without attached AuNPs was used as control. From the data in Figure 2.2E, it is evident that 
high levels of peptide conjugation are observed for IVLNs with AuNP present, but not on the 
IONP core alone (black symbols). Additionally, the correlation analysis revealed a positive 
correlation between peptide loading and AuNP number (R = 0.95) (Figure S2). Taken together, 
these results suggest that, although there is low-level non-specific physical association to the 
core (~12% under saturated loading conditions), peptide loading is AuNP dependent. Thus, 
peptide conjugation to IVLN surfaces is AuNP localized, which implies that the IVLN is 
characterized by patchy peptide distribution. In this way, the IVLN facilitates patterned antigen 
display in patchy clusters confined to spiky structural elements with defined 5-10 nm spatial 
intervals. This patterned antigen display is viral-like in nature and cannot be reproduced by 
traditional nanoparticle systems that employ homogeneous antigen distribution on their 
surfaces.  
 The density and capacity of peptide loading on IVLN surfaces was evaluated under 
three separate formulation conditions: 0%, 10% and 30% Au to Fe final weight loading ratio 
(wt/wt), which corresponds to 0 AuNPs, 4 AuNPs and 13 AuNPs per IONP-polymer core, 
respectively (Figure 2.2A). Peptide quantification revealed that, at saturated peptide loading 
conditions, the 0%, 10% and 30% wt/wt formulations were loaded with 232 ± 73, 888 ± 42 and 
1954 ± 157 peptides per IVLN, respectively (Figure 2.2E). When these same values were 
standardized by total number of AuNPs per IVLN it was determined that maximum peptide 
loading per AuNP was 227 ± 5 (Figure S2).  
 The optimal size and surface charge are also critical for viral mimicry1,28. Accordingly, 
we next assessed the IVLN’s material properties to determine if the material was suitable for in-
vivo applications, as well as being appropriately aligned with virally relevant physiochemical 
properties. Before incubation with peptide, IVLNs prepared at a 30% Au to Fe final weight 
loading ratio (IVLN-Blank) were shown to have a 55 ± 3 nm particle size, 0.19 ± 0.04 PDI and a 
-16 ± 4 mV zeta-potential (Figure 2.2G, Table S1). After peptide loading of IVLNs under 
saturating conditions (IVLN-Peptide), the IVLN-Peptide was shown to have a 60 ± 2 nm particle 
size, 0.20 ± 0.03 PDI and a -17 ± 1 mV zeta-potential. Significantly, under in-vivo relevant 
serum conditions, IVLN-peptide samples were shown to be stable between 12 and 24 hours 
(Figure S3). Taken together, IVLN-Peptide was determined to have optimal material properties 
for in-vivo applications.  
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Inorganic Virus-Like Nanoparticles Enhanced Antigen-Specific Antibody Production in Mice  
 
 As previously introduced, viral mimicking nanoparticles have been utilized in a wide-
range of in-vitro and in-vivo applications, but the most significant application of viral-like 
structure and function is to activate B-cells for antigen-specific antibody production9,13,17,55,57-59. 
Accordingly, based on the established viral-like material properties of IVLNs, we first set out to 
test if the IVLN can utilized to induced antigen-specific antigen production in-vivo against a non-
capsid oncogenic human HER2/neu-specific peptide (HER2). For these experiments, IVLNs 
were prepared at a final Au to Fe weight loading ratio of 30% wt/wt (~14 AuNP per IONP core) 
with high density peptide conjugation (~2000 peptide per IVLN). To effectively evaluate the 
significance of viral-like properties for the application of antigen-specific antibody production, we 
directly compared our IVLN to a traditional nanoparticle system, lipid-coated iron-oxide 
nanoparticle (IONP-HER2), formulated with an identical number of HER2 peptides per 
nanoparticle. IONP-HER2 has a 30-nm iron-oxide nanoparticle core and a functionalized DSPE-
PEG(2000)-maleimide shell that facilitates facile peptide conjugation (Figure 2.1B). Notably, 
IONP-HER2 has similar material properties in terms of volume-weighted hydrodynamic particle 
size (68 ± 5 nm), PDI (0.22 ± 0.02) (Figure 2.2H, Table S2).  and maximum peptide number per 
particle (2323 ± 394 peptides per IONP) as compared to IVLN-HER2 (Figure 2.2F). However, as 
a traditional nanoparticle system, IONP-HER2 have smooth PEGylated surfaces with 
homogeneous peptide distribution. Therefore, the side-by-side comparison of IVLN-HER2 and 
IONP-HER2 would offer valuable insights into the role of viral mimicry for in-vivo function.  
 To begin these studies, BALB/c mice were immunized with IVLN-HER2, IONP-HER2 or 
soluble HER2 peptide (50 µg peptide, 10 µg cGAMP) at day 0 and boosted twice at 14-day 
intervals (Figure 2.3A). The dose of HER2 peptide was matched across all treatment groups. 
Complete serum analysis was performed after two booster immunizations (day 38) because this 
time point was determined to be most responsive and therefore most relevant (Figure S4). At 
day 38, 10 days after the second booster immunization, serum was analyzed for total IgM, total 
IgG, antigen-specific IgG and the antigen-specific IgG isotypes, IgG1 and IgG2a. From this 
serum analysis, IVLN-HER2 was determined to have a 4-fold higher antigen-specific IgG titer 
(35840 ± 14022 vs. 9600 ± 9051; p < 0.01) a 3-fold higher antigen-specific IgG1 titer (11200 ± 
9600 vs. 3840 ± 2427; p = 0.15) and a 5-fold higher antigen-specific IgG2a titer (15680 ± 10144 
vs. 3200 ± 1960; p < 0.05) as compared to IONP-HER2; Moreover, VLN-HER2 yielded a 12-fold 
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higher antigen-specific IgG titer (35840 ± 14022 vs. 2880 ± 2086; p < 0.001), an 8-fold higher 
antigen-specific IgG1 titer (11200 ± 9600 vs. 1360 ± 1117; p < 0.05) and a 14-fold higher 
antigen-specific IgG2a titer (15680 ± 10144 vs. 1140 ± 1288; p < 0.01) as compared to soluble 
HER2 peptide. Interestingly, this analysis revealed that IVLN-HER2 generated significantly 
higher HER2 antigen-specific IgG antibody titers (3 to 12-fold) as compared to both IONP-HER2 
and soluble HER2 peptide, despite the fact that both IVLN-HER2 and IONP-HER2 were both 
shown to significantly increase the quantity of total IgG (non-specific) as compared to soluble 
HER2 peptide treated (IVLN: p < 0.001; IONP: p < 0.001) and PBS control mice (IVLN: p < 
0.001; IONP: p < 0.001) (Figure 2.3B). No statistically significant difference in total IgM antibody 
production was observed between any treatment groups (Figure S5, p = 0.22). Overall, these 
data are revealing and significantly suggest that the viral-like properties of IVLNs are beneficial 
for antigen-specific antibody production.  
 After establishing the potential of viral-like properties for antigen-specific antibody 
production, we next asked if these observations were applicable at low dose. Accordingly, to 
test if a low dose of IVLN-HER2 was also effective for the induction of HER2-specific antibody 
production, we lowered the dose from 50 µg to 5 µg while maintaining the adjuvant dose and 
repeated the study above (Figure 2.3C). Despite a 10-times lower dose, IVLN-HER2 enhanced 
HER2-specific IgG antibody production by 7 to 18-fold in comparison with IONP-HER2. 
Specifically, IVLN-HER2 generated an 8-fold higher HER2-specific IgG titer (23040 ± 16689 vs. 
2880 ± 716; p < 0.05) am 18-fold higher HER2-specific IgG1 titer (6400 ± 4525 vs. 350 ± 100; p 
= 0.15) and a 13-fold higher HER2-specific IgG2a titer (12800 ± 9050 vs. 1000 ± 400; p < 0.05) 
as compared to IONP-HER2. Moreover, IVLN-HER2 yielded a 14-fold higher antigen-specific 
IgG titer (23040 ± 16689 vs. 1200 ± 566; p < 0.05), a 7-fold higher antigen-specific IgG1 titer 
(6400 ± 4525 vs. 450 ± 252; p < 0.05) and a 14-fold higher antigen-specific IgG2a titer (12800 ± 
9051 vs. 1800 ± 1617; p < 0.05) as compared to soluble HER2 peptide. Thus, IVLNs have not 
only demonstrated to maintain functional efficacy across the range of peptide doses typically 
employed for antibody production in commercial application, but they have also displayed the 
dose sparing potential that would be critical to potential therapeutic applications and clinical 
translations.  
 Based on an understanding of the requirement of B-cell receptor crosslinking for B-cell 
activation33,36,53 and subsequent germinal center formation, we also tested how different antigen 
density and spatial distributions on IVLN surfaces effected anti-HER2 antibody production. 
Control over antigen density and spatial distribution was achieved either by attaching variable 
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quantities of AuNPs per IVLN surface with identical peptide number per AuNP (variable - AuNP 
#), or by conjugating different peptide amounts to AuNPs on IVLN surfaces with identical 
numbers of AuNP (variable – peptide #). In this study, BALB/c mice were immunized with HER2 
peptide (50 µg HER2 peptide, 10 µg cGAMP) as adjuvant at day 0 and boosted once at day 14. 
Serum was collected for analysis 10-days following administration.  
 We first evaluated the role of AuNP number and inter-particle distances on IVLN 
surfaces on HER2-specific IgG antibodies production using three different Au to Fe final weight 
loading ratios: 10%, 20% and 30% wt/wt. These IVLNs have AuNP to IONP ratios between 4:1 
to 14:1 and distances between AuNPs ranging from ~12 to ~5 nm. The HER2-specific IgG tilters 
were 10540 ± 5298, 23820 ± 10717 and 64500 ± 30765 for 10%, 20% and 30% wt/wt LLN, 
respectively (Figure S6). This initial result suggested that minimizing antigen spatial distributions 
on IVLN surfaces improved antibody production.  
 Subsequently, we evaluated the effect of antigen density on HER2-specific antigen 
production for IVLNs with a fixed number of AuNPs per IONP core. For the IVLN with 30% wt/wt 
ratio (AuNP to IONP ratio is 14:1, distance between AuNP is ~5 nm), low density peptide on 
IVLN surfaces yielded a mean antigen-specific IgG antibody titer of 16340 ± 6107, while high 
density peptide on IVLN surface yielded a median titer of 64500 ± 30765 (Figure S6). This trend 
was also observed in IVLN with 20% wt/wt ratio (AuNP to IONP 9 to 1, distance between AuNPs 
is ~8 nm), where low peptide density produced median titers of 2100 ± 1067 and high peptide 
density generated antibody titer of 23820 ± 10717, respectively. However, for IVLN with the 
10% wt/wt Au/Fe ratio (AuNP to IONP ratio is 4 to 1, distance between peptide patch is ~12 
nm). Peptide density did not correlate with antibody production. Presumably, this is due to a 
greater than 10 nm distance between AuNPs on IVLN surfaces. These data suggest that higher 
peptide density (2000 peptides/IVLN) and higher number of AuNPs per IVLN surface (14:1, 
distance between AuNP less than 10 nm) are the optimal viral-like properties for antigen-
specific antibody production, which was used in Figure 2.3.  
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Inorganic Virus-Like Nanoparticles Enhance HER2-specific Antibody Production with 
Preventative Efficacy to Inhibit HER2+ Breast Cancer Growth in Mice 
 
 Next, we asked whether the antigen-specific antibodies induced by IVLN-HER2 
immunization were functionally active as intended. As previously introduced, the peptide of 
interest in this study is an oncogenic human HER2/neu-specific peptide. Based on previously 
reported literature, this epitope is contained with the original whole protein immunogen used to 
produce pertuzumab (Perjeta®)54. Pertuzumab has known anti-cancer efficacy against HER2+ 
breast cancer, and thus is an ideal model for the functional evaluation of antibodies produced by 
IVLN-HER260,61. Therefore, we employed IVLN-HER2 as a vaccine to test if the induced HER2-
specific antibodies had in-vivo prophylactic efficacy to inhibit tumor growth using breast cancer 
xenograft model using a murine breast cancer cells (D2F2/E2) with high HER2 expression The 
D2F2/E2 cell line is a BALB/c derived murine breast cancer cell line with a human HER2/neu 
transfection and cell surface expression40.  
 The prophylactic tumor inhibition study was initiated by subcutaneous flank inoculation 
with 2.5x105 cells per mouse at day 49 following a primary immunization plus three additional 
booster administrations at 14-day intervals (Figure 2.4A). The results of this prophylactic anti-
tumor study revealed that, as compared to the PBS control, IVLN-HER2 displayed a marked 
statistically significant reduction in tumor volume over 6-weeks at a dose of 50 µg (125 ± 239 
mm2 vs. 1843 ± 661 mm2, p < 0.001) (Figure 2.4B) and 5 µg (583 ± 392 mm2 vs. 1843 ± 661 
mm2, p < 0.001) (Figure 2.4C). In addition, the prophylactic anti-cancer efficacy appears to be 
directly correlated not only to the specificity of these endogenous antibodies to the D2F2/E2 cell 
line (Figure S7), but also to the titer of antigen-specific antibody. These results highlight the 
therapeutic potential of and provides functional validation for endogenous HER2-specific 
antibodies induced by IVLN-HER2 administration.  
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Inorganic Virus-Like Nanoparticles Promote Lymph Node Homing and Viral-Like Distribution 
and Uptake by Immune Cells in Lymph Nodes.  
 
 Upon validating that IVLNs can be utilized to facilitate enhanced antigen-specific 
antibody production as to compared traditional nanoparticle systems and soluble peptides, we 
next set out to test if our IVLNs have viral-like functions as compared to traditional nanoparticles 
(Figure 2.5). In order to test if IVLNs has viral mimicking functionality, we first evaluated its 
propensity for lymph node homing in terms of delivery extent and retention62,63. Second, within 
the lymph node, we need to determine if IVLNs can be specifically targeted to B-cell zones 
since the lymph nodes are primary sites for B-cell activation and the formation of germinal 
centers that are ultimately responsible for initiating antigen-specific IgG antibody production64-66. 
Third, we also tested if IVLNs had viral-like cellular distribution patterns within lymph nodes. As 
sites with dense populations of antigen-presenting cells and lymphocytes, the lymph nodes are 
known to be critically important in viral sequestration and directed immune activation39,67. This 
functionality is the result of unique physiological features that have been developed for viral 
recognition and viral-specific immune activation. For example, subcapsular sinus macrophages 
are a highly specialized phenotype of macrophage that is responsible for viral uptake and direct 
presentation to B-cells to promote directed viral clearance via antigen-specific antibody 
production39,68.  
 Lymph node homing was quantified for IVLN-HER2, IONP-HER2 and soluble HER2 
peptide following administration by subcutaneous hock immunization, which was determined to 
be the most efficient delivery pathway69 (Figure S8). IVLN-HER2 and IONP-HER2 delivery 
kinetics to the lymph nodes (popliteal and inguinal) was determined using ICP-MS quantification 
of Fe in excised lymph nodes based on previously reported techniques with minor 
modifications42,48. It was determined that while the tmax of both IVLN-HER2 and IONP-HER2 was 
3 hours post-administration, the percent of initial nanoparticle dose delivered was 5.1 ± 1.6% 
and 1.9 ± 0.8% (p < 0.05) for IVLN-HER2 and IONP-HER2, respectively (Figure 2.6A). Over 48 
hours, IVLN-HER2 was shown to have a 3.5-fold higher (p < 0.05) in overall exposure 
compared to IONP-HER2 based on area under the curve (AUC) measurements. Moreover, the 
retention of nanoparticles within the lymph node over 48 hours was higher for IVLN-HER2 (68 ± 
11%) as compared to IONP-HER2 (43 ± 18%) (p = 0.12). In addition to the direct quantification 
of nanoparticle delivery by ICP-MS, fluorescently labeled peptides were also used to monitor the 
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lymph node delivery for IVLN-HER2, IONP-HER2 and soluble HER2 peptides at 3 hours using 
IVIS imaging of excised popliteal and inguinal lymph nodes (Figure 2.6B). IVIS imaging revealed 
that IVLN-HER2 led to a 4.3-fold improvement in lymph node homing as compared to both the 
IONP-HER2 and soluble HER2 peptide (p < 0.001; p < 0.001), where IONP-HER2 and HER2 
have no statistically significant difference in delivery (p > 0.99).  
 Subsequently, we tested if IVLN-HER2 had viral-like distributions within the lymph 
node, especially in subcapsular sinus macrophage and B-cell populations, as compared to 
IONP-HER265,66,68. To answer this question, fluorescently labeled IVLN-HER2 were injected by 
subcutaneous hock immunization and flow cytometry was applied 3 hours post-administration to 
identify IVLN-HER2 or IONP-HER2 positive cells of different phenotypes. More specifically 
subcapsular sinus macrophages where identified as CD11b+CD169high double-positive and B-
cells were identified as B220+68,70. This analysis revealed that after 3-hours and relative to the 
IONP-HER2, IVLN-HER2 improved subcapsular sinus macrophage uptake by 1.7-fold (86.7 ± 
2.4% vs. 52.2 ± 2.8%, p < 0.001) and B-cell uptake by 3.4-fold (63.9 ± 1.1% vs. 19.7 ± 2.2%, p 
< 0.001) (Figure 2.6C).  
 Cellular uptake of IVLN-HER2 and IONP-HER2 was confirmed in-vitro in RAW 264.7 
macrophages and primary B-cells isolated from murine spleens.  Compared to the IONP-HER2 
control group, IVLN-HER2 improved cellular uptake by 3-fold in macrophages (30.3 ± 1.1 pg 
Fe/cell vs. 11.8 ± 1.3 pg Fe/cell, p < 0.001) and 2-fold in B-cells (2.0 ± 0.4 pg Fe/cell vs. 0.8 ± 
0.4 pg Fe/cell, p < 0.01) (Figure 2.6D). The mechanism for IVLN uptake was further evaluated 
in-vitro by comparison of cellular uptake with increasing AuNP number and density of IVLN 
surfaces. Notably, without peptide loading and as directly compared to the blank IONP core 
without AuNP association, IVLN improved cellular uptake by 6-fold in macrophages (30.3 ± 1.1 
pg Fe/cell vs. 4.7 ± 0.9 pg Fe/cell, p < 0.001), and 4-fold in primary B-cells (2.0 ± 0.4 pg Fe/cell 
vs. 0.5 ± 0.2 pg Fe/cell, p < 0.001) (Figure S9). Notably, the viral-like spiky structures and rough 
surface topography provided by AuNP complexation to IVLN surfaces led to increased cellular 
uptake with increasing number of AuNP loading on IVLN surfaces and matched an exponential 
function for both cell types (RAW264.7, R2 = 0.902; B-cells, R2 = 0.918) (Figure S9).  
 
 
72 
 
Inorganic Virus-Like Nanoparticles Increase Germinal Center Formation and Immune Cell 
Activation in the Lymph Node  
 
 To further mechanistically evaluate the inductive capacity of IVLNs for antigen-specific 
antibody production, we next examined both the extent of germinal center formation and 
activation of antigen-specific B-cells in-vivo. Firstly, the extent of germinal center formation was 
evaluated 10 days after the primary immunization of BALB/c mice with IVLN-HER2, IONP-HER2 
and soluble HER2 peptide at a dose of 50 µg. Germinal centers were identified as class-
switched B-cells (B220+IgDlow) that are double-positive for CD95 and GL-7 markers71,72 (Figure 
2.7A). Quantification of by flow cytometry revealed that immunization with IVLN-HER2 resulted 
in a 2.6-fold and an 8-fold increase in the proportion of germinal center type B-cells 
(B220+IgDlowCD95+GL7+) as compared to IONP-HER2 (18.1 ± 2.4% vs. 7.0 ± 2.1%, p < 0.001) 
and soluble HER2 peptide (18.1 ± 2.4% vs. 2.2 ± 0.9%, p < 0.001), respectively (Figure 2.7B). 
Additionally, IONP-HER2 administration yielded an approximately 3-fold increase in germinal 
centers as compared to soluble HER2 peptide (7.0 ± 2.1% vs. 2.2 ± 0.9%, p < 0.05). These 
results correlate nicely to the observed increase of antigen-specific IgG antibodies described 
previously.   
 Secondly, the proliferation of antigen-specific B-cells was measured utilizing 
fluorescently-labeled streptavidin HER2 peptide tetramer staining based on previously reported 
protocols49 (Figure 2.7C). Antigen-specific B-cells were identified as viable lymph node cells that 
were double positive for CD19 and the HER2 peptide tetramer. The results of this analysis 
demonstrate that IVLN-HER2 treatment produced an approximately 6-fold proliferation in the p 
antigen-specific B-cell population as compared to both IONP-HER2 (3.0 ± 2.0 % vs. 0.5 ± 0.2%, 
p < 0.05) and soluble HER2 peptide (3.0 ± 2.0 % vs. 0.5 ± 0.1%, p < 0.05) (Figure 2.7D). No 
statistical differences in the antigen-specific B-cell population were detected for IONP-HER2 vs. 
soluble HER2 peptide (p = 0.72). Taken together, these data suggest that the viral mimicking 
features of IVLN-HER2 have the unique ability to activate antigen-specific B cells, which is 
associated with increased antigen-specific antibody production.  
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2.5 Discussion:  
 Viral-like characteristics are ideal material properties for the rational design and 
engineering of nanomaterials critical to the advancement of nanotechnology for 
immunomodulatory applications1,26,28. These nanomaterials have robust potential to stimulate 
both humoral and cellular immunity. As such, nanoparticles with viral-like structural and function 
could be used for the induction of antigen-specific immunity leading to the production of high 
quantity and affinity antibodies. These antibodies could be deployed in as invaluable research 
tools or as therapeutic agents in the treatment of infection disease and cancer.   
 To date, only 4-5 different virus-like particles (VLPs) are FDA-approved and clinically 
available, all of which are designed to prevent viral infection based on viral capsid 
composition73. For example, prophylactic VLP vaccines for HPV (such as Gardasil®) have been 
generated using the self-assembly of HPV L1 capsid proteins to provide durable long-term 
efficacy against HPV infection74. Indeed, these VLP-based vaccines are more effective than 
monomer capsid proteins alone for the activation of B cell-mediated humoral immunity and 
production of neutralizing antibodies as a result of multivalent interactions with B cell 
receptors14,53,75,76. However, these VLP-based vaccines are ineffective in the treatment of 
established HPV tumors because the HPV VLP only contains capsid proteins, not the oncogenic 
E6/E7 antigens that are responsible for HPV associated cancer14,77,78. Most recently, a VLP with 
HER2 peptides was generated using acinetobacter phage coat protein AP205, which showed 
excellent efficacy against HER2+ breast cancer in animal model79. Despite the success of this 
application however, traditionally it is extremely challenging to generate VLP using oncogenic 
proteins since the oncogenic proteins do not have necessary properties to facilitate VLP-self-
assembly VLP80,81. The simplest solution to this problem is to chemical conjugate oncogenic 
proteins and peptides to VLP surfaces. However, the strong B-cell response and antibody 
production against the capsid proteins of VLP itself yields a high-level non-specific (anti-carrier) 
immunological response with regard to the intended application of the nanomaterial to generate 
an immunological response for the specific cargo of interest (i.e. HER2 peptide)24,25.   
 Although many alternative nanoparticle technologies claiming viral influence have been 
developed for antigen delivery and immunomodulation, these more traditional nanoparticle 
systems are not truly effective viral mimics and are therefore potentially limited in application 
scope. Here, we report the development of true inorganic virus-like nanoparticle (IVLN), which 
employs a more holistic approach to viral mimicry material design. This IVLN not only mimics 
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viral-like structure and material properties1,27,33,37,38,53 (spiky and rough surface topography, 
variable antigen density, patterned antigen distribution and sub-100 nm particle size), but also 
demonstrates viral-like functional capabilities39,62,65,67 (lymph node homing and cellular 
distributions, immune cell activation and antigen-specific antibody production). IVLNs are 
composed of a hybrid Au@Fe core-satellite type nanoparticle, which utilizes a 16-nm 
polysiloxane and polyethylene glycol containing diblock polymer coated iron-oxide nanoparticle 
core (IONP) with 2.5-nm gold nanoparticle satellites (AuNP). IVLNs can be produced with 
variable surface topography, antigen density and antigen spatial resolution. Moreover, the IVLN 
has optimal particle size, shape and surface charge for efficient lymph node delivery and 
retention. Further, these IVLNs can be easily manufactured with large scale for future 
applications.  
 To evaluate the viral-like functions of our IVLN, we purposely utilized, as antigen, a 
HER2 peptide containing both B-cell and CD4 T-cell epitopes such that we could evaluate the 
IVLN for B-cell activation and antigen-specific antibody production in mice54-56. In this study, we 
compared IVLNs to a traditional nanoparticle system, lipid-coated iron-oxide nanoparticles 
(IONP-HER2) with the same antigen at identical peptide loading per nanoparticle. By 
conventional thought, lipid-coated iron-oxide nanoparticles would be considered a viral-
mimicking nanoparticle technology based on its’ particle size and antigen density. However, we 
demonstrate our IVLN-HER2 is uniquely different from IONP-HER2 in both structure and 
function.   
 Our results showed that the IVLN-HER2 is truly significant for B-cell activation and 
antigen-specific antibody production. Specifically, by manipulating the spatial distribution of 
AuNPs on IVLN surfaces and the peptide density confined to those AuNPs, antigen-specific IgG 
antibody titers were increased by 3 to 18-fold as compared to IONP-HER2. Significantly, as 
compared to IONP-HER2 at high dose, IVLN-HER2 was determined to have 4-fold, 3-fold and 
5-fold higher antigen-specific IgG, IgG1 and IgG2a titers, respectively; at low dose, IVLN-HER2 
was shown to improve antigen-specific IgG, IgG1 and IgG2a titers 8-fold, 18-fold and 15-fold, 
respectively. Since both IVLN-HER2 and IONP-HER2 have highly comparable hydrodynamic 
particle size, surface charge, core shape and peptide loading per unit nanoparticle, any 
quantifiable differences in antibody production by these two structures could be attributed to 
increasingly viral-like structure and function. Mechanistically, IVLN-HER2 immunization led to 
enhanced antigen-specific antibody production as a result of greater homing capacity to the 
lymph nodes, unique viral-like distribution in lymph nodes and higher intracellular uptake, which 
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together promoted a significant increase in overall antigen-specific B-cell proliferation and 
germinal center formation. Finally, IVLN-HER2 induced HER2/neu-specific antibody production 
in mice, which were functional in the prophylactic inhibition of HER2+ breast cancer growth, as 
intended based on the known HER2+ anti-tumor efficacy of pertuzumab60,61. It is noteworthy, 
that while IVLN-HER2 may have the potential to serve as a B-cell based cancer vaccine for 
HER2+ breast cancer in the future, this was not the main emphasis of this current work. Current 
evidence suggests that research in this direction is warranted, but no major conclusions can be 
surmised at this time.  
 In summation, we generated an inorganic virus-like nanoparticle (IVLN) platform using a 
holistic philosophy for viral mimicking material design and engineering. The IVLN has unique 
viral-like spiky topographical structures, spherical geometry, optimal size and negatively 
charged surfaces. The high-density antigen display and organization on IVLN surfaces is 
controlled by the surface density of and peptide binding specificity to AuNPs, which facilitate the 
patchy patterned distribution of antigen at 5-10 nm spatial intervals optimal for B-cell activation. 
In addition to these viral-like structural elements, the IVLN also exhibits viral mimicking 
functionality in terms of lymph node homing, lymph node cellular distributions, immune cell 
activation and enhanced functionally active antigen-specific antibody production. These data 
suggest that our unique IVLN technology, which redefines conventional knowledge of viral 
mimicking nanoparticle design, may have broad applications for efficient delivery and efficacious 
immunomodulation in-vivo.  
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2.8 Figures:  
 
 
Figure 2.1. Nanoparticle Formulation and Viral-Like Structure Schematic. (A) Schematic 
representation of the step-wise production of peptide functionalized inorganic virus-like 
nanoparticles (IVLN-HER2) by the (1) self-assembly of AuNPs to polymer-coated IONP 
surfaces via the gold-siloxane interaction (IVLN) followed by the (2) conjugation of terminal 
cysteine-modified HER2 peptide to IVLN via gold-thiol bonding. (B) Schematic representation of 
step-wise formulation of peptide functionalized lipid-coated iron-oxide nanoparticles (IONP-
HER2) by the (1) coating of iron-oxide nanoparticles with maleimide activated DSPE-mPEG 
phospholipids followed by the (2) conjugation of terminal cysteine-modified HER2 peptide to 
IONP via non-reducing thiol-directed chemistry.  
 
 
1 2 
1 2 
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Figure 2.2. Inorganic Virus-Like Nanoparticle (IVLN) Formulation and Viral Mimicry. (A) 
Quantitative analysis of ultra-small gold nanoparticle (AuNP) loading per polymer-coated iron-
oxide nanoparticles core (IONP-polymer) by inductively coupled plasma mass spectrometry 
(ICP-MS); data represent mean ± SD, n ≥ 6; curve is fit using linear regression model, R2 = 
0.998, p < 0.001. (B) Representative transmission electron microscopy (TEM) images of IVLN 
formulations at increasing gold (Au) to iron (Fe) final weight loading ratios from 0-30% wt/wt; 
scale-bar: 0% wt condition (50 nm); scale-bar: 5-30% wt conditions (20 nm). (B-insert) High 
resolution TEM image of single nanoparticle from 30% wt condition with background subtraction 
image processing. (C) Mathematical modeling of theoretical distances between AuNPs on IVLN 
surfaces. (D) Mathematical modeling of theoretical density (nanoparticles per unit area) of 
AuNPs on IVLN surfaces and as compared to the known antigen density on viral capsids 
(symbol legend: square = HIV; diamond = rotavirus; triangle = hepatitis B virus; circle = human 
papillomavirus). (E) Quantification of peptide loading capacity and mechanism on IVLNs with 
variable AuNP surface loading (0 AuNPs – black; 4 AuNPs – blue; 12 AuNPs – red) determined 
by a modified fluorescamine fluorescent detection assay; data represent mean ± SD, n = 3; 
curve is fit using linear regression model, (0 AuNPs: R2 = 0.904, p < 0.01; 4 AuNPs: R2 = 0.962, 
p < 0.01; 12 AuNPs: R2 = 0.977, p < 0.001). (F) Quantification of peptide loading capacity on 
lipid-coated iron-oxide nanoparticles (IONP-HER2); data represent mean ± SD, n = 3; curve is fit 
using linear regression model (R2 = 0.989, p < 0.001). (G) Representative volume-weighted 
particle size distributions for IONP-polymer core (red), IVLN-blank (blue) and IVLN-HER2 
(green) by dynamic light scattering (DLS). (H) Representative volume-weighted particle size 
distributions for blank lipid-coated iron-oxide nanoparticles (IONP Lipid, black) and peptide 
coated IONP Lipid (IONP-HER2, red). SD, standard deviation; DLS, dynamic light scattering.  
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Figure 2.3. Inorganic Virus-Like Nanoparticle (IVLN) Enhanced Antigen-Specific Antibody 
Production in Mice. (A) Animal study immunization and analytical sampling timeline. (B) 
Quantification of non-specific total IgG and antigen-specific antibody titers (IgG, IgG1 and 
IgG2a) from the serum of BALB/c mice at day 38 and at 50 µg HER2 peptide + 10 µg cGAMP 
as adjuvant; data represent mean ± SE, n = 5. (C) Quantification of non-specific total IgG and 
antigen-specific antibody titers (IgG, IgG1 and IgG2a) from the serum of BALB/c mice at day 38 
and at 5 µg HER2 peptide + 10 µg cGAMP as adjuvant; data represent mean ± SE, n = 5. 
Statistical comparisons are based on one-way ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. The asterisks denote statistical significance at the level of * p < 0.05, ** p < 0.01, 
*** p < 0.001. ANOVA, analysis of variance; SE, standard error; n.s., no statistical significance. 
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Figure 2.4. Prophylactic HER2+ Breast Cancer Anti-Tumor Efficacy. (A) Animal study 
immunization and HER2+ breast cancer (D2F2/E2) tumor inoculation timeline. (B) Tumor 
volume growth curves for D2F2/E2 tumors subcutaneously implanted into the flank of BALB/c 
mice at 250,000 cells per mouse treated with 50 µg HER2 peptide dose + 10 µg cGAMP and 
(C) 5 µg HER2 peptide dose + 10 µg cGAMP; data represent mean ± SE, n = 5. Statistical 
comparisons are based on one-way ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. The asterisks denote statistical significance at the level of * p < 0.05, ** p < 0.01, 
*** p < 0.001. ANOVA, analysis of variance; SE, standard error. 
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Figure 2.5. Lymph Node Distribution and Viral-Like Function Schematic. (A) Schematic 
representation of lymph node architecture and physiological features. (B) Schematic 
representation of the viral-like function of lymph node homing. IVLN-HER2 displays highly 
efficient delivery to and retention within the lymph node by viral-like passive targeting to 
subcapsular sinus macrophages and B-cells. IONP-HER2 displays less efficient delivery to and 
poor retention within the lymph node by failing to achieve viral-like passive targeting to 
subcapsular sinus macrophages and B-cells. (C) IVLN-HER2 nanoparticle step-wise journey to 
the lymph node through afferent vesicles, viral-like interactions with subcapsular sinus 
macrophages, translocation across the subcapsular sinus and direct presentation to B-cells with 
bivalent B-cell receptor crosslinking in the lymph node follicle.  
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Figure 2.6. Viral-like Functionality Assessment: Lymph Node Homing, Distribution and Immune 
Cell Uptake. (A) Quantification of nanoparticle delivery to lymph nodes (popliteal + inguinal) 
ipsilateral to the administration site at designated time intervals represented as the percentage 
of initial iron-oxide delivered using ICP-MS; data represent mean ± SE, n = 3. (B) 
Representative ex-vivo IVIS fluorescence images and semi-quantitative analysis (popliteal (top) 
+ inguinal (bottom)) of peptide delivery to lymph nodes acquired 3 hours after administration of 
Cy5.5-labeled soluble HER2 peptide, IONP-HER2-Cy5.5 and IVLN-HER2-Cy5.5 (Ex/Em = 
675/720 nm, exposure = 0.5 s). The color bar represents mean radiant efficiency 
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(p/s/cm2/sr)/(μW/cm2); data represent mean ± SD, n = 3. (C) Quantification of in-vivo 
nanoparticle distribution to specific immune cell populations in the lymph nodes as identified by 
flow cytometry (Cy5.5-labeled nanoparticles); Subcapsular sinus macrophages are identified as 
CD11b+CD169high; B-cells are identified as B220+; data represent mean ± SD, n = 3. (D) 
Quantification of in-vitro cell uptake of nanoparticles in RAW264.7 macrophages and murine 
primary B-cells by ICP-MS quantification of total Fe standardized by cell count (pg Fe per cell); 
data represent mean ± SD, n = 3. Statistical comparisons are based on one-way ANOVA, 
followed by post hoc Tukey’s pairwise comparisons or by Student’s unpaired T-test. The 
asterisks denote statistical significance at the level of ** p < 0.01, *** p < 0.001. ANOVA, 
analysis of variance; SD, standard deviation; SE, standard error.  
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Figure 2.7. In-vivo Germinal Center Formation and Antigen-Specific B-cells. (A) Representative 
FACS plots for the gating strategy of germinal center cells. Germinal center cells were identified 
as the B220+IgDlow population that was double-positive for mature germinal center cell marker 
CD95 and GL-7. (B) Quantification of percentage of germinal center type cells of the total 
B220+ B-cell population induced 10 days after the primary immunization at 50 µg HER2 peptide 
dose + 10 µg cGAMP as adjuvant; data represent mean ± SE, n ≥ 3. (C) Representative FACS 
plots for the gating strategy of HER2-specific B-cells using B-cell receptor tetramer staining, 
identified as the CD19+Tetramer+ population. (D) Quantification of the percentage of HER2-
specific B-cells of total viable cells induced 10 days after the primary immunization at 50 µg 
HER2 peptide dose + 10 µg cGAMP as adjuvant; data represent mean ± SE, n ≥ 3. Statistical 
comparisons are based on one-way ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. The asterisks denote statistical significance at the level of * p < 0.05, *** p < 
0.001. ANOVA, analysis of variance; SE, standard error. 
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2.9 Supporting Information  
The supporting information, figures and tables from Chapter 2 are available in Appendix A. 
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CHAPTER 3 
Size-Controlled Iron Oxide Nanoplatforms with Lipidoid-
Stabilized Shells for Efficient MRI-Trackable Lymph Node 
Targeting and High Capacity Biomolecule Display 
 
3.1 Abstract  
Nanoplatforms for biomolecule delivery to the lymph nodes have attracted considerable 
interest as vectors for immunotherapy. Core-shell iron oxide nanoparticles are particularly 
appealing because of their potential as theranostic MRI-trackable vehicles for biomolecule 
delivery. The key challenge to utilizing iron oxide nanoparticles in this capacity is control of their 
coating shells to produce particles with predictable size. Size determines both the carrier 
capacity for biomolecule display and the carrier ability to target the lymph nodes. In this study, 
we develop a novel coating method to produce core-shell iron oxide nanoparticles with 
controlled size. We utilize lipid-like molecules to stabilize self-assembled lipid shells on the 
surface of iron oxide nanocrystals, allowing formation of consistent coatings on nanocrystals of 
varying size (10-40 nm). We further demonstrate the feasibility of leveraging the ensuing control 
of nanocarrier size for optimizing the carrier functionalities. Coated nanoparticles with 10 nm 
and 30 nm cores supported biomolecule display at 10-fold and 200-fold higher capacities than 
previously reported iron oxide nanoparticles, while preserving monodisperse sub-100 nm size 
populations.  In addition, accumulation of the coated nanoparticles in the lymph nodes could be 
tracked by MRI and, at 1-hour post injection, demonstrated significantly enhanced lymph node 
targeting. Notably, lymph node targeting was 9-40 folds higher than for previously reported 
nanocarriers, likely due to the ability of these nanoparticles to robustly maintain their sub-100nm 
size in vivo. This approach can be broadly applicable for rational design of theranostic 
nanoplatforms for image-monitored immunotherapy. 
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3.2 Introduction  
The presentation of immunoactive biomolecules to the lymph nodes has the potential to 
treat a number of intractable human diseases including infectious diseases and cancer. The 
lymph nodes are the central sites for immune activation, and thus, present an important target 
for therapeutic immunomodulation1. Because soluble immunoactive biomolecules are typically 
inefficient in accessing lymph nodes and stimulating immunity, nanoparticles have attracted 
considerable interest as platforms for biomolecule delivery and presentation2. The nanoparticles’ 
performance as lymph node carriers is largely determined by their material properties, such as 
size and capacity for biomolecule surface display3. Although a variety of nanoparticle systems 
have been investigated, development of biomolecule-displaying nanocarriers with well-defined 
material characteristics still represents a considerable challenge4. 
One key criterion in developing nanoparticles as lymph node carriers is the ability to 
control nanocarrier size5. Size is critical to several aspects of nanocarriers’ biological 
performance. For example, size largely determines the multivalency of biomolecule display on 
the nanoparticle surface5, 6. High multivalency can mimic the natural presentation of antigens 
and adjuvants by pathogens and can play a significant role in directing immune responses7. 
Larger nanoparticles possess larger surface area per particle, and thus, can achieve higher 
multivalency compared to their smaller counterparts3. In addition, the size of nanocarriers also 
determines their efficiency in reaching the lymph nodes from their intradermal injection site8. 
Nanocarriers with small sub-100 nm size are efficient in accessing lymph nodes because they 
can leverage the size-restrictive mechanism of lymphatic drainage9. Thus, to control delivery 
and presentation of immunoactive biomolecules, there is a need in development of nanocarriers 
with controlled size5. 
Among nanoparticles investigated for lymph node targeting, nanoparticles based on 
FDA-approved biodegradable and biocompatible iron oxide are particularly appealing10, 11. Iron 
oxide nanocrystals can be synthesized as controlled monodisperse populations over a range of 
particle size (10-40 nm)12, 13. These well-defined cores provide a scaffold for engineering 
controlled core-shell nanocarriers. Furthermore, iron oxide also exhibits magnetic properties and 
high r2 relaxivities for MRI detection, and can be tracked by MRI imaging in vivo14, 15. Imaging is 
being widely explored as a companion technology for drug delivery because it can be leveraged 
to validate delivery, optimize dosage regiments, or monitor therapeutic response16. The unique 
combination of properties of the iron oxides makes them attractive candidates for development 
of theranostic nanoplatforms with well-defined material characteristics17, 18.  
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One key aspect in developing core-shell iron oxide nanoparticles is the engineering of 
their coating shells. Engineering surface coatings with controlled size and high capacity to 
display biomolecules, while optimally leveraging the nanocrystal’s magnetic properties for MRI 
detection, represents a considerable challenge12. As-synthesized, iron oxide nanocrystals are 
stabilized by surface-grafted hydrophobic ligands, such as oleic acid, and require coating with 
hydrophilic shells19. Although myriad coating strategies exist, most methods render 
nanoparticles non-biodegradable or attenuate magnetic properties12, 20. For example, 
biopolymer coatings typically require covalent cross-linking, which can compromise 
biodegradability21. Alternatively, coatings by surface-anchoring ligands, such as catechols, 
involves replacement of the original ligands, which can perturb the nanocrystal and compromise 
magnetic properties20.   
One alternative approach utilizes amphiphilic lipids22. Amphiphilic lipids can form 
protective lipid gels on the nanocrystal’s surface by assembling with the surface-grafted 
ligands23. Coating by self-assembly is advantageous because it circumvents the need for 
covalent cross-linking or chemical alterations to the nanocrystal, thus preserving 
biodegradability and magnetic properties. A number of formulations have been developed to 
coat nanocrystals with amphiphilic lipids, such as phospholipid-PEG23, 24. However, controlling 
the coating shell across a range of iron oxide sizes is still a difficult challenge. Spherical 
nanocrystals with different diameters exhibit different surface curvatures, which significantly 
impact lipid self-assembly25, 26.  Packing of amphiphilic lipids on surfaces of larger nanocrystals 
resembles packing on planar surfaces, which generates structural gaps on the surface27. This 
leads to lower packing densities for larger nanocrystals, non-homogenous coatings, and 
difficulty in controlling size28. Although coating of small nanocrystals (<20 nm) has been widely 
explored, few examples of coating larger nanocrystals (>20 nm) have been reported to date29. 
Larger nanocrystals offer higher relaxivities for MRI detection29, 30 and larger surface area per 
particle for increasing multivalency of biomolecule display3. Thus, to rationally design 
theranostic iron oxide nanocarriers, there is a need to engineer controllable coatings over a 
range of nanocrystal sizes.  
Here, we develop a method to generate self-assembled lipid coatings on iron oxide 
surfaces that provide robust control of nanoparticle size. Our approach is inspired by a 
biophysical phenomenon of “lipid stitching”. It has been demonstrated that non-covalent 
stitching of lipid bilayers by agents that can link opposing monolayers of lipid membranes can 
significantly improve the coherency of lipid gels on planar surfaces27. Previous strategies to form 
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self-assembled coatings on nanocrystal surfaces relied on micelle-like self-assembly mediated 
solely by hydrophobic interactions23, 24. In contrast, the activity of the “stitching” agents is likely 
due to a combination of hydrophobic and electrostatic interactions. We hypothesized that if lipid-
stitching could be applied to the iron oxide nanocrystals, consistent stabilization of both small 
and large nanocrystals could be achieved, thus allowing control of nanoparticle size. To test this 
hypothesis, we coated oleic acid stabilized nanocrystals with phospholipid-PEG and lipidoids 
(Figure 3.1A). We considered that lipidoids, cationic agents with hydrophobic tails, could act as 
“stitching” agents to stitch hydrophobic and anionic regions of surface bilayers. Our results 
reveal the feasibility of this approach. Our method produced consistent coatings on nanocrystals 
of varying size (10-40 nm), allowing robust control of particle size. We demonstrate that the 
ability to control the nanocarriers’ size could be leveraged to optimize their functionality. 
Significantly, compared to previously reported spherical particles of sub-100 nm size, our coated 
nanoparticles were 9- to 40-fold more efficient in reaching the lymph nodes, likely due to robust 
size preservation in vivo. Furthermore, larger nanoparticles (30 nm core) displayed 3-fold higher 
r2 relaxivity and 20-fold higher capacity for biomolecule display compared to their smaller 
counterparts (10 nm core), while reaching the lymph nodes with similar efficiency. Notably, 
larger nanoparticles could carry thousands of model antigen and adjuvant biomolecules per 
particle, exhibiting 200-fold higher multivalency than previously reported iron oxides, while 
preserving the advantageous sub-100nm size to efficiently access the lymph nodes, deliver 
biomolecules and allow tracking of delivery by MRI. To our knowledge, our method to coat 
nanocrystals is the first to provide robust size control across a range of available iron oxide 
nanocrystal sizes (10-40 nm), which can be leveraged to optimize the nanocarrier performance. 
Our approach is broadly applicable for engineering rationally designed nanoplatforms for image-
guided biomolecule delivery to the lymph nodes. 
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3.3 Experimental Section  
Materials. All reagents were used as obtained from commercial sources without further 
purification. Lipids including DSPE-mPEG [1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] and DSPE-PEG-PDP [1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[PDP(polyethylene glycol)-2000] were acquired from Avanti Polar 
Lipids. Oleic acid stabilized iron oxide nanoparticles in chloroform were obtained from Ocean 
Nanotech. CpG oligonucleotides with a 3’-terminal disulfide bridge modification were purchased 
from IDT DNA Technologies. These sequences included CpG-S-S-CH3 [CpG (5’) 
TTGCAGTTCTTGCAGTACCT-(CH2)3-S-S-CH3 (3’)] and CpGcomp-Cy5.5 [CpG-Cy5.5 (5’) 
AGGTACTGCAAGGACTGCAA-(CH2)3-Cy5.5 (3’)]. The model peptide with a terminal free thiol 
(peptide-SH) [GLSQNRDVRENQRAREC] was obtained from GenScript custom peptide 
synthesis. TCEP [Tris(2-carboxyethyl) phosphine hydrochloride], chloroform, absolute ethanol, 
phenol, sulfuric acid, dichloromethane and methanol were procured from Sigma-Aldrich. SYBR 
Gold Nucleic Acid Gel Stain (10,000X) was obtained from Thermo Fisher.  
Mice. All animal experiments were conducted according to the protocols approved by the 
University of Michigan Committee on Use and Care of Animals (UCUCA). C57BL/6 mice and 
C57BL/6 albino mice were purchased from Charles River Labs. 
Formulation of Multi-Lipid-Coated Iron-Oxide Nanoparticles (IONP-ML). Prior to 
formulation, the concentration of IONP-OA was determined by inductively coupled plasma 
optical emission spectroscopy (ICP-OES, Perkin-Elmer Optima 2000 DV) as previously 
described31. Multi-lipid-coated iron-oxide nanoparticles (IONP-ML) were formulated by a three-
step ethanol thin film hydration and solvent exchange method. In step one, IONPs stabilized by 
oleic acid (IONP-OA), lipidoid and DSPE-mPEG were dispersed in chloroform and dried by 
nitrogen evaporation to produce a lipid film. This lipid film contained 3.32 mg of total lipid/lipidoid 
per mg Fe with a lipid composition of lipidoid:DSPE-mPEG at a mol % ratio of 77:23, unless 
otherwise specified. In step two, the IONP lipid film (an equivalent of 1mg Fe) is rehydrated in 
absolute ethanol (500 μL) at 65°C for 2 hours. In step three, the samples are cooled to room 
temperature and then dialyzed against phosphate-buffered saline (PBS, 100 mM PBS, pH 7.4; 
MWCO = 20,000). 
Analysis of IONP-ML Recovery in Aqueous Solution.  To evaluate the recovery of stabilized 
IONP-ML in aqueous solution, the stabilized fraction of nanoparticles was separated from 
unstable and agglomerated IONPs by gravity filtration and magnetic separation. The stabilized 
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fraction was analyzed for total iron (Fe) with ICP-OES and compared to the initial quantity of 
iron oxide added per formulation. Iron oxide recovery was calculated as follows: 
Iron Oxide Recovery in Aqueous Solution (%)= Resuspended Iron Oxide  in aqueous solution (mg Fe)Initial Iron Oxide in chloroform (mg Fe) x100%  
 
Characterization of IONP-ML.  The composition of IONP-ML lipid coatings was analyzed by 
thin layer chromatography (TLC) according to a previously reported protocol with minor 
modifications32. Briefly, prior to analysis, lipid-coated nanoparticles were purified by magnetic 
separation using MidiMACS MS magnetic columns (Miltenyi Biotec), frozen with liquid nitrogen 
and lyophilized. To extract lipids, dried samples were dispersed in chloroform (15 mg/mL). The 
lipid-containing soluble fraction was separated from the iron oxide precipitate using magnetic 
separation. This fraction was spotted on TLC plates (silica gel matrix, Sigma-Aldrich), run with 
dichloromethane/methanol (DCM:MeOH) mobile phase (80:20 v/v) and stained with iodine. FT-
IR spectra were collected using a Perkin-Elmer Spectrum BX FT-IR spectrophotometer. The 
morphological characterization of nanoparticle samples was performed using transmission 
electron microscopy operating at 300 kV (TEM, JEOL USA, Inc.). Quantitative analysis of TEM 
images to evaluate particle size and shell layer thickness was conducted using Image J 
software. Background subtraction was employed to better visualize IONP-OA and IONP-ML 
shells according to the method of Hartig33. The hydrodynamic diameters (volume-weighted) and 
zeta potentials of all materials were analyzed using dynamic light scattering (DLS) and phase 
analysis light scattering, respectively at 25°C, 100 mM PBS, pH 7.4 (Malvern Zetasizer Nano-
ZS). The magnetization of IONP-OA and IONP-ML were performed at 293K using the MPMS-
XL Superconducting Quantum Interference Device (SQUID) magnetometer (Quantum Design 
Inc. San Diego, CA). The r2 relaxivity of ML-IONP was determined by T2-weighted MRI. MRI 
was performed using a 33 cm horizontal-bore, 7 T Agilent MR imaging system (Agilent, Palo 
Alto, CA). A quadrature 59 mm volume radiofrequency coil was used to scan a 396-well 
polystyrene plate containing nanoparticle solutions. MRI scans were acquired using fast spin 
echo multi-slice sequence (fsems) with the following parameters: TR = 4000 s, TE = 30 ms and 
60 ms, FOV: 20 x 20 mm over 256 x 128 matrix; slice thickness = 1 mm). Image analysis to 
estimate transverse (r2) relaxivity was conducted as previously described14. 
Synthesis of IONP-ML-CpG. PDP-activated lipid-coated iron-oxide nanoparticles (IONP-ML-
PDP) were prepared as described above for IONP-ML, with a modified lipid composition of C12-
98(5):DSPE-mPEG:DSPE-PEG-PDP at a mol % ratio of 77:11.5:11.5 (denoted as 50% PDP). 
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IONP-ML-PDP, were functionalized with CpG oligonucleotides in a two-step process (IONP-ML-
CpG). In the first step, the 3’-terminal disulfide bridge of CpG-S-S-CH3 was reduced with TCEP 
overnight to produce a free terminal sulfhydryl group (CpG-SH). CpG-SH was then purified with 
anion exchange chromatography (HiTrap Q FF column, GE Healthcare), desalted and 
concentrated by ultrafiltration (1,000 Da MWCO). Subsequently, the oligonucleotide content was 
determined by spectrophotometric analysis (260nm, Nanoquant Plate, Tecan Infinite M1000 
PRO). In the second step, IONP-ML-PDP was incubated with CpG-SH (at 3:1 molar ratio of 
CpG:PDP) at room temperature overnight. The product (IONP-ML-CpG) was separated from 
unreacted CpG using magnetic chromatography.   
Synthesis of IONP-ML-Peptide. IONP-ML-PDP was prepared as described above. To 
conjugate thiolated peptide (Peptide-SH) to IONP-ML-PDP, the reactants were incubated at a 
molar ratio of 3:1 (Peptide-SH:PDP) in PBS (100 mM, pH 7.4) at room temperature overnight. 
The product (IONP-ML-Peptide) was separated from unreacted peptide using magnetic 
chromatography.  
Characterization of IONP-ML-CpG. To validate conjugation of CpG, IONP-ML-CpG was 
evaluated by anion exchange chromatography and agarose gel electrophoresis. Anion 
exchange chromatography was performed using columns with quaternary ammonium matrix 
(HiTrap Q FF column, GE Healthcare). Samples were loaded onto anion exchange columns. 
The columns were washed with 10 column volumes of PBS (100 mM, pH 7.4) and then with 10 
column volumes of NaCl (2M) to elute matrix-retained nanoparticles. Wash and elution fractions 
(2 mL) were analyzed for IONP-ML content by spectrophotometric analysis (600 nm, Tecan 
M1000 PRO). Elution profiles of IONP-ML-CpG were compared to an IONP-ML-PDP control. 
Electrophoretic migration of IONP-ML-CpG was assessed using agarose gel electrophoresis 
0.8% agarose, TAE, 75V, 30 minutes. Gels were imaged with the UVP ChemiDoc-It2 Imager 
and migration distances were quantified using Image J software. CpG content in the 
functionalized IONP-ML-CpG was analyzed by densitometry based on previously described 
procedures with minor modifications34. Briefly, the IONP-ML-CpG samples were first digested 
for 2 hours with TCEP (100 mM aqueous solution), and then subjected to electrophoresis to 
visualize CpG by SYBR gold staining (4% agarose, TAE, 75 V, 30 minutes). Gels were imaged 
using UVP ChemiDoc-It2 Imager. Concentrations of CpG were quantified by densitometry using 
known concentrations of free CpG for calibration. To estimate CpG content of the nanoparticles 
per unit nanoparticle, CpG concentrations in IONP-ML-CpG samples were normalized by 
nanoparticles’ concentrations. Nanoparticle concentrations were determined by ICP-OES.  
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Characterization of IONP-ML-Peptide. To validate conjugation of a model peptide, IONP-ML-
Peptide was evaluated by a Ninhydrin colorimetric assay35. Briefly, IONP-ML-Peptide (100 μg 
total Fe) was mixed with 6M HCl (0.4 mL) at 125°C for 30 minutes. After acid digestion, 6M 
NaOH (0.4 mL) was added to neutralize the pH. Subsequently, the resulting solution (500 uL) 
was mixed with an equal volume of Ninhydrin reagent (2 g Ninhydrin, 75 mL DMSO, 25 mL 3M 
Sodium Acetate, pH 5.5) and heated in a boiling water bath for 20 minutes. Samples volumes 
were adjusted by addition of PBS to offset solvent losses due to evaporation, and then samples 
were analyzed by spectrophotometry (570 nm, Tecan M1000 PRO). Calibration curves were 
constructed using standard peptide solutions also containing IONP-ML-PDP. The iron 
concentration of IONP-ML-PDP in the standard solutions was equivalent to the iron 
concentration of the analyte to offset the absorbance of iron at 570 nm.  
In-vivo MRI-tracked Delivery to the Lymph Nodes. To examine delivery of IONP-ML (10 nm 
and 30 nm cores) and IONP-ML-CpG (30 nm cores) to the lymph nodes in-vivo, mice (C57BL/6 
mice, n = 3) were injected with the nanoparticles (12 mg Fe/kg36) intradermally into the forepaw. 
Delivery to the lymph nodes was evaluated by MRI imaging in-vivo and by analysis of excised 
lymph nodes ex-vivo. MRI was performed using a 33 cm horizontal-bore, 7 Tesla Agilent MR 
imaging system (Agilent, Palo Alto, CA). Animals were anesthetized with 2% isoflurane/air 
mixture and maintained at 37°C with forced heated air inside the magnet. The thoracic region of 
the animals was placed in the center of a 35 mm diameter quadrature RF volume coil. Images 
were acquired before and 1 hour post-administration of nanoparticles. IONP-ML delivery to 
lymph node was monitored utilizing gradient echo (TR = 300 ms, TE = 5 ms, slice thickness, 
FOV of 25 x 25 mm over 128 x 128 matrix) and T2-weighted fast spin-echo multi-slice (TR = 
4000 ms, TE = 60 ms, slice thickness = 1 mm, FOV of 25 x 25 mm over 256 x 128 matrix) MRI 
sequences. During image acquisition, a spatial saturation band was placed over the region of 
the lungs in order to reduce respiratory noise interference.  
Following MRI post-scans, the animals were euthanized, brachial and axillary lymph nodes 
ipsilateral and contralateral to the injection site were excised for ex-vivo analysis and stored at -
80°C until analysis.  
To evaluate delivery of biomolecules using the IONP-ML nanoplatforms, the IONP-ML-CpG was 
complexed with a fluorescently tagged complementary sequence (CpGcomp-Cy5.5).  Mice were 
treated with IONP-ML-CpG/CpGcomp-Cy5.5 (n=4) or free CpGcomp-Cy5.5 (n = 4) via an 
intradermal injection into the forepaw (12 mg Fe/kg). One hour post-administration animals were 
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imaged by whole body fluorescence imaging (675/720 nm ex/em, exposure = 0.25 seconds)  
using IVIS imaging system. Subsequently, the animals were euthanized and brachial and 
axillary lymph nodes were excised for ex-vivo analysis. 
Ex-vivo Analysis of Lymph Node Delivery.  Excised lymph nodes were analyzed for the 
content of iron oxide nanoparticles and the content of the model biomolecule CpGcomp-Cy5.5, by 
electron spin resonance (ESR) spectroscopy and fluorescence imaging, respectively. ESR 
spectroscopy was performed using an EMX ESR spectrometer (Bruker Instruments Inc., 
Billerica, MA) according to the method of Chertok et al14. The acquisition parameters were: 
resonant frequency: ~9.3 GHz, microwave power: 200 mW, temperature: 145K, modulation 
amplitude: 5G and receiver gain: 5×104.  Fluorescence imaging of the excised lymph nodes 
(640/675 nm ex/em, exposure = 0.25 seconds) was carried out using IVIS Spectrum. Image 
analysis was conducted with the Living Image software. 
Statistical Analysis. Data are expressed as mean ± S.D., unless otherwise specified. 
Comparisons between two groups were made using the unpaired Student’s t test. Means of 
multiple groups were compared with the one-way ANOVA, followed by post hoc Tukey’s 
pairwise comparisons. All probability values are two-sided, and values of p < 0.05 were 
considered statistically significant. Curve fitting and statistical analyses were carried out using 
OriginPro8 (OriginLab) and GraphPad Prism 7 software packages. 
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3.4 Results and Discussion   
Formation of lipid-PEG/lipidoid coated iron oxide nanoparticles 
 
To coat oleic acid stabilized nanocrystals with phospholipid-PEG and lipidoids, we used 
a variation of a thin film hydration method24.  Thin film hydration method typically involves 
dispersion of the nanocrystals and the lipids in a thin film, followed by hydration of the film with 
an aqueous buffer to produce coated nanoparticles. Although this method is simple and 
commonly utilized to coat iron oxide nanocrystals, it suffers from several drawbacks. The abrupt 
introduction of solid lipid/nanocrystal dispersions to a non-solvent, water, induces phase 
separation and often results in irreversible aggregation of nanocrystals and low yields. Instead 
of directly hydrating the film with water, we pursued a gradual solvent exchange.  We first 
hydrated the film with ethanol (EtOH) and then dialyzed the resulting nanoparticle suspension 
into water. We considered that replacing the abrupt introduction of solid lipid/nanocrystal 
dispersions to a non-solvent, water, with a gradual solvent exchange could allow the lipids to 
phase transition gradually minimizing phase separation and aggregation37. Thin film hydration in 
EtOH yielded higher recoveries of lipidoid-stabilized nanoparticles than the direct hydration with 
aqueous PBS (Supporting Information, Figure S11). Therefore, we adopted this modified 
method for our subsequent studies. 
Using this method, we tested a series of lipidoids and traditional cationic lipids for their 
ability to facilitate stabilization of 20-nm iron oxide nanocrystals (Supporting Information, Figure 
S12 and Figure S13). As a measure of nanoparticle stabilization, we calculated the recovery of 
water dispersible iron oxide relative to the initial amount of iron oxide in formulations. While 
negligible recoveries were observed without lipidoids, addition of 25% lipidoids (w/w) into lipid 
compositions resulted in aqueous recovery of a significant fraction (14-27%) of initial iron. This 
finding indicated that lipidoids were a critical component for nanoparticle stabilization in our 
system. Interestingly, lipidoids with high numbers of alkyl chains (4-5) yielded significantly 
higher stabilization than traditional cationic phospholipids with two alkyl chains (e.g. C12-98(5) 
vs DOTAP: 27 ± 6% vs 3 ± 2%, p< 0.001).  It is possible that in contrast to cationic 
phospholipids that are oriented to expose their headgroups on the surface, lipidoids can fully 
intercalate the hydrophobic interior and “stitch” the opposing monolayers together. Lipidoid C12-
98(5) exhibited the highest level of stabilization (27 ± 6%) and was selected for further studies. 
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We next asked whether lipidoid C12-98(5) could stabilize nanocrystals of different sizes 
(Figure 3.1B). Indeed, addition of 22% w/w lipidoid to coating compositions resulted in 
significantly higher nanoparticle recoveries compared to coatings without lipidoids for 
nanocrystals of all tested sizes (10 nm: 0.6 ± 0.4% vs. 9 ± 2%, p <0.01; 20 nm: 1.0 ± 0.8% vs. 
18 ± 4%, p <0.001; 30 nm: 0.8 ± 0.8% vs. 35 ± 5%, p < 0.001; 40 nm: 2 ± 1% vs. 62± 8%, p 
<0.001). Further increases in the stabilization efficiency could be achieved by increasing C12-
98(5) concentration in lipid compositions. The stabilization efficiency increased sigmoidally 
(Boltzmann sigmoidal model, R2 = 0.99; p < 0.001 (40 nm) or three parameter non-linear logistic 
model, R2 = 0.99; p < 0.001 (30 nm), R2 = 0.99; p < 0.001 (20 nm), R2 = 0.99; p < 0.001 (10 
nm)), reaching saturation at threshold C12-98(5) concentrations of approximately 45% (%w/w). 
Significantly, at saturation, about 85% recovery could be obtained for nanocrystals of all particle 
sizes (10 nm-40 nm, Figure 3.1B).  
To examine the nature of the nanoparticle coatings, we assessed the coatings by TLC, 
FT-IR, and zeta potential. For TLC analysis, we lyophilized magnetically-separated 
nanoparticles and extracted the coating from the surface by re-dispersing the nanoparticles in 
chloroform. TLC chromatograms confirmed presence of the lipidoid C12-98(5) and 
phospholipid-PEG on the nanoparticles’ surfaces (Supporting Information, Figure S14). FT-IR 
provided further evidence of the coating composition (Figure 3.1C). The spectrum of coated 
nanoparticles IONP-ML displayed additional peaks (1100 cm-1, 1560 cm-1 and 1650 cm-1) not 
observed for oleic acid stabilized nanocrystals IONP-OA. The peaks at 1100 cm-1 corresponded 
to the ether bond (C-O-C stretching) of the PEG chains, while the peaks at 1560 cm-1 and 1650 
cm-1 corresponded to the amide bond (N-H bending and C=O stretching, respectively) of the 
acrylamide chains. These peaks confirmed the addition of the PEG-containing DSPE-
mPEG(2000) and acrylamide-containing C12-98(5), respectively, to the nanocrystal’s surface. 
Interestingly, coated nanoparticles of all sizes displayed nearly electroneutral zeta 
potential (~4 mV, Table 3.1). Our measurements of PEG packing densities indicated that IONP-
ML with a 30 nm nanocrystal’s diameter contain 11,740 phospholipid-PEG molecules per 
particle (Supporting Information, Section 5). Given the negative charge of the phosphate 
groups, this density of the anionic phospholipids on the nanoparticle’s surface should have 
translated to a strongly negative zeta potential. Indeed, previous studies reported highly 
electronegative zeta potentials (-29 mV) for iron oxide coatings that contained DSPE-
mPEG2000 as a single component26, 38. Thus, the electroneutral zeta potential of our IONP-ML 
provides additional evidence for surface integration of cationic lipidoids and reveals charge 
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neutralization. It is likely that the charge neutralization is a manifestation of the electrostatic 
interactions between the cationic amine groups of the lipidoids and anionic phosphate groups of 
the DSPE-mPEG, which stabilize the coating shell.  
 
Lipidoid stitched coatings mediate formation of iron oxide nanoparticles with robust size control 
across a range of nanocrystal sizes 
 
We next examined the morphology and size of coated nanoparticles by TEM and DLS. 
Lipid-PEG/lipidoid stabilized nanocrystals IONP-ML were individually coated and exhibited 
monocrystalline core-shell morphology (Figures 3.2A and 3.2B). Notably, this IONP-ML 
morphology in aqueous solution was reproducible across a range of nanocrystal sizes, similar to 
the original IONP-OA dispersed in chloroform (Figure 3.2A). 
Distinct homogenous shells could be observed by TEM for IONP-ML nanoparticles of all 
sizes (Figure 3.2C). The shells of the IONP-ML nanoparticles measured about 5 nm and were 
significantly thicker than the shells of the IONP-OA nanocrystals for each examined nanocrystal 
size (p < 0.001, Figure 3.2D). The observed shell on the IONP-ML surface likely represents the 
tightly packed hydrophobic portion of the coating.  The reported length estimates for the oleic 
acid and the DSPE are 1.7 nm and 3.2 nm, respectively25. Given these estimates, the 
hydrophobic part of the phospholipid-PEG is unlikely to directly interdigitate with the surface-
anchored oleic acid. Rather, both the oleic acid and the DSPE-mPEG shell components likely 
interdigitate with the alkyl chains of the lipidoid, which “stitches” the oppositely oriented tails of 
the two hydrophobic monolayers together. Notably, quantitative analysis of the coating 
thicknesses revealed that the shell thicknesses did not differ significantly for the nanoparticles of 
different size (p = 0.18, Figure 3.2D). This finding indicated that the coating could be formed 
reproducibly across a range of nanocrystal sizes. 
We next examined the hydrodynamic diameters of IONP-ML (Figure 3.3 and Table 3.1). 
The IONP-ML of all particle sizes exhibited monodisperse populations, as evident by their 
polydispersity indices of less than 0.2 (Table 3.1)39. Notably, for nanocrystals of a given core 
size, the mean hydrodynamic diameter of coated IONP-ML was highly reproducible between 
formulations (Figure 3.3A). Most significantly, the mean hydrodynamic diameters of the IONP-
ML displayed a very strong positive correlation with the nanocrystals’ core diameters (Pearson 
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R2 coefficient of 0.98, p < 0.001, Figure 3.3B). This finding indicated that our coating method 
provided a way to achieve control of nanoparticle’s hydrodynamic size using nanocrystals of 
defined size as a starting material.  
Interestingly, our experimentally measured values of the hydrodynamic diameter for 
nanoparticles of different sizes were in a close agreement with the theoretical estimates 
calculated using a scaling model (Figure 3.3B and Supporting Information, Section 6)40-42. The 
hydrodynamic diameter of the PEGylated nanoparticles in aqueous solution is known to depend 
on the extent of coiling or stretching of PEG chains on the nanoparticle’s surface (Figure 
3.3C)40, 42. Surface-grafted PEG chains extend out from the particle’s surface, forming a layer of 
thickness L. The scaling model provides an estimate of this layer while accounting for the three 
major factors: 1) the radius (Rc) of the nanoparticle’s sphere to which the PEG chains are 
attached, the so-called “hard sphere”, 2) the packing density of PEG, and 3) the characteristics 
of the PEG chains. For a system with given characteristics of the PEG polymer, PEG2000, 
direct dependence of the PEG layer thickness on the radius of the nanocrystal’s core implies 
consistent structure of the coating shell. Thus, the close agreement between the calculated and 
the measured values of the hydrodynamic diameters in our system supports consistent structure 
of the shell across nanoparticles of different core sizes. 
Notably, our coating shells displayed very high PEG packing densities (Supporting 
Information, Section 5 and 6). Among previously reported DSPE-mPEG coatings for iron oxide, 
the highest PEG packing densities were ~0.5 PEG/nm2 per unit area of the “hard sphere”40. In 
previous studies, because the coatings with DSPE-mPEG have typically been formed by a 
micelle-like self-assembly, these densities are similar to the packing densities for DSPE-mPEG 
micelles42. In contrast, our shells displayed packing densities of ~2.5 PEG/nm2 per unit area of 
the “hard sphere”, which is 5-fold higher than the values reported previously. The high packing 
density is likely due to the lipidoids’ ability to “stitch” the components of lipid shells on the iron 
oxide surfaces. This stitched high-density packing likely is the factor that governs size control by 
allowing formation of consistent shell structures for nanocrystals of different sizes. 
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IONP-ML retain magnetic properties of the original iron oxide nanocrystals and display high r2 
relaxivities 
 
One challenge in developing core-shell iron oxide nanocarriers as theranostics is 
maintaining magnetic properties during formation of the coating shells12. Magnetic properties, 
which determine the ability of iron oxides to function as MRI-trackable theranostics, can be 
significantly attenuated by the coating process20. The attenuation is typically related to 
perturbation of the nanocrystal’s surface during processes such as ligand exchange. Coating by 
amphiphilic self-assemblies is typically advantageous in maintaining magnetic properties 
because it does not rely on direct interactions of the coating material with the inorganic surface 
of the nanocrystal. To confirm the ability of our coating procedure to maintain magnetic 
properties, we assessed the saturation magnetization (Ms) of the IONP-ML (Figure 3.4A). The 
Ms values for IONP-ML with 10 nm (44 ± 7 emu/g Fe) and 30 nm core sizes  (83 ± 5 emu/g Fe) 
were in close agreement with the previously reported Ms values for oleic acid-stabilized 
nanocrystals of the same sizes (10 nm:45 emu/g Fe ; 30 nm:87 emu/g Fe)43. Furthermore, 
IONP-ML and IONP-OA with 10 nm crystals exhibited no significant differences in saturation 
magnetization (44 ± 7 emu/g Fe vs 48 ± 7 emu/g Fe, p = 0.43, Figure 3.4A-insert). These 
findings validated that our coating method can robustly preserve the original magnetic 
properties of the iron oxide nanocrystals. 
We further assessed the superparamagnetic property of the stabilized IONP-MLs (Figure 
3.4B). Superparamagnetic behavior signifies that while the IONPs can be magnetized by an 
applied magnetic field, they regain zero net magnetic moment in the absence of magnetic 
field44. This property is essential for preventing magnetically induced agglomeration of IONPs in 
vivo30, 44. Superparamagnetic behavior is typically determined by nanocrystal size and can be 
exhibited by nanocrystals with up to 35 nm diameters45. Indeed, following initial attainment of 
induced magnetization of 39 ± 6 emu/g Fe (10 nm core) and 78 ± 4 emu/g Fe (30 nm core) in 
the applied fields of 4000 Ga, IONP-ML were found to completely demagnetize (10 nm core: 0 ± 
2 emu/g Fe; 30 nm core: 0 ± 3 emu/g Fe) in the applied field of 0 Ga, confirming their desirable 
superparamagnetic behavior. The superparamagnetic behavior of the IONP-ML suggested that 
they are unlikely to magnetically agglomerate in vivo. 
Finally, we also assessed the transverse r2 relaxivities of the IONP-ML (Figures 3.4C 
and 3.4D). The transverse r2 relaxivity is an inherent property of iron oxides, which determines 
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their ability to function as MRI contrast agents46. The relaxivity of the IONP-ML with 10 nm cores 
(66 ± 4 mM-1s-1) was similar to that of clinically utilized MRI contrast agents (e.g. Combidex, 65 
mM-1s-1; Ferumoxytol 83 mM-1s-1)47, 48. Notably, larger IONP-ML with 30nm cores exhibited a 3-
fold enhancement in r2 relative to their smaller counterparts (30 nm: 205 ± 10 mM-1s-1 vs 10 nm: 
66 ± 4 mM-1s-1, p<0.001). This enhancement is likely due to the larger nanocrystal size and 
stronger saturation magnetization.  High transverse relaxivities of the IONP-ML suggested that 
these particles would be detectable by MRI in vivo. 
 
IONP-ML can rapidly and efficiently access lymph nodes and allow tracking of delivery by MRI 
 
The advantageous combination of properties of the IONP-ML, including sub-100 nm 
size, high r2 relaxivity and superparamagnetic behavior, prompted us to examine their potential 
as theranostic vehicles for MRI-trackable lymph node delivery. To assess this potential, we 
injected the IONP-ML intradermally into the forepaw of C57BL/6 mice and examined delivery to 
the draining lymph nodes by MRI (Figure 3.5). 
Baseline T2-weighted (T2W) axial images through the thoracic region allowed clear 
delineation of the brachial lymph nodes. We therefore chose these lymph nodes for qualitative 
assessment of the IONP-ML delivery by MRI. We examined both the 10 nm core (Figure 3.5A) 
and the 30 nm core (Figure 3.5B) IONP-ML. At one-hour post-administration, Gradient Echo 
(GE) and T2W images for both nanocarriers displayed a region of pronounced hypointensity 
relative to their respective GE and T2W pre-scans. This hypointensity was co-localized with the 
brachial lymph nodes ipsilateral to the injection site. The observed hypointensity reflects the 
presence of iron oxide within the tissue and, thus, the delivery of the IONP-ML to the draining 
brachial lymph nodes. In contrast, no GE/T2W signal reduction could be discerned in the lymph 
nodes contralateral to the injection site, consistent with draining-node selective delivery. To 
validate the MRI results, we quantified the iron oxide content in excised ipsilateral and 
contralateral lymph nodes (brachial + axillary) of test mice injected with either the 10 nm or 30 
nm core nanoparticles (Figure 3.5C). The lymph nodes of the “blank” mice that received no 
nanoparticles were used as controls. Consistent with the MRI observations, no increase in the 
iron oxide content relative to controls was observed for the contralateral lymph nodes, from 
either the 10 nm (10 nm: 0.15 ± 0.04 μg Fe (baseline) vs. 0.20 ± 0.04 μg Fe (contralateral), p > 
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0.99) or the 30 nm (30 nm: 0.13 ± 0.01 μg Fe (baseline) vs. 0.18 ± 0.06 μg Fe (contralateral), p 
> 0.99) test groups. In contrast, the ipsilateral lymph nodes of each test group displayed more 
than 100-fold higher iron oxide content relative to controls (10 nm: 0.15 ± 0.04 μg  Fe (baseline) 
vs. 21 ± 11 μg Fe (ipsilateral), p < 0.001; 30 nm: 0.13 ± 0.01 μg Fe (baseline) vs. 21 ± 5 μg Fe 
(ipsilateral), p < 0.001). These findings validated the MRI results and firmly corroborated that 
IONP-ML with both 10 nm and 30 nm cores could be delivered to the draining lymph nodes and 
tracked by MRI. 
Significantly, both the 10 nm core and the 30 nm core IONP-ML could access the 
draining lymph nodes rapidly and efficiently. To reach the lymph nodes from the intradermal 
injection site, nanocarriers can either be actively shuttled to the lymph node by migratory 
dendritic cells or passively drain to the lymph nodes through the lymphatics5, 9. The latter 
mechanism is much more rapid and efficient than the former. Following administration, 
nanocarriers that leverage the lymphatic drainage typically reach the lymph nodes within 1-2 
hours while the delivery based on the migratory cells typically displays an 8-24 hour lag time5, 9. 
In addition, delivery of 0.2%-1% of the initial dose (ID) within 2 hours of administration has been 
previously reported for nanocarriers that drain through the lymphatics, while the delivery by 
migratory cells is typically at least 10-fold less efficient8, 9, 49. Notably, we achieved 
accumulations of 9 ± 4 and 8 ± 2 % ID within 1 hour of administration for the IONP-ML with 10 
nm and 30 nm cores, respectively. In addition, nanoparticles could be observed in the draining 
lymph nodes as early as 15 minutes post injection (Figure 3.5D). This rapid and efficient 
delivery is consistent with the lymphatic drainage path. Interestingly, 1-hour GE post-scans 
displayed a hypointense trail from the site of administration to the ipsilateral brachial lymph node 
(Figure 3.5D). This trail likely reflects the lymphatic vessels enhanced by the nanocarriers as 
they drain to the lymph nodes, directly mapping delivery of the IONP-MLs by the lymphatic 
drainage.  
To drain to the lymph nodes following intradermal or subcutaneous administration, the 
nanoparticles must be convectively transported through the interstitial matrix and enter the 
afferent lymphatic vessels50. For spherical nanoparticles, this pathway is typically restricted to 
carriers of sub-100 nm size, likely due to the network geometry of the interstitial extracellular 
matrix and the sieving action of the valve-like cell-cell junctions in the lymphatic vessels51. Thus, 
the ability of the IONP-ML to leverage the lymphatic drainage reflects that these particles can 
robustly maintain their small sub-100 nm size in vivo. Interestingly, despite their larger size, the 
30 nm core IONP-ML (~53 nm hydrodynamic diameter) could access the lymph nodes as 
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efficiently (p= 0.96) as their smaller 10 nm core counterparts (~34 nm hydrodynamic diameter). 
These findings are consistent with previous reports, demonstrating little difference in lymphatic 
trafficking between carriers within the 30-70 nm size range52, 53.  Most significantly, the extent of 
the lymph node delivery for the IONP-ML of both the 10 nm and the 30 nm core sizes was 9- to 
40-fold more efficient compared to the previously reported spherical particles of sub-100 nm 
size within similar time frames (0.2%-1% ID within 2 hr)52. This enhanced efficiency is likely due 
to the high density of surface PEGylation of the IONP-ML (~2.5 molecules/nm2) enabled by their 
lipidoid-stitched coatings. Previous work demonstrated that PEGylation could significantly 
enhance lymph node drainage of nanocarriers by blocking interactions with the extracellular 
matrix at the injection site49, 54. It is likely that dense PEG layers on the surfaces of the IONP-ML 
exerted a similar effect.  
 
IONP-ML allow surface conjugation of biomolecules at high grafting capacity and density, while 
maintaining sub-100 nm particle size 
 
Delivery vectors that can rapidly and efficiently traffic to the lymph nodes while 
displaying biomolecules on their surfaces are highly advantageous in the context of therapeutic 
immunomodulation because they can mimic the presentation of antigens and adjuvants by 
pathogens5, 55. Given the highly efficient trafficking of the IONP-ML to the lymph nodes, we next 
sought to examine whether IONP-ML could facilitate surface display of biomolecules. To test 
biomolecule conjugation to the IONP-ML surface, we chose a peptide and a CpG 
oligonucleotide as model biomolecules. These biomolecules have demonstrated considerable 
potential as immunomodulatory antigens and adjuvants, respectively56, 57. 
To conjugate these model biomolecules to the nanoparticle’s surface, we replaced 50% 
of DSPE-mPEG in the coating formulations with the functionalized lipid DSPE-PEG-PDP. 
Integration of functionalized phospholipids had no significant effect on either the recovery (10 
nm: p = 0.99; 30 nm: p = 0.98) or the particle size (10 nm: p = 0.84; 30 nm: p = 0.99) of the 
resulting formulations (Supporting Information, Figure S15). Using disulfide exchange chemistry, 
we coupled either the CpG oligonucleotide or the peptide, each functionalized with a free thiol, 
to the surface of IONP-ML-PDP and then purified the nanoparticles by magnetic separation to 
remove unreacted biomolecules (Figure 3.6A). Quantitative analysis confirmed successful 
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conjugation (Figures 3.6B and 3.6C). Comparison to control (0% PDP) formulations further 
revealed that the majority of the nanoparticle-associated biomolecules (~95% and ~90% for the 
CpG and the peptide, respectively) were covalently conjugated rather than non-specifically 
adsorbed to the nanoparticle’s surface. Under equivalent experimental conditions, higher extent 
of coupling was observed for the peptide compared to the CpG (10 nm: p<0.001, 30 nm: 
p=0.02). This is likely due to lower thiol reactivity and higher level of electrostatic repulsions 
associated with the higher thiol pKa and higher charge density of the oligonucleotides58-60. To 
further corroborate accessibility of the conjugated biomolecules on the nanoparticle surface, we 
analyzed CpG-loaded nanoparticles (IONP-ML-CpG) by anion exchange chromatography 
(Figure 3.6E). Control IONP-ML nanoparticles could be eluted from the quaternary ammonium 
column matrix with the flow-through, consistent with their nearly electroneutral surface potential 
(30 nm: -5 ± 2 mV, Table 3.2). In contrast, electronegative (30 nm: -20 ± 4 mV, Table 3.2) CpG-
modified nanoparticles were retained by the cationic matrix and required solutions of high ionic 
strength (2M NaCl) for elution. Because interaction of the nanoparticle-loaded biomolecules with 
the column matrix requires display of the biomolecule on the particle’s surface, this finding 
corroborated accessibility of anionic CpG on the surface of IONP-ML-CpG.  
Most significantly, conjugation yielded strikingly high multivalencies and densities of 
biomolecule display. IONP-ML with 10 nm cores could be loaded with 102 ± 9 and 240 ± 36 
molecules of CpG and peptide per particle, respectively (Figure 3.6B). These loadings are 10-
fold higher than the loadings previously reported (10 molecules of CpG per particle and 23 
molecules of peptide per particle) for lipid-coated iron oxide nanoparticle of similar sizes (~40 
nm)61, 62. Furthermore, increasing the particle sizes from 10 nm to 30 nm cores allowed further 
increase of the loading by 27-fold (30 nm vs 10 nm: 2771 ± 205 molecules/particle vs 102 ± 9 
molecules/particle, p<0.001) and 22-fold (30 nm vs 10 nm: 5452 ± 1654 molecules/particle vs 
240 ± 36 molecules/particle) for CpG and peptide, respectively (Figure 3.6C). These loading 
multivalencies are comparable to the highest loadings reported so far for nanoparticles of similar 
sizes  (2.5x10-11 µg peptide per particle for gold nanoparticles vs 1.8 x10-11 µg peptide per 
particle for IONP-ML-peptide, 30 nm core)63. Likewise, the high multivalencies also translated to 
high densities of biomolecule display per unit surface area. Peptide loading could be achieved 
at densities of ~0.06 molecules/nm2 and ~0.6 molecules/nm2 for the 10 nm and 30 nm core 
IONP-MLs, respectively (Supporting Information, Table S9). These densities are more than 10-
fold and 100-fold higher, respectively, than the estimated density (~0.005 molecules/nm2) for 
previously reported lipid-coated iron oxide nanoparticle of similar sizes (~40 nm)62.  
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Accumulating evidence reveals that the multivalency and the density of biomolecule 
display can significantly impact immune response because these features are pivotal to 
pathogen-induced immune activation7. In this context, several studies have explored how 
pathogen-associated biophysical attributes such as antigen/adjuvant surface densities affect 
immunity and have begun formulating the rules for design of nanoparticle-based 
immunomodulating technologies64. One elegant meta-analysis of existing viral vaccines 
suggested that high densities (0.01-0.05 molecules/nm2) display of protein antigens on a 
nanocarrier’s surface is likely to be the key for stimulating strong immune responses7. Each 
immunogenic protein further contains about 10 epitopes, yielding the density requirement of 
about 0.1-0.5 epitopes/nm2 65. Notably, our 30 nm core IONP-ML nanoparticles can robustly 
fulfill this requirement, suggesting that they embody the potential for design of efficient vaccines.  
Until now, high surface loadings of biomolecules could only be achieved with 
nanoparticles that allow direct covalent conjugation of PEG tethers to the nanoparticle’s surface, 
such as gold nanoparticles63. In contrast, achieving high-capacity loading of biomolecules on 
nanoparticles coated by lipid self-assemblies appears to be difficult. Reported loadings have 
been limited to only few tens of molecules per particle61, 62. Previous methods to coat 
nanocrystals by phospholipid coatings have been based on micelle-like self-assembly23. 
Although such assemblies can facilitate biomolecule attachment, they may not be sufficiently 
stable to withstand biomolecule loadings at high capacity. Indeed, previous reports 
demonstrated significant enhancement in biomolecule loading onto the phospholipid-coated iron 
oxide with covalently cross-linked phospholipids66. In our system, the stability of the self-
assembled lipid shell is likely enhanced by lipidoid-mediated stitching.  This stabilization allows 
the shell to withstand surface loading of biomolecules at high capacity, while circumventing the 
need for covalent cross-linking. Examination of the nanoparticle morphology by TEM supports 
this notion, as high density CpG conjugation to the IONP-ML’s surface did not appear to 
substantially perturb the nanoparticle’s shell (Figure 3.6D). 
Importantly, despite high-capacity conjugation of biomolecules, IONP-MLs were still able 
to maintain small sub-100 nm hydrodynamic diameters (Table 3.2). The biomolecule-loaded 
IONP-ML preserved their monodispersity as reflected by their polydispersity index of less than 
0.2 (Table 3.2)39. In addition, both 10 nm core and 30 nm core IONP-ML-CpG (hydrodynamic 
diameters: 43 ± 2 nm and 81 ± 2 nm) migrated on the agarose gel (0.8%) as single bands with a 
narrow band spread (10 nm: ± 0.65 mm, 30 nm: ± 0.83 mm) and no evident trailing (Figure 
3.6F). These migration patterns further corroborated lack of aggregation and monodispersity of 
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nanoparticle populations following conjugation of biomolecules67, 68.  In addition, the content of 
biomolecules attached to the nanoparticle’s surface was not significantly affected by incubation 
with serum (Supporting Information, Figure S16), suggesting that the biomolecule-loaded 
nanoparticles could be leveraged for delivery in vivo.  
 
IONP-ML with 30 nm core size can facilitate biomolecule delivery to the lymph nodes 
  
Intrigued by the fact that the 30 nm core IONP-ML exhibited remarkable capacity for 
biomolecule display while preserving small sub-100 nm size, we asked whether these particles 
could traffic to the lymph nodes and facilitate biomolecule delivery. To address this question, we 
examined lymph node delivery of the IONP-ML-CpG with 30 nm cores. To visualize the delivery 
of the nanocarrier-attached CpG, we complexed the CpG with the complementary fluorophore-
tagged oligonucleotide strand, CpGcomp-Cy5.5 (Figure 3.7A). Thus, both components of our 
system, the nanocarrier and the biomolecule cargo, could be tracked by imaging: MRI and 
fluorescence imaging, respectively. 
Indeed, similar to the biomolecule-free IONP-ML, biomolecule-loaded IONP-ML-CpG 
could efficiently access the lymph nodes as evidenced by MRI (Figure 3.7B). One hour after 
injection, pronounced hypointensity in the ipsilateral brachial lymph nodes was observed on 
both the GE and T2W images compared to respective pre-scans. This signal reduction reflected 
successful delivery of the biomolecule-displaying nanocarriers to the draining lymph nodes. 
Notably, IONP-ML-CpG showed no significant decrease in iron oxide uptake in the ipsilateral 
lymph nodes relative to the IONP-ML (IONP-ML: 8 ± 2% ID vs. IONP-ML-CpG: 6 ± 2% ID, p = 
0.22, Figure 3.7C). This finding indicated that the display of CpG on the nanocarrier’s surface 
did not significantly interfere with lymphatic trafficking. Furthermore, fluorescence imaging in 
vivo revealed a strong fluorescence signal in the axillary area ipsilateral to the injection site 
(Figure 3.7B). Imaging of intact excised ipsilateral and contralateral lymph nodes further 
confirmed that the fluorescence signal was localized to the draining brachial and axillary lymph 
nodes (Figure 3.7D). Moreover, comparison to a soluble antiCpG-Cy5.5 control revealed a 3.5-
fold higher fluorescence for biomolecule delivery via IONP-ML-CpG relative to the control (p < 
0.001, Figure 3.7E). These findings corroborated that the IONP-ML-CpG nanocarrier could 
effectively mediate the delivery of its biomolecule cargo to the draining lymph nodes. Thus, 
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IONP-ML can serve as a MRI-trackable platform for delivery of biomolecules to the lymph 
nodes. 
3.5 Conclusions 
Taken together, our results demonstrate that core-shell iron oxide nanoparticles IONP-
ML display the desired material characteristics for MRI-trackable biomolecule delivery to the 
lymph nodes and surface display of biomolecules at high capacity. These functionalities of the 
IONP-ML are largely determined by their controlled particle sizes.  To engineer IONP-ML with 
controlled size, we developed a novel method to coat iron oxide nanocrystals with lipid-stitched 
shells. This method relies on integration of lipidoids, cationic agents with hydrophobic tails, into 
lipid coatings to “stitch” together the opposing lipid monolayers on the iron oxide surface, likely 
by a combination of hydrophobic and electrostatic interactions. Formation of consistent 
nanocrystal coatings allowed engineering of core-shell nanoparticles with controlled particle 
sizes. Unlike previous methods to coat iron oxide with amphiphilic lipids, our method is not 
limited to coating nanocrystals with small size (< 20 nm) but can provide robust stabilization of 
nanocrystals with both small (< 20 nm) and large (> 20 nm) sizes.   
In the context of immunomodulation, size is one of the key parameters in determining 
the nanocarrier’s biological performance. The range of nanoparticle sizes that can achieve 
direct access to the lymph nodes through lymphatic drainage has an upper limit of 
approximately 100 nm. Thus, it is important to develop biomolecule-displaying nanocarriers with 
sizes below this threshold. Indeed, the IONP-ML with both 10 nm and 30 nm core sizes, 
translating to ~34 nm and ~53 nm hydrodynamic diameters, could rapidly and efficiently access 
the lymph nodes. Within the sub-100nm size range, larger nanocarriers offer an additional 
advantage of larger surface area and thus larger capacity for biomolecule display while still 
preserving the capability to leverage lymphatic drainage. Indeed, the 30 nm core (~53 nm 
hydrodynamic diameter) IONP-ML displayed biomolecule loading capacities among the highest 
reported to date while also accessing the lymph nodes rapidly and efficiently. Carriers that can 
mimic the biophysical attributes of pathogens, including small size and high multivalency/density 
of biomolecule display, possess a significant potential for design of effective pathogen-mimetic 
vaccines.  Thus, by allowing stabilization of nanocrystals of both small and large sizes, our 
method offers a versatile nanoplatform design that could potentially be leveraged to direct 
immune responses for specific therapeutic applications. 
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Finally, our coating method also allowed preservation of the iron oxide’s magnetic 
properties. Consequently, high r2 relaxivities of the IONP-ML could be harnessed for in vivo 
tracking of these nanoparticles by MRI. The ability to visualize the nanocarriers by non-invasive 
imaging offers attractive benefits of tracking delivery and personalizing dosage regimens to 
augment therapeutic benefit. 
Overall, the combination of properties displayed by IONP-ML including controlled sub-
100 nm size, high r2 relaxivities and high capacities for biomolecule display makes these 
particles attractive platforms for MRI-trackable delivery of biomolecules to the lymph nodes. The 
versatility and multifunctionality of these platforms could potentially be leveraged for rational 
design of a wide variety of image-guided immunomotherapy applications. 
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3.8 Figures  
Figure 3.1 - Formulation of multi-lipid-coated iron-oxide nanoparticles (IONP-ML). (A) Schematic 
depiction of IONP-ML formulation method. (B) Dependence of the nanocrystal stabilization 
efficiency on the content of C12-98(5) lipidoid in lipid formulations; Data represents mean ± 
S.D., n ≥ 3; the curves depict fits using Boltzmann sigmoidal model, R2 = 0.99; p < 0.001 (40 
nm) or three parameter non-linear logistic model, R2 = 0.99; p < 0.001 (30 nm), R2 = 0.99; p < 
0.001 (20 nm), R2 = 0.99; p < 0.001 (10 nm); (C) Representative FT-IR spectra of IONP-ML and 
formulation components. S.D., standard deviation.  
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Figure 3.2 - Characterization of IONP-ML by TEM. (A) Representative TEM micrographs of the 
original oleic acid stabilized nanocrystals (IONP-OA) dispersed in chloroform (left column) and 
the multi-lipid stabilized IONPs (IONP-ML) dispersed in water (right column). (B) Representative 
TEM micrograph of 30 nm IONP-ML dispersed in water, arrows identify lipid shell layer. (C) 
Representative IONP-OA and IONP-ML TEM micrographs; background subtraction was carried 
out according to the method of Hartig to better visualize shell morphology.59 (D) Quantitative 
analysis of the lipid shell thickness, quantified from TEM micrographs; Data represents mean ± 
S.D, n ≥ 50. TEM, transmission electron microscopy; S.D., standard deviation. Scale bars: 50 
nm. 
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Figure 3.3 - Size control of the IONP-ML. (A) Reproducibility of particle size across formulations: 
histograms represent distributions of mean particle size for repeated IONP-ML formulations and 
respective original nanocrystal samples IONP-OA with 30 nm cores (n = 18, formulation 
replicates). (B) Correlation between the hydrodynamic diameter of the coated particles IONP-
ML (DLS, 10 nm - 30 nm: n = 7, 40 nm: n = 3) and the core diameters of respective 
nanocrystals IONP-OA (TEM, 10 nm – 40 nm: n ≥ 75); Data represents mean ± S.D; Pearson 
R2 coefficient 0.98, p < 0.001; Theoretical values were calculated using a scaling model; model 
is described in Supporting Information, Section 5 and 6. (C) Schematic depiction of the scaling 
model; L= thickness of the PEG layer, Rs = radius of the interdigitated lipid shell, RIO =radius of 
the iron-oxide nanocrystal’s core, Rc = radius of the “hard sphere”; description of the model is 
provided in Supporting Information, Section 5 and 6. TEM, transmission electron microscopy; 
DLS, dynamic light scattering; S.D., standard deviation. 
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Table 3.1. Characterization of the IONP-ML nanoparticles  
1Core diameters measured by TEM; Data represents mean ± S.D., n = 75.  
2Samples were dispersed in phosphate-buffered saline (PBS), pH 7.4; Data represents mean ± 
S.D.,  
n ≥ 5.  
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Figure 3.4 - Evaluation of IONP-ML’s magnetic properties. (A) Induced magnetization of the 
IONP-ML in an applied magnetic field, measured by SQUID magnetometry; Data represents 
mean ± S.D., n = 3. (A-Insert) Comparison of the induced magnetization for original IONP-OA 
and IONP-ML (10 nm core); Data represents mean ± S.D., n = 3. (B) Analysis of 
superparamagnetic behavior: induced magnetization with increasing and subsequently 
decreasing applied magnetic fields; Data represents mean ± S.D, n = 3; the curves depict fits 
using hyperbolic model, R2 = 0.92; p < 0.001 (10 nm ascending), R2 = 0.93; p < 0.001 (10 nm 
descending), R2 = 0.99; p < 0.001 (30 nm ascending), R2 = 0.99; p < 0.001 (30 nm descending); 
Data represents mean ± S.D., n = 3. (C) Representative R2 relaxivity maps for aqueous 
solutions of IONP-MLs in-vitro; Color bar represents R2 relaxivity values (mM-1s-1). (D) R2 
relaxivity of IONP-MLs dispersed in 100 mM PBS, pH 7.4; Data represents mean ± S.D, n = 3; 
Curves are fitted using linear regression model R2 = 0.97; p < 0.001 (10 nm), R2 = 0.99; p < 
0.001 (30 nm). SQUID, superconducting quantum interference device; S.D., standard deviation.  
 
123 
 
 
Figure 3.5 - In-vivo MRI-tracked lymph node delivery of the IONP-ML following intradermal 
administration. (A) Representative gradient-echo (GE) and T2-weighted (T2) MRI images 
acquired before (baseline) and after (1-hour) administration of 10 nm core IONP-ML. Arrows 
depict contralateral (yellow), and ipsilateral (red) brachial lymph nodes. (B) Representative 
gradient-echo (GE) and T2-weighted (T2) MRI images acquired before (baseline) and after (1- 
hour) administration of 30 nm core IONP-ML. Arrows depict contralateral (yellow), and ipsilateral 
(red) brachial lymph nodes. (C) Quantitative analysis of iron oxide concentrations in intact 
excised lymph nodes by ESR spectroscopy; Data  (mean ± S.D, n ≥ 3) represent percent of 
injected dose delivered to either ipsilateral or contralateral lymph nodes (axillary and brachial 
lymph nodes combined). (D) Representative GE images depicting ipsilateral brachial lymph 
nodes before and sequentially after injection of IONP-ML with 30 nm cores. Statistical 
comparisons are based on one-way ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. Asterisks denote statistical significance at the level of **p < 0.01, ***p < 0.001. 
ANOVA, analysis of variance; S.D., standard deviation. MRI, magnetic resonance imaging; ESR 
spectroscopy, electron spin resonance spectroscopy; S.D., standard deviation.  
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Figure 3.6 - Conjugation of model biomolecules (CpG oligonucleotide and peptide) to the 
surface of IONP-ML. (A) Schematic depiction of the chemical conjugation route to load model 
biomolecules to the surface of IONP-ML. (B) Quantitative analysis of functionalization with CpG 
oligonucleotide and peptide for IONP-ML-PDP with 10 nm core size; Data represents mean ± 
S.D, n = 3;. (C) Quantitative analysis of functionalization with CpG oligonucleotide and peptide 
for IONP-ML-PDP with 30 nm core size; Data represents mean ± S.D, n = 3;.(D) Representative 
TEM micrographs of IONP-ML-PDP before and after surface modification with CpG (IONP-ML-
CpG); scale bar: 10 nm. (E) Evaluation of IONP-ML-CpG by anion exchange chromatography 
(2M NaCl eluent). (F) Evaluation of IONP-ML-CpG by agarose gel electrophoresis (0.8% 
agarose, TAE, 75 V, 15 minutes; Lanes: (1) 10 nm core IONP-ML-PDP control,  (2) 10 nm core 
IONP-ML-CpG, (3) 30 nm core IONP-ML-PDP control, (4) 30 nm core IONP-ML-CpG; Statistical 
comparisons are based on two-tailed unpaired Student’s t-test. Asterisks denote statistical 
significance at the level of **p < 0.01, ***p < 0.001. TEM, transmission electron microscopy; 
S.D., standard deviation.  
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Table 3.2 - Characterization of IONP-ML-CpG and IONP-ML-Peptide nanoparticles.  
Samples were dispersed in phosphate-buffered saline (PBS), pH 7.4;  
Data represents mean ± S.D., n ≥ 5. 
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Figure 3.7 - In vivo lymph node delivery of biomolecule-displaying IONP-ML-CpG following 
intradermal injection. (A) Labeling of IONP-ML-CpG with a fluorescently-tagged CpGcomp-Cy5.5 
via complementary base pairing (IONP-ML-CpG/CpGcomp-Cy5.5. (B) Representative GE and T2 
weighted MRI images and IVIS fluorescence images (Ex/Em = 675/720 nm, exposure = 0.25 s) 
acquired before (baseline) and after (1 hour) administration of fluorescently labeled IONP-ML-
CpG/CpGcomp-Cy5.5 (30 nm core); Arrows identify brachial lymph node on GE and T2-weighted 
MRI images. Color bar represents mean radiant efficiency expressed as photon flux per second 
per square centimeter per steradian divided by microwatt per square centimeter 
(p/sec/cm2/sr)/(μW/cm2). (C) Ex vivo quantitative analysis of nanoparticle delivery to the 
ipsilateral and contralateral lymph nodes (axillary and brachial lymph nodes combined) following 
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intradermal injection of 30 nm core IONP-ML and IONP-ML-CpG, (measured by ESR 
spectroscopy); Data represents mean ± S.D, n ≥ 3. (D) Representative fluorescence images of 
ipsilateral and contralateral lymph nodes ex vivo, acquired 1 hour after intradermal injection of 
IONP-ML-CpG/CpGcomp-Cy5.5 and free CpGcomp-Cy5.5 (Ex/Em = 640/675 nm, exposure = 0.25 
s). Color bar represents mean radiant efficiency (p/sec/cm2/sr)/(μW/cm2). (E) Quantitative 
analysis of CpGcomp-Cy5.5 delivery to ipsilateral and contralateral lymph nodes (axillary and 
brachial lymph nodes combined) following intradermal injection of free CpG-Cy5.5 and IONP-
ML-CpG/CpGcomp-Cy5.5; Data represents mean ± S.D, n = 4; Statistical comparisons are based 
on one-way ANOVA, followed by post hoc Tukey’s pairwise comparisons. Asterisks denote 
statistical significance at the level of *p < 0.05, **p < 0.01, ***p < 0.001. N.S. denotes no 
statistical significance. MRI, magnetic resonance imaging; ESR spectroscopy, electron spin 
resonance spectroscopy; ANOVA, analysis of variance; S.D., standard deviation.  
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3.8 Supporting Information  
This material is published in ACS Applied Materials and Interfaces. The following supporting 
information and figures are available in Appendix B. Coating of iron oxide nanocrystals by 
modified thin film hydration, lipidoid synthesis, screening of lipidoids and cationic phospholipids 
for iron oxide stabilization, analysis of lipid coating composition by TLC, determination of PEG 
packing density, theoretical size estimation of PEGylated core-shell iron oxide nanoparticles, 
characterization of PDP-functionalized nanoparticles, estimation of biomolecule loading: 
mutivalency and surface density.  
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CHAPTER 4 
The Content of CpG-DNA in Antigen-CpG Conjugate 
Vaccines Determines Their Cross-Presentation Activity 
 
4.1 Abstract  
 
Cross-presentation, the process that facilitates display of exogenous antigens on MHC-I 
molecules, is a crucial step in the cascade of CD8 T cell activation. Potentiation of cross-
presentation therefore represents an essential design criterion for development of subunit 
vaccines that target the induction of CD8 T cell immunity. Covalent conjugation of CpG-DNA to 
antigenic proteins has shown the potential to promote cross-presentation and has attracted 
great interest as a promising approach for vaccine development. However, heterogeneous 
product mixtures that result from typical conjugation schemes precluded identification of active 
conjugate species and impeded optimization of cross-presentation activity. In this report, we 
explore the effect of molecular composition of antigen-CpG conjugates on their cross-
presentation activity using model Ovalbumin (OVA)-CpG conjugates. We developed a method 
to generate antigen-CpG conjugates with defined molecular compositions and leveraged this 
method to produce a series of OVA-CpG conjugates with one, two and three CpG molecules 
linked to OVA. We observed that conjugates containing one CpG per OVA enhanced cross-
presentation by 4-fold compared to native OVA, while conjugates with higher contents of CpG 
provided no cross-presentation enhancement. These differences are likely due to enhanced 
aggregation propensity observed for conjugates that carry more than one CpG per OVA. Our 
findings suggest that tuning molecular composition of antigen-CpG conjugates to maintain 
physical stability may be essential for achieving potent cross-presentation activity. Our method 
to generate defined conjugates could facilitate such molecular tuning and may be useful for 
continued development of antigen-CpG vaccines. 
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4.2 Introduction  
 Synthetic subunit vaccines that can elicit CD8 T cell immunity are highly desirable as a 
potential therapeutic strategy for combating intracellular pathogens and cancer1, 2. Subunit 
vaccines are often based on purified or recombinant protein antigens3. Activation of antigen-
specific CD8 T cell immunity requires display of antigenic epitopes on the surface of antigen-
presenting cells (APCs) in the context of MHC class I molecules4, 5.  Routing of exogenous 
proteins in APCs for display on MHC class I molecules relies on a process known as cross-
presentation4, 5. Because cross-presentation is a pivotal step in the CD8 T cell activation 
cascade, potentiation of cross-presentation is an essential design criterion for development of 
subunit vaccines that target the induction of CD8 T cell immunity6. To overcome the poor 
performance of exogenous proteins as substrates for the cross-presentation pathway, vaccine 
formulations typically integrate adjuvants to promote cross-presentation7. One potent class of 
adjuvants that can enhance cross-presentation is unmethylated cytosine-phosphate-guanine 
(CpG) oligodeoxynucleotides8, 9. The enhancement of the cross-presentation activity by CpG 
adjuvants largely depends on a vaccine formulation10, 11. Although a wide range of subunit 
vaccine formulations utilizing CpG has been explored, tuning vaccine compositions for 
enhanced cross-presentation still represents a considerable challenge6, 12. 
 One extensively studied approach to develop CpG-containing vaccine formulations relies 
on covalent conjugation of CpG with protein antigens11, 13-17.  While physical addition of CpG to 
vaccine formulations can enhance immunity, close proximity of antigenic proteins and CpG in 
antigen-presenting cells was found to be crucial for stimulating robust cross-presentation10, 18. 
Covalent conjugation of CpG to antigenic proteins can co-localize both the antigen and the 
adjuvant components in the same antigen-presenting cell11. Because this co-localization activity 
was found to promote cross-presentation, antigen-CpG conjugates have attracted considerable 
interest as potential vaccines10, 19-21. Nevertheless, the translational potential of antigen-CpG 
conjugates has not been realized to date22, 23. Although antigen-CpG conjugates have been 
widely studied, discrepancies in their ability to induce cross-presentation exist. While some 
studies have shown dramatic, many-fold potentiation of cross presentation11, 24 compared to 
corresponding antigen/CpG mixtures, other studies investigating conjugates with the same CpG 
and antigen components reported modest enhancement of cross-presentation activity10, 16. 
Elucidation of factors that underlie this variability is pivotal for further translational development 
of antigen-CpG conjugate vaccines. 
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 One factor that has recently come into focus in the context of cross-presentation is the 
physical stability of protein antigens25-28. Accumulating evidence suggests that antigenic proteins 
need to preserve their physical stability for effective routing into the cross-presentation pathway 
in APCs26, 28. While chemical conjugation of CpG with antigens offers an attractive advantage of 
antigen/adjuvant co-delivery into the same antigen-presenting cell, conjugation may also 
provoke protein destabilization and aggregation29-31. It has been demonstrated that protein 
destabilization induced by functionalization chemistries depends on the degree of 
functionalization30, 32, 33. Antigen-CpG conjugates have been previously synthesized as highly 
heterogeneous mixtures containing a wide range of molecular species with different contents of 
CpG11, 14, 16, 34. Different extents of CpG functionalization may differentially affect conjugate 
stability, and thus the conjugate intracellular routing and activity. Surprisingly, despite significant 
interest in antigen-CpG vaccines, the effect of the extent of conjugation on conjugate activity 
has not been evaluated to date. 
 Herein, we explore the effect of molecular composition of the antigen-CpG conjugates 
on their cross-presentation activity. We developed a method to produce antigen-CpG 
conjugates with defined molecular compositions. Using this method, we generated a series of 
model Ovalbumin (OVA)-CpG conjugates with different contents of CpG. We observed that 
OVA-CpG conjugates with higher CpG contents exhibited higher propensity to aggregation 
compared to their counterparts with lower contents of CpG. Most significantly, we found that 
only conjugates containing one mol CpG per mol Ovalbumin, but not the conjugates with higher 
contents of CpG, promoted cross-presentation activity, likely due to increased aggregation 
propensity of the conjugates with higher CpG contents. To our knowledge, this study is the first 
to evaluate the effect of molecular composition of CpG-based conjugate vaccines on their 
stability and cross-presentation activity. Our findings suggest that tuning molecular composition 
of antigen-CpG conjugates to maintain physical stability may be essential for their continued 
development as vaccines with potent cross-presentation activity. 
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4.3 Results and Discussion  
 Previous synthetic methods to produce protein-CpG conjugates included coupling of 
protein and CpG via maleimide-sulfur thioether linkages and di-sulfide linkages14, 19, 35. We 
selected di-sulfide chemistry based on recent reports demonstrating the enhanced vaccination 
potential of di-sulfide linked conjugates compared to thioether conjugates in vivo19. Ovalbumin 
(OVA) was selected as a model antigenic protein, because of its wide previous use in this 
capacity, and the availability of well-characterized model systems to evaluate the cross-
presentation of OVA11, 14, 36, 37. To synthesize model di-sulfide-linked OVA-CpG conjugates we 
utilized di-sulfide exchange chemistry using a heterobifunctional cross-linker SPDP38. This 
chemistry involves functionalization of lysines’ side chains with SPDP to introduce PDP 
functional groups onto the protein surface, and subsequent reaction of functionalized proteins 
with free-thiol carrying CpG oligonucleotide to produce di-sulfide linked conjugates (Scheme 
1A).  
 Previous methods to produce protein-CpG conjugates resulted in highly heterogeneous 
product mixtures. For example, up to 5 different conjugate species were previously identified in 
a single OVA-CpG product11, 14, 16. Such heterogeneity precludes identification of the active 
conjugate species. To generate conjugates with better defined molecular compositions, we 
developed a method that integrates two levels of compositional control (Scheme 1B). First, we 
employed functionalization of OVA with controlled contents of PDP functional groups. Previous 
studies demonstrated that the extent of PDP functionalization can be controlled by varying the 
feed ratio of the SPDP to protein32. Consistent with previous reports, we found that in the range 
of 5-15 mol SPDP per mol OVA, the PDP content in the resulting OVA-PDP products increased 
linearly (R2=0.99) with the increasing ratios of SPDP to OVA, allowing tunable functionalization 
(Figure S17). Using this method, we produced a series of differentially functionalized OVA-PDP 
species with average PDP contents of 1.4 ± 0.1, 2.1 ± 0.3 and 3.3 ± 0.3 mol PDP per mol OVA. 
We termed these species OVA-1-PDP, OVA-2-PDP and OVA-3-PDP, respectively. 
 Subsequently, we reacted the functionalized OVA-PDP with thiolated CpG (CpG-SH) at 
a 1:1 molar ratio to produce OVA-CpG conjugates. The crude conjugates exhibited a multi-band 
pattern on SDS-PAGE electrograms (Figure S18). Within the molecular weight range of 
expected conjugates (34-77 kDa), a combination of a dominant high-density band and several 
auxiliary low-density bands was observed. This pattern suggested enrichment in formation of a 
predominant conjugate species, but it also revealed that separation is required to isolate the 
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major product. We therefore sought to develop a separation procedure as a second level of 
compositional control. Based on previous reports, separation of protein-CpG conjugates with 
different molecular compositions appears to be difficult11, 14, 16.  Previous attempts to achieve 
separation relied on size exclusion chromatography11, 14, 16, 19, 37. However, conjugates could not 
be resolved likely due to small size differences (~6.5kDa) between conjugates with different 
CpG contents. Because CpG possesses high density of negative charge, we considered that 
the conjugates could be separated based on differences in CpG-imparted charge. We 
developed a separation method that utilizes anion exchange chromatography with a stair-step 
sodium chloride elution gradient (Supporting Information, Figure S19). This method allowed us 
to resolve the crude products into fractions eluting at different ionic strengths. Consistent with 
the SDS-PAGE electrograms, anion exchange chromatograms of the crude products revealed 
presence of one predominant and several auxiliary species. For example, reaction products of 
the OVA-3-PDP with equimolar CpG-SH resulted in a predominant peak eluting at 0.75 M NaCl, 
and three smaller auxiliary peaks eluting at 0.5 M, 0.4 M and 0.3 M of NaCl, respectively (Figure 
S19).  
 Using this method, we isolated the major product from each of the three crude conjugate 
mixtures obtained by reacting CpG-SH with the OVA-1-PDP, OVA-2-PDP and OVA-3-PDP, 
respectively. Isolated desalted species displayed a single peak on anion exchange 
chromatograms, corroborating successful separations (Figure 4.1A). To identify the composition 
of the recovered species, we performed analysis by SDS-PAGE electrophoresis and quantified 
the oligonucleotide content per unit protein for each species. Within the molecular weight range 
of 34-77 kDa, all species displayed a single band on SDS-PAGE electrograms, suggesting 
formation of homogenous conjugate products (Figure 4.1B). Successive species requiring 
increasing ionic strengths for elution from the quaternary ammonium matrix exhibited 
corresponding progressive increase in molecular weight, suggesting that they carried increasing 
content of anionic CpG. Estimated molecular masses  of ~51.6 kDa, ~59.9 kDa and ~67.7 kDa 
for different conjugate species were in a reasonably good agreement with the expected 
molecular masses for conjugates containing 1 mol CpG/mol OVA (51.3kDa), 2 mol CpG/mol 
OVA (57.6kDa) and 3 mol CpG/mol OVA (63.9 kDa), respectively. Consistent with this 
observation, quantitative analysis revealed molecular compositions of 0.8±0.1, 2.2±0.2 and 
3.3±0.2 mol CpG per mol OVA for respective conjugates (Figure 4.1C). Taken together, these 
results corroborated generation of conjugates with defined molecular compositions and different 
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contents of CpG. We termed the resulting conjugates OVA-1-CpG, OVA-2-CpG and OVA-3-
CpG and used them for further analysis. 
 Having generated a series of OVA-CpG conjugates with different CpG contents, we 
asked whether the CpG content in these conjugates affects their cross-presentation activity. To 
assess cross-presentation, we quantified activation of B3Z hybridoma CD8 T cells36. These cells 
produce β-galactosidase upon recognition of the OVA-derived epitope SIINFEKL in the context 
of MHC class I molecules on antigen-presenting cells and, therefore, provide a measure of 
vaccine’s ability to facilitate cross-presentation (Figure 4.2A). To assess the effect of 
conjugation on the cross-presentation activity, we compared performance of the covalently 
conjugated OVA-CpG species (OVA-1-CpG, OVA-2-CpG and OVA-3-CpG) with the respective 
physical mixtures of the conjugate’s molecular components (OVA-1-PDP+1 CPG, OVA-2-
PDP+2 CPG, OVA-3-PDP+3 CPG, respectively; Figure 4.2B). Interestingly, the OVA-2-CpG 
and OVA-3-CpG conjugates failed to enhance the cross-presentation activity beyond the basal 
levels observed with the physical mixtures (OVA-2-CpG: 6 ± 1 mU vs. OVA-2-PDP+2CpG: 4.3 
± 0.3 mU, p= 0.85; OVA-3-CpG: 4 ± 2 mU vs. OVA-3-PDP+3 CpG: 5 ± 2 mU, p= 0.95). In 
contrast, the monomeric OVA-1-CpG conjugate induced a 4-fold enhancement of the cross-
presentation activity compared to the physically mixed controls (OVA-1-CpG: 19 ± 1 mU vs. 
OVA-1-PDP+1 CpG: 5 ± 1 mU, p <0.0001). 
 Recent studies demonstrated that denaturation and aggregation of antigenic proteins 
may skew their routing in antigen-presenting cells and diminish their cross-presentation 
activity25-28. We therefore asked whether the observed differences in the activities of OVA-CpG 
conjugates could be related to their physical stability. Previous studies demonstrated that the 
tendency of misfolded and destabilized proteins to form early multimeric intermediates on their 
path to aggregation, or the aggregation propensity, can be used as a measure of protein 
destabilization39. To assess aggregation propensity, we carried out SDS-PAGE analysis of the 
conjugates followed by densitometry analysis of SDS-PAGE electrograms40. The conjugates 
displayed two distinct density peaks; a peak of lower molecular weight (<77kDa) corresponding 
to the soluble conjugate and a peak of higher molecular weight corresponding to early 
aggregation intermediates (>77kDa). We observed that the fraction of the monomeric conjugate 
decreased and the fraction of multimeric aggregation intermediates increased with the 
increasing CpG content in the conjugates (Figure 4.3A). Quantitative analysis further revealed 
that the aggregation propensities of both the OVA-2-CpG and OVA-3-CpG conjugates were 
significantly higher than that of the native OVA (OVA-2-CpG: 24 ± 8 % vs OVA: 7 ± 5 %, p= 
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0.035; OVA-3-CpG: 57 ± 9 % vs OVA: 7 ± 5 %, p <0.001). In contrast, the aggregation 
propensity of the OVA-1-Cpg conjugate did not differ significantly from that of the native OVA 
(OVA-1-CpG: 8 ± 6 % vs OVA:  7 ± 5 %, p= 0.99; Figure 4.3B). These findings demonstrate that 
the monomeric OVA-1-CpG conjugate is superior to conjugates with higher CpG contents in 
preserving physical stability, similar to the native OVA.  
 Interestingly, the aggregation propensity of the OVA-CpG conjugates was in a 
reasonably good agreement with their ability to facilitate cross-presentation. While minimally 
aggregated monomeric OVA-1-CpG conjugate induced pronounced enhancement in cross-
presentation compared to native OVA (OVA-1-CpG: 19 ± 1 mU vs. OVA: 5 ± 1 mU, p < 0.001), 
the OVA-2-CpG and OVA-3-CpG conjugates with increased propensity to aggregation failed to 
provide cross-presentation enhancement (OVA-2-CpG: 6 ± 1 mU vs. OVA: 5 ± 1 mU, p = 0.99; 
OVA-3-CpG: 4 ± 2 mU vs. OVA: 5 ± 1 mU, p = 0.99). Previous studies demonstrated that cross-
presentation efficiency of exogenous proteins could be pronouncedly reduced by protein 
destabilization and aggregation. For example, Palliser et al. found that aggregated forms of heat 
shock proteins displayed a 4-10-fold reduction in cross-presentation compared to the 
monomeric forms of these proteins26. Similarly, the misfolded aggregation-prone variant of OVA 
was found to exhibit a significantly lower cross-presentation efficiency compared to its stable 
soluble counterparts28. In the context of these findings, the increased propensity of the OVA-2-
CpG and OVA-3-CpG conjugates to aggregation has likely played an important role in reducing 
their cross-presentation activity compared to the stable OVA-1-CpG conjugates.  
 The differences in cross-presentation efficiency for monomeric and aggregated proteins 
were previously ascribed to differences in the mechanism of cell internalization, which in turn 
determines the efficiency of intracellular routing into the cross-presentation machinery26. For 
example, the monomeric heat shock proteins were shown to internalize via receptor-mediated 
endocytosis, leading to efficient routing into the cross-presentation pathway26. In contrast, 
aggregated proteins were found to be uptaken by phagocytosis, leading to less efficient cross-
presentation26. Previous analysis of protein-CpG conjugates demonstrated that enhancement in 
cross-presentation efficiency by covalent conjugation could be largely attributed to the CpG-
guided internalization of the conjugates via DNA receptor-mediated endocytosis11, 24. It is 
possible that aggregation of the destabilized conjugates with high content of CpG (OVA-2-CpG 
and OVA-3-CpG) redirects their uptake toward phagocytosis, thereby skewing the intracellular 
processing toward less efficient cross-presentation, but further work is needed to discern the 
mechanism 
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4.4 Conclusions  
 In summary, we developed a novel method to produce defined protein-CpG conjugate 
species and leveraged this method to assess the effect of CpG content in protein-CpG 
conjugates on cross-presentation activity. Although numerous studies examined protein-CpG 
conjugates as potential vaccines, the effect of conjugate composition on activity has been 
largely overlooked likely due to the difficulty in generating protein-CpG conjugates with defined 
molecular compositions. Our results reveal that only the conjugate functionalized with one mol 
CpG per mol protein, but not the conjugates with higher degree of CpG functionalization, 
enhance cross-presentation activity. These differences are likely due to enhanced aggregation 
propensity observed for conjugates that carry more than one CpG per OVA. Our results suggest 
that tuning molecular composition of protein-CpG conjugates to preserve physical stability may 
be essential for potentiation of cross-presentation activity. Our method to generate defined 
protein-CpG conjugates may be useful for tuning conjugate compositions and stability and, 
therefore, warrants further investigation for development of conjugate vaccines with potent 
cross-presentation activity. 
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4.7 Figures  
 
Figure 4.1 - Analysis of OVA-CpG conjugates. 
(A) Representative anion exchange 
chromatograms for isolated and purified 
conjugate species OVA-1-CpG (blue), OVA-2-
CpG (red) and OVA-3-CpG (green). Anion 
exchange chromatography was carried out 
using quaternary ammonium solid phase with 
a stair-step sodium chloride (NaCl) elution 
gradient (purple dashed line). Native 
Ovalbumin (OVA, black) was used as a 
control. (B) Representative image of SDS 
polyacrylamide gel electrophoresis (SDS-
PAGE) (10%, 75V, 90 minutes) for OVA (lane 
1), OVA-1-CpG (lane 2), OVA-2-CpG (lane 3) 
and OVA-3-CpG (lane 4), visualized using 
silver staining. Molecular weights were 
analyzed using the ladder of protein standards. 
(C) Quantification of molecular compositions of 
the OVA-CpG conjugates. Molar ratios of CpG 
to OVA were quantified by BCA and SYBR 
Gold assays to determine the contents of 
protein and single-stranded DNA, respectively. 
Data represents mean ± S.D., n = 3.  
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Figure 4.2 - In vitro cross-presentation assay using B3Z CD8 T-cell hybridoma. (A) Schematic 
depiction of the assay: Step I - OVA-CpG conjugates are routed into the cross-presentation 
pathway in Antigen-Presenting Cells (APCs). As a result, the Ovalbumin’s predominant 
immunogenic epitope SIINFKEL is displayed in the context of MHC class I molecules on the 
APCs surface. Step II- In response to recognition of the SIINFKEL-MHC class I complexes on 
APCs, B3Z T cells are activated to produce β-galactosidase enzyme (β-Gal) providing a 
quantitative measure of the cross-presentation. (B) Quantitative analysis of the cross-
presentation for OVA-CpG conjugates and the physical mixtures of the respective conjugate’s 
molecular components.  The activity of β-Gal is expressed in milliUnits (mU), based on 
calibration with the purified β-Gal enzyme of known enzymatic activity. Data represent mean ± 
SD, n = 3. Statistical analysis is based on a one-way ANOVA, followed by post hoc Tukey's 
pairwise comparisons. Asterisks denote statistically significant differences at the level of ***p < 
0.001.  
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Figure 4.3 - Analysis of the aggregation propensity in OVA-CpG conjugates. (A) Representative 
SDS-PAGE densitograms for OVA-CpG conjugates. Molecular weights were calibrated using 
the ladder of protein standards. (B) Quantitative analysis of aggregation propensity for OVA-
CpG conjugates with difference contents of CpG relative to native OVA. Data represent mean ± 
SD, n = 3. Statistical analysis is based on a one-way ANOVA, followed by post hoc Tukey's 
pairwise comparisons. Asterisks denote statistically significant differences: *p < 0.05, **p < 0.01, 
***p < 0.001, n.s.: p>0.05. 
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4.8 Supporting Information  
A final version of this chapter is published in Bioconjugate Chemistry. The following supporting 
information and figures are available in Appendix C. Synthesis, purification and characterization 
procedures for Ovalbumin-CpG conjugates, description of the in vitro cross-presentation assay, 
supplementary figures: OVA functionalization with controlled extent of PDP, SDS-PAGE and 
anion exchange chromatography characterization of crude OVA-CpG conjugates. 
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CHAPTER 5 
Conclusions and Future Directions  
 
5.1 Iron-Oxide Nanoplatforms for B-cell Activation Conclusions 
 
For longer than a decade now, scientists have been attempting to translate their 
fundamental knowledge of viruses and viral-like material properties to the rational design and 
engineering of novel nanomaterials1-5. The earliest iterations of these nanomaterials were the 
so-called virus-like particles (VLPs)6-10. VLPs are protein-based nanoparticles that are the 
product of viral capsid protein self-assembly6. To date, VLPs have been successfully developed 
as five different FDA-approved and clinically available products (e.g. Gardasil®)11,12. Yet, despite 
the success of this product and other similar products, the wide-spread application of VLPs as 
universal carriers has not yet been realized. This failure is most likely the result of 
manufacturing difficulties due to the reliance on protein self-assembly for formulation, as well as 
a high-level anti-carrier immunological response that both reduces re-dosing efficacy and limits 
the extent and specificity of the intended immune response against loaded cargo6,13-15.  
As a result of these challenges, there has been increasing interest in the development of 
alternative nanoparticle systems that are viral inspired1,2,4,5. These so-called, viral mimicking 
nanoparticles are rationally designed and engineered based on a fundamental understanding of 
viral physical and chemical material properties. The viral material properties most commonly 
utilized to inform the design of viral mimicking nanoparticles include: particle size, particle 
shape, charge, hydrophobicity, antigen display, antigen organization, antigen density and 
surface topography1,2,4,5. While many advances have been made in the design, engineering and 
application of viral-mimicking nanoparticles, no one truly universal nanoparticle system has 
emerged. We believe that this failure is because, at present, researchers appear to be taking 
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too selective of a view of the material properties to be mimicked16-19. Based upon the limitations 
of current viral-mimicking nanoparticle systems, we surmised that it may be time to take a more 
holistic approach to viral-mimicking nanoparticle design. More specifically, we wanted to 
incorporate a level of antigen display organization that could not be achieved with established 
technologies.  
To accomplish this, we developed an inorganic virus-like nanoparticle (IVLN). The IVLN 
has unique viral-like spiky topographical structures, high-density antigen display, spherical 
geometry, optimal size and negatively charged surfaces. The IVLN was produced using a hybrid 
Au@Fe core-satellite nanoparticle technology based on previously established technique by our 
group. More specifically, the IVLN is composed of a single 15 nm poly(siloxane) and 
poly(ethylene glycol) diblock copolymer coated iron-oxide nanoparticles with a defined quantity 
of 3 nm gold nanoparticles (AuNPs), or satellites, attached to the surface via gold-siloxane 
binding. The extent of AuNP attachment to IVLN surfaces was determined by initial weight ratio 
incubations of Au to Fe in solution. Depending on the formulation conditions, the IVLN could be 
produced with between 2 to 14 AuNPs per IVLN. In other words, the IVLN can be produced with 
inter-satellite distance between ~20 to 5 nm and satellite density between 1500 to 25,000 
satellites per micron square. For the specific application of B-cell activation, antigen density 
between 5-10 nm is ideal for B-cell receptor crosslinking; while for viral mimicry, antigen density 
between ~200 to 30,000 (HIV to HPV) antigens per micron square is most relevant3,20,21.  
In this way, the extent of AuNPs attachment is absolutely critical to the viral-like 
character of the IVLN. Depending on the extent of AuNPs attachment, IVLNs can be produced 
with variable surface topography, antigen density and antigen spatial resolution because 
antigen loading is specific to AuNPs and not to the polymer-coated core. Specifically, under 
saturating conditions with 12 AuNPs per IVLN, ~2000 peptides can be conjugated to IVLN 
surfaces with ~12% non-specific binding to the core and ~200 peptides per individual AuNP. In 
this way, the IVLN have more biologically relevant surfaces with patchy patterned distribution of 
antigen at 5-10 nm spatial intervals. This patterned antigen display is viral-like in nature and 
cannot be reproduced by traditional nanoparticle systems that have smooth surface with 
homogeneous antigen distribution.  
Beyond viral-like structural properties, the IVLN is additionally capable of performing 
viral-like function. The most significant of these functions is B-cell activation and antigen-specific 
antibody production8,22-27. As compared to a traditional viral mimicking nanoparticle with similar 
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particle size, peptide loading and serum stability, the IVLN resulted in between 4 to 18-fold 
higher antigen-specific antibody titers. Notably, this functionality was directly connected to the 
viral-like structural properties of the IVLN. Specifically, by decreasing inter-nanoparticle distance 
(~12 nm to ~5 nm distance) to a range ideal for B-cell receptor crosslinking while maintain 
antigen loading per gold nanoparticle (200 peptides per IVLN) it was possible to improve 
antigen-specific IgG antibody titers by 6-fold. Additionally, by increasing the antigen loading per 
gold nanoparticle (50 to 200 peptides per IVLN) for a given inter-nanoparticle distance (~5 nm) 
the antigen-specific IgG antibody titers was increased by 4-fold. Taken together, these data 
points indicate that inter-nanoparticle (antigen cluster) distance and antigen density (within the 
cluster) are both critical for B-cell activation. Significantly, this is a deviation from conventional 
knowledge that only consider the antigen density for homogeneously distributed systems.  
Mechanistically, the improved functional efficacy of the IVLN formulated under optimal 
conditions was correlated to significant improvements in viral-like functional elements in terms of 
lymph node homing, cellular distributions and immune cell activation7,28-31. More specifically, as 
compared to a traditional viral mimicking nanoparticle control, the IVLN facilitated 3.5-fold higher 
lymph node exposure over 48 hours, 3-fold higher relevant immune cell uptake (B-cells and 
subcapsular sinus macrophages), 2.5-fold higher germinal center formation and 6-fold higher 
stimulation of antigen-specific B-cells.  
Overall, we believe that the IVLN is not only capable of viral-like structural mimicry, but 
also function mimicry for the application of B-cell activation and antigen-specific antibody 
production. Significantly, since both the IVLN and the traditional viral mimicking nanoparticle 
control have equivalent hydrodynamic size, zeta potential, shape and peptide capacity, the 
unique functional differences by these two materials should be credited to a more sophisticated 
and unconventional viral mimicry by design. Thus, these results provide substantial evidence to 
support our hypothesis that a more holistic approach to viral-mimicking nanoparticle design is 
required to provide optimal functionality.  
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5.2 Iron-Oxide Nanoplatforms for B-cell Activation Future Directions 
 
Moving forward, IVLNs have could be utilized in numerous therapeutic applications 
including as B-cell epitope-based cancer vaccines, autoimmune disease treatment and anti-viral 
vaccinations. For example, IVLNs could be employed for HER2+ breast cancer therapy through 
the production of endogenous antibodies with equivalent functionality of the established 
treatments with pertuzumab and trastuzumab32-34. In this way, IVLN treatment could facilitate 
sustained titer of these anti-HER2 antibodies in the blood, thereby dramatically limiting the re-
dosing requirement and providing a memory response. Before this potential could be realized, a 
significant hurdle to overcome would be to determine the IVLNs inductive capacity for antigen-
specific antibody against self-antigens. While the ability to produce auto-antibodies is a hallmark 
of viral-like particles, this ability has not yet been explored for the IVLN platform35,36. Beyond the 
ability to produce these antibodies, a completely separate issue is whether or not you should 
produce them. More specifically, the chronic exposure of auto-antibodies for therapeutic 
purposes could have unintended non-specific immunity and inflammatory responses37.  
 One therapeutic application of the IVLN platform that would not require the production of 
auto-antibodies is anti-viral vaccinations. In this context, the IVLN platform would be utilized as 
previously VLPs have for anti-viral immunity (e.g. Gardasil®)12,38. Notably, given the formulation 
ease and potential diversity of antigenic cargo, the IVLN platform could serve as a universal 
delivery platform for anti-viral immunity for those diseases that currently do not have FDA-
approved vaccines in production such as West Nile Virus, Crimean-Congo Hemorrhagic Fever 
Virus, Chikungunya Virus amongst others39-41. Unfortunately, due to established regulatory 
standards and uncertainty around nanoparticle toxicity analysis, the clinical translation of the 
IVLN platform for therapeutic applications would be extremely challenging based on 
nanoparticle composition (i.e. inorganic materials and synthetic polymers)42-45.  
 The most realistic application of the IVLN platform would be as a universal vehicle for 
antigen-specific antibody production in commercial applications. Established commercial 
techniques for antibody production in animal models most commonly rely on the use of the 
carrier protein keyhole limpet hemocyanin (KLH) in addition to high antigen and toxic adjuvant 
requirement46-48. Based on preliminary data and as compared to KLH controls, the IVLN 
platform could dramatically improve the titer and specificity of antibody production while 
necessitating lower antigen doses and eliminating the toxic adjuvant requirement in a mouse 
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model. As result of this functional improvement and given the ease and reproducibility of 
formulation, functionalization and purification of the IVLN platform, we believe the 
commercialization of these materials is truly feasible. Preliminary data sets demonstrate this 
potential and justify further investigation in this area.  
 
5.3 Iron-Oxide Nanoplatforms for T-cell Activation Conclusions 
 
Theranostic nanoparticles have a myriad of exciting potential diagnostic and therapeutic 
applications49-52. However, to realize these applications, nanomaterials must facilitate high 
capacity for cargo loading, while maintaining appropriate size and stability for effective in-vivo 
administration53-57. Only lipidoid stabilized, lipid-coated iron-oxide nanoparticles (IONP-ML) can 
fulfil these requirements. Based on the phenomenon of lipid-stitching58, the methodology used 
to formulate the IONP-ML platform yields highly stable and uniform materials that are capable of 
high-density antigen display and unprecedentedly efficient MRI-monitored lymph node 
targeting59-61.  
The demonstrated success of the IONP-ML platform is largely due to effective particle 
size control after biomolecule surface conjugation53. Control of particle size is among the most 
significant determinants of nanoparticle’s in-vivo performance53,62. Specifically, in the context of 
immunomodulation and lymph node targeting, the size limiting nature of lymphatic vessels leads 
to inefficient delivery for those nanoparticles incapable of maintaining sub-100 nm particle size 
in-vivo56,57. Notably, as compared to alternative methodologies for the production of lipid-coated 
iron-oxide nanoparticles, the IONP-ML platform is highly stable after biomolecule conjugation 
both in terms of biomolecule surface adherence and colloidal stability. Thus, the IONP-ML 
platform promotes highly efficient lymphatic trafficking with high-density antigen display that is 
critical for immune activation. 
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5.4 Iron-Oxide Nanoplatforms for T-cell Activation Future Directions 
The IONP-ML platform offers promising potential as a lymph node delivery vehicle for 
subunit vaccines with intended applications in cancer immunotherapy and infectious disease 
treatment. To date, the delivery of cargo-loaded nanoparticles to lymph nodes remains highly 
inefficient. Commonly, less than 1% of the initial dose reaches the intended site. This limited 
efficiency is due to difficulties in controlling particle size and preventing colloidal destabilization 
after antigen loading59-61. Moreover, of the 1% that reaches the lymph nodes, the majority of 
delivered nanoparticles access the lymph nodes via “active” cell-mediated mechanisms that can 
reduce the functional efficacy of the vaccine53,56,57. As a result, cargo-loaded nanoparticles are 
typically unable to induce sufficient priming and activation of relevant immune cell populations, 
namely dendritic cells and CD8+ T-cells, required for induction of robust cellular immunity 
against cancer and intracellular pathogens. 
To address this challenge, we are currently developing the IONP-ML platform as a highly 
efficient delivery vehicle for subunit vaccines. More specifically, DNA-based covalent conjugate 
subunit vaccines. As introduced in Chapter 4, subunit vaccines often suffer from poor inherent 
immunogenicity and thus require co-delivery of adjuvant for improved efficacy. This efficacy can 
be further improved by physical or chemical association of said adjuvant to the subunit vaccine. 
One shining example of such a material in the literature is the model DNA-based covalent 
conjugate vaccine based on the antigen ovalbumin and TLR9 agonist CpG oligonucleotide 
(OVA-CpG)63-68. While soluble OVA-CpG has been applied consistently in the literature as a 
model, very limited research has been shown for nanoparticle delivered OVA-CpG as an intact 
covalent conjugate loaded onto nanoparticle surfaces60,61,63-65,67. The failures in this area are 
most likely are result of unsuitable nanoparticle technologies for this application.  
Moving forward, we have proposed to loaded OVA-CpG as a model of a DNA-based 
covalent conjugate vaccine onto IONP-ML surfaces via DNA-directed immobilization, in a 
process coined “DNA-tethering”69-74. Our initial experimental evidence suggests that DNA-
tethering is a highly directed and non-damaging mechanism for nanoparticle loading that allows 
for maintenance of particle size for highly efficient lymph node delivery. With this technology, we 
believe that we can harness the full potential benefit of applying iron-oxide nanoplatforms in the 
context of cellular immunity. Although extensive experimental validations are still required, the 
potential of these nanomaterials for the treatment of a debilitating disease is seeming limitless. 
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Appendix A 
 
Supporting Information in Chapter 2 
 
 
Supplementary Figures 
 
 
Figure S1. Transmission Electron Microscopy of Individual IVLN Components. (A) 
Representative transmission electron microscopy (TEM) image of polymer-coated iron-oxide 
nanoparticle (IONP-Polymer); scale-bar: 50 nm. (B) Representative transmission electron 
microscopy (TEM) image of gold nanoparticles (AuNP); scale-bar: 20 nm.  
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Figure S2. Peptide loading of IVLNs standardized on a per gold nanoparticle basis (R = 0.95).  
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Figure S3. Serum stability study of IVLNs. Studies performed in 50% FBS/PBS at 37C. Stability 
changes were determined by Z-average particle size (nm) as determined by dynamic light 
scattering; data represent mean ± SD, n = 3. Statistical comparisons are based on one-way 
ANOVA, followed by post hoc Tukey’s pairwise comparisons. The asterisks denote statistical 
significance at the level of *** p < 0.001. ANOVA, analysis of variance; SD, standard deviation. 
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Table S1. IVLN material properties. Analysis performed before and after peptide conjugation 
under saturating conditions.  
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Table S2. Lipid-coated IONP material properties. Analysis performed before and after peptide 
conjugation under saturating conditions.  
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Figure S4. Antigen-Specific IgG Antibody Production Kinetics. Quantification of antigen-specific 
IgG antibodies by indirect ELISA represented as antibody titer from serum collected 10 days 
after every immunization (day 10, day 24 and day 38) with either (A) 5 µg HER2 peptide dose + 
10 µg cGAMP or (B) 50 µg HER2 peptide dose + 10 µg cGAMP; data represent mean ± SE, n = 
5. Statistical comparisons are based on one-way ANOVA, followed by post hoc Tukey’s 
pairwise comparisons. The asterisks denote statistical significance at the level of *** p < 0.001. 
ANOVA, analysis of variance; SE, standard error.  
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Figure S5. Total non-specific IgM antibody production. Quantification at 10 days post-boost 2 
(day 38) for either (A) 5 µg HER2 peptide dose + 10 µg cGAMP or (B) 50 µg HER2 peptide 
dose + 10 µg cGAMP; data represent mean ± SD, n = 5. SD, standard deviation. 
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Figure S6. IVLN Antigen-Specific IgG Antibody Production at Different Au/Fe Ratios and 
Peptide Density. (A) Quantification of antigen-specific IgG antibodies by indirect ELISA 
represented as the background subtracted absorbance signal (OD) at 450 nm and 500-fold 
dilution; data represent mean ± SD, n = 5. (B) Quantification of antigen-specific IgG antibodies 
by indirect ELISA represented as antibody titer; data represent mean ± SE, n = 5. Statistical 
comparisons are based on one-way ANOVA, followed by post hoc Tukey’s pairwise 
comparisons. The asterisks denote statistical significance at the level of * p < 0.05, ** p < 0.01, 
*** p < 0.001. ANOVA, analysis of variance; SE, standard error.  
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Figure S7. Antigen-Specificity Antibody D2F2/E2 Cell Specificity. (A) Schematic representation 
of the flow cytometry detection method of anti-HER2 antibody binding specificity to D2F2/E2 
cells using PE-labeled IgG secondary antibody detection. (B/C) Anti-HER2 antibody binding 
specificity to D2F2/E2 cells of serum obtained from mice immunized with (B) 5 µg HER2 peptide 
dose + 10 µg cGAMP or (C) 50 µg HER2 peptide dose + 10 µg cGAMP; data represent mean ± 
SD, n = 3. Statistical comparisons are based on one-way ANOVA, followed by post hoc Tukey’s 
pairwise comparisons. The asterisks denote statistical significance at the level of *** p < 0.001. 
ANOVA, analysis of variance; SD, standard deviation. N.S, no statistical significance.  
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Figure S8. IVLN Lymph Node Delivery by Different Administration Routes. Quantification of 
nanoparticle delivery to lymph nodes (popliteal + inguinal) ipsilateral to the administration site at 
designated time intervals represented as the percentage of initial iron-oxide delivered using 
ICP-MS; data represent mean ± SE, n = 3. 
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Figure S9. In-vitro Nanoparticle Cell Uptake Study – Surface Topography Effects. Quantification 
of in-vitro cell uptake of nanoparticles in (A) RAW264.7 macrophages, (B) DC2.4 dendritic cells 
and (C) murine primary B-cells by ICP-MS quantification of total Fe standardized by cell count 
(pg Fe per cell); data represent mean ± SD, n = 3. SD, standard deviation. 
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Mathematical Modeling:  
 
Gold Nanoparticle (AuNP) Loading per Inorganic-Virus Like Nanoparticle (IVLN)  
 The extent of gold nanoparticle (AuNP) loading to inorganic virus-like nanoparticle 
(IVLN) surfaces was determined by ICP-MS determination of total elemental gold (Au) and iron 
(Fe) weights. These weights were then utilized to quantify total number spheres of a given 
element and particle size based on previously reported methods1,2. The ratio of these 
experimental values was then interpreted as AuNPs per IVLN, or the number of AuNPs per 
single IONP core.  
 Due to the crystalline structure of iron-oxide nanoparticles, it is possible to quantify the 
number of nanoparticles per unit Fe based on known particle size accordingly to previously 
establish methodologies (Table S3)1. Using transmission electron microscopy (TEM), the exact 
particle size of iron-oxide nanoparticles was quantified using the ImageJ software. The particle 
size of the polymer-coated iron-oxide nanoparticle core of the IVLN was 15 nm, while the 
particle size of the lipid-coated iron-oxide nanoparticle control was 30 nm. Based on the known 
unit cell volume of iron-oxide (Fe3O4) and quantified particle size, the number of nanoparticles 
per gram Fe was determined to be 1.5x1017 and 1.9x1016 for 15 nm and 30 nm cores, 
respectively (Table S3).  
 The number of gold nanoparticles per unit Au was quantified by two considerations. 
First, based on literature values reported by Lu et al2, AuNPs with 3 nm diameters have 479 
gold atoms per nanoparticle, which is 56% of the number of gold atoms per solid gold metallic 
colloids of the same diameter (835 gold atoms per nanoparticle). Therefore, by conversion from 
weight of Au to atoms of Au through Avogadro’s Number it is possible to quantify the number of 
gold nanoparticle per unit Au. Quantification by this methodology revealed that number gold 
nanoparticle per gram Au was 6.38x1018 (Table S4). Second, based on literature values 
reported for the mass of a single AuNP for 2 nm, 5 nm and 10 nm particle size, the mass of a 
single 2 nm AuNP was interpolated based on curve fitting. Through curve fitting, the mass of a 
single 3 nm AuNP was determined to be 2.67x10-19 grams or 3.67x1018 AuNPs per gram Au 
(Table S4). Notably, this quantified value matches those values reported for solid gold colloids 
based on 835 gold atoms per nanoparticle and is therefore was not considered truly 
representative of our materials. 
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Table S3. Iron-oxide nanoparticle calculations. Quantification of total number of spheres per unit 
Fe and total surface area per unit Fe for 15-nm and 30-nm iron-oxide nanocrystal cores. 
Calculations were performed based on equations outlined previously by Kokate et al1. 
 
 
 
 
178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. Gold nanoparticle calculations. Quantification of total number of spheres per unit Au 
for 3 nm AuNPs  
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Gold Nanoparticle Spatial Distribution – Inter-Nanoparticle Distance   
 The distance between AuNPs on IVLN surfaces was modeled based on two 
methodologies. The first technique was based on the arc length equation for a circle. If 
homogeneous distribution of AuNPs on a sphere is assumed, the loading of 2, 6 and 14 AuNPs 
on IVLN surface will yield AuNPs in a single plane (circle) oriented at central angles equivalent 
to 180º, 90º and 45º, respectively. Using the arc length equation for a circle with radius 7.5 nm, 
2, 6 and 14 AuNPs will be located 23.6, 11.8 and 5.9 nm apart, respectively. Plotting these three 
points and using a power function curve fitting model (R2 = 0.99) allows for interpolations of 
inter-nanoparticle distances between 2-14 AuNPs per IVLN surface (Figure S10A, Table S5). 
The benefit of this technique is that it accounts for arc length and is not a straight-line distance 
calculation. However, this model represent AuNPs are single points and only has three points 
for the curve fitting model thereby limiting potential power and accuracy.  
 The second technique used to quantify inter-nanoparticle distance on IVLN surfaces was 
based on a triangulation methodology. With the number of AuNPs per IVLN surface known and 
assuming homogeneous distribution of AuNPs on a sphere around a single central focal point, 
AuNPs can be triangulated. For AuNP per IVLN equal to or greater than 4, the number of 
triangles formed around a central focal point is 2n, where n is the number of AuNPs per IVLN.  𝐴𝑢𝑁𝑃	𝑇𝑟𝑖𝑎𝑛𝑔𝑙𝑒𝑠	𝑝𝑒𝑟	𝐼𝑂𝑁𝑃	𝑐𝑜𝑟𝑒	 = 𝐴𝑢𝑁𝑃	𝑝𝑒𝑟	𝐼𝑂𝑁𝑃	𝑐𝑜𝑟𝑒 × 2 
With the number of triangles determined, the surface occupied by a single triangle was 
quantified given the surface area of spherical IVLN with 7.5 nm radius. 
𝑆𝑢𝑟𝑓𝑎𝑐𝑒	𝐴𝑟𝑒𝑎	𝑝𝑒𝑟	𝑇𝑟𝑖𝑎𝑛𝑔𝑙𝑒 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒	𝐴𝑟𝑒𝑎	𝑜𝑓	𝐼𝑉𝐿𝑁𝑁𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑇𝑟𝑖𝑎𝑛𝑔𝑙𝑒𝑠  
Assuming an equilateral triangle, the surface area of a single triangle can be used to determine 
the length of a side of the triangle, and therefore the distance between AuNPs represented as 
single points. By subtracting 2x the radius of the AuNPs, a better surface to surface contact 
distance can be interpreted (Figure S10B, Table S6).  
𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒	𝑏𝑒𝑡𝑤𝑒𝑒𝑛	𝐴𝑢𝑁𝑃𝑠 = F4	 × 𝑇𝑟𝑖𝑎𝑛𝑔𝑙𝑒	𝑆𝑢𝑟𝑓𝑎𝑐𝑒	𝐴𝑟𝑒𝑎√3 − (	2 × 𝐴𝑢𝑁𝑃	𝑟𝑎𝑑𝑖𝑢𝑠) 
The benefit of this technique is that does not rely on interpolation. However, this model is limited 
due to the reliance of straight-line distances between AuNPs. 
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Figure S10. Modeling of inter-nanoparticle distance on IVLN surfaces. (A) Power function curve 
fit model based on the arc length between 2 (central angle: 180º), 6 (central angle: 90º) and 14 
AuNPs (central angle: 45º) homogeneously distributed in 3D space around an IONP core with 
15 nm diameter. (B) Power function curve fit model based on the triangulation methodology 
described above. (C) Overlay comparison of both modeling strategies for inter-AuNP distance 
(nm).  
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Au/Fe Ratio (wt/wt) 
 
AuNP per IVLN 
 
Inter-Nanoparticle Distance 
Arc Length (nm) 
 
0.05 2.1 23.18 
0.1 4.2 14.19 
0.15 6.4 10.65 
0.2 8.5 8.69 
0.25 10.6 7.42 
0.3 12.7 6.52 
0.35 14.9 5.84 
0.4 17.0 5.32 
 
Table S5. Inter-nanoparticle distance: Arc Length Interpolation Model. Interpolation data set for 
inter-AuNP distances based on AuNP per IVLN determined by ICP-MS (Figure 2.2A) and the 
curve fitting model presented in Figure S10A (y = 39.51x-.708, R2 = 0.99).   
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Au/Fe Ratio (wt/wt) 
 
AuNP per IVLN 
 
Inter-Nanoparticle Distance 
Arc Length (nm) 
 
0.05 2.1 17.10 
0.1 4.2 11.36 
0.15 6.4 8.82 
0.2 8.5 7.30 
0.25 10.6 6.27 
0.3 12.7 5.50 
0.35 14.9 4.91 
0.4 17.0 4.43 
 
Table S6. Inter-nanoparticle distance: Triangulation Model. Data set for inter-AuNP distances 
based on AuNP per IVLN determined by ICP-MS (Figure 2.2A) and mathematic modeling 
presented above, and curve fitting model presented in Figure S10B (y = 28.69x-.649, R2 = 0.99).   
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Appendix B 
 
Supporting Information in Chapter 3 
 
 
 
Section 1: Comparison of the stabilization efficiency by the standard and the modified 
thin film hydration methods 
 
 
To compare the standard and the modified thin film hydration methods, we tested the 
ability of both methods to stabilize 20 nm iron oxide nanocrystals with DSPE-mPEG(2000)/C12-
98(5) lipidoid (75:25 %w/w) formulations. The thin films of identical composition were hydrated 
with either phosphate-buffered saline (PBS) or ethanol, heated at 65°C for 2 hours and dialyzed 
into PBS. The hydration with ethanol resulted in more than 30-fold higher aqueous recovery of 
stabilized nanoparticles compared to the hydration with PBS (27.0 ± 6.0% vs 0.7 ± 0.8%, 
p<0.001, Figure S11). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S11. IONP Formulation Method Comparison Images. Representative formulations of 20 
nm iron oxide nanocrystals stabilized with DSPE-mPEG(2000)/C12-98(5) lipidoid (75:25 %w/w) 
using the standard (A, hydration with PBS) or the modified (B, hydration with ethanol) thin film 
hydration methods.  
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Section 2: Lipidoid synthesis  
 
 
Lipidoids were synthesized by conjugate addition of alkyl-acrylamide (N-
dodecylacrylamide) to amines using neat synthesis as described by Akinc, et al1 (Figure S2,A). 
Briefly, the reactants were mixed in a glass vial and the mixture was stirred at 90C for 7 days. A 
series of amine monomers (63, 96,98,113) with different structures were used to synthesize 
lipidoids with different numbers of alkyl chains (“tails”) (Figure S2,B). The molar ratios of N-
dodecylacrylamide to amine were altered to obtain the desired number of tails per lipidoid . For 
example, C12-98 was synthesized with a 5:1 molar ratio of N-dodecrylacrylamide (C12) to 
triethylenetetraamine (98) to yield a 5-tailed lipidoid C12-98(5). The products were purified by 
gravity silica column chromatography using Silicycle SiliaFlash P60 (230-400 mesh) and 
dichloromethane/methanol/ammonium hydroxyde (75:22:3 %v/v) as the stationary and the 
mobile phases, respectively. Lipidoid formation was confirmed by electrospray ionization (ESI) 
mass spectrometry (Waters Micromass LCT Mass Spectrometer). For example, the lipidoid 
C12-98(5) [C81H164N9O5] yielded the m/z ratio of 1343.2 [M+H]+, consistent with the previously 
reported m/z ratio of 1343.3.1  
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Figure S12. Synthesis of lipidoids. (A) Schematic depiction of the lipidoid synthesis reaction; (B) 
The chemical structures of the N-dodecylacrylamide (C12) and the amine reactants 
(96,63,113,98) used for the lipidoid synthesis; (C) Chemical structures of the cationic 
phospholipids 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), and 1,2-dioleoyl-3-
dimethylammonium-propane (DODAP); (D) Mass spectrograph of the lipidoid C12-98(5) 
 
 
 
 
 
 
 
 
D C12-98(5)C12-98(5) 
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Section 3: Initial Screening of Lipidoids and Cationic Phospholipids for Iron Oxide 
Stabilization 
 
 
Using the thin film ethanol hydration method (S1), we tested a series of lipidoids and 
cationic phospholipids (Figure S2A, B and C) for their ability to stabilize iron oxide nanocrystals 
(20 nm). Formulations containing a lipidoid or a cationic phospholipid (25% w/w) were dispersed 
in a thin film, hydrated with ethanol and dyalized into the aqueous PBS (as described in the 
Methods section). The cationic phospholipids displayed negligible stabilization efficiency 
(DODAP: 2± 1%, DOTAP: 3±1%), which could not be significantly improved by either the 2-
tailed (C12-62(2), p=0.99) or the 3-tailed (C12-96(3), p=0.55) lipidoids. In contrast, the lipidoids 
with 5 (C12-98(5), p<0.001) and 4 tails (C12-113(4), p=0.026) were significantly more efficient 
than cationic lipids in mediating iron oxide stabilization. The 5-tail lipidoid C12-98(5) displayed 
the highest stabilization efficiency (27 ± 6%) among the tested compounds, and therefore, was 
selected for further studies. 
 
 
 
 
Figure S13. Formulation Stability Lipidoid Comparision. Aqueous stabilization of the iron oxide 
nanocrystals (20 nm) by lipid formulations containing lipidoids or cationic phospholipids (25% 
w/w). Stabilization was measured as percent of nanocrystals added to the formulations that 
could be recovered in aqueous phosphate-buffered-saline (PBS) solution. Data represents 
mean ± S.D.; asterisks denote statistical significance at the level of *** p < 0.001.  
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Section 4: Analysis of Lipid Coating Composition of stabilized iron oxide nanoparticles 
(IONP-ML) by Thin Layer Chromatography 
 
 
To assess the composition of the lipid coatings extracted from the IONP-ML surface, we 
carried out the thin layer chromatography (TLC) analysis. TLC was performed as described in 
the methods section. Coatings extracted from the surfaces of both the 10-nm core (lane 3) and 
30-nm core (lane 4) IONP-ML displayed 3 spots on the TLC chromatograms. Two spots with the 
Rf values of 0.59 ± 0.03 and 0.40 ± 0.02 corresponded to the spots of the DSPE-mPEG(2000) 
standard (lane1: 0.59 ± 0.07, p=0.99; and 0.41 ± 0.02, p=0.99). The third spot with the Rf value 
of 0.51 ± 0.06 corresponded to the spot of the C12-98(5) lipidoid standard (lane 2: 0.49 ± 0.02, 
p=0.99). These results confirmed the presence of the DSPE-mPEG and the C12-98(5) lipidoid 
on the surface of the stabilized IOMP-ML nanoparticles. 
 
Figure S14:  TLC analysis of the IONP-ML coating composition. Representative TLC 
chromatogram, lane 1: DSPE-mPEG(2000) standard, lane 2: C12-98 (5) standard, lane 3: 
coating extracted from the 10 nm IONP-ML, lane 4:  coating extracted from the 30 nm IONP-ML.  
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Section 5: Experimental Determination of DSPE-mPEG(2000) Packing Density in the 
IONP-ML Coatings 
 
 
To estimate the packing density of the DSPE-mPEG(2000) in the IONP-ML coatings, we 
replaced the DSPE-mPEG(2000) with the DSPE-PEG(2000)-PDP in the coating formulations. 
The content of the DSPE-PEG(2000)-PDP that contains the 2-pirydyldithio (PDP) group can be 
determined by the pyridine-2-thione spectrophotometric assay2.  Based on the 1:1 molar ratio of 
DSPE-PEG:PDP in each DSPE-PEG(2000)-PDP molecule, the content of PDP per known 
quantity of nanoparticles represents the DSPE-PEG(2000)-PDP (or PEG) packing density in the 
nanoparticle formulations. 
 
Coated nanoparticles (IONP-ML-PDP) were prepared as described in the Methods 
section using the following lipid composition: C12-98(5):DSPE-PEG(2000)-PDP (77:23 mol %). 
The resulting formulations were purified by magnetic column chromatography (Miltenyi Biotec) 
to remove any free lipid micelles and analyzed for Fe content by ICP-EOS. The content of the 
DSPE-PEG(2000)-PDP in the purified IONP-ML-PDP was quantified by a pyridine-2-thione 
assay. Briefly, IONP-ML-PDP nanoparticles (at known Fe concentrations) were reduced to 
release the pyridine-2-thione chromophore (λ=343 nm) by incubation with the reducing agent 
TCEP-HCl (100 mM aqueous) for 2 hours at 65°C. To prevent absorbance interference, the 
nanoparticles were removed from the reaction mixture by magnetic separation. The 
concentration of pyridine-2-thione in nanoparticle-free solutions was determined 
spectrophotometrically (343 nm, Tecan M1000 PRO) using pyridine-2-thione standard solutions 
for calibration. The content of PDP per unit Fe (nmole PDP per mg Fe) was calculated as a ratio 
of the pyridine-2-thione to nanoparticle (IONP-ML-PDP, Fe equivalent) concentrations.  
 
To calculate the content of PDP per single iron oxide sphere, we estimated the Fe 
content of a single iron oxide nanoparticle as previously described3. Assuming that iron oxide 
nanocrystals comprise of magnetite (Fe3O4), iron content of a single nanocrystal can be 
estimated based on the dimensions and the iron content of the magnetite’s crystalline unit cell 
(Table S7) as following: 
(S1)                      𝑁LM,OP = QRS×TUV,WXQWX = YZ[(\RS)Z×TUV,WX(]WX)Z  
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(S2)                      𝑚LM,OP = 𝑁LM,OP × 𝑀𝑊LM/𝑁a 
 
Where Vuc – volume of the unit cell, luc – cubic edge of the unit cell, RIO – radius of the 
nanocrystal,  VIO – volume of the nanocrystal, NFe,UC – number of iron atoms per unit cell, NFe, IO 
– number of iron atoms per iron oxide nanocrystal, mFe,IO – mass of Fe per iron oxide 
nanocrystal, MWFe – molar mass of Fe, NA – Avogadro’s number 
 
The number of DSPE-PEG(2000)-PDP molecules per iron oxide nanoparticle (NPEG per IO) 
and the number of DSPE-PEG(2000)-PDP molecules per unit nanoparticle surface area (NPEG 
per SA) were calculated using equations (S3) and (S4), respectively: 
 
 (S3)                     𝑁bcd	eMf	OP = 𝐶bcd	eMf	LM × 𝑚LM,OP × 𝑁a 
 (S4)     𝑁bcd	eMf	ha = Tijk	lVm	RSn[(\o)p  
 
Where CPEG per Fe is the molar content of PEG (PDP) per unit mass of Fe, and Rc is the 
radius of the “hard sphere” of the coated iron oxide nanoparticles (section S5). 
 
Table S7 summarizes the parameters and the representative estimates of the PEG 
packing density for the 30 nm core IONP-ML-PDP nanoparticles calculated using equations 
(S1)-(S4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) 
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Parameters Symbol Value Units Ref. 
Cubic edge of the magnetite’s unit cell lUC 0.84 nm 4 
Number of iron atoms per unit cell NFe,UC 24  4 
Molar mass of Fe MWFe 55.85 g/mol  
Avogadro’s Number NA 6.022 x 1023 atoms/mole 
 
Radius of the nanocrystal (measured by TEM) RIO 14.5 nm  
Radius of the “hard sphere” Rc 19.5 nm  
Estimated values     
Molar content of PEG per unit Fe CPEG per Fe 405± 20 nmol/mg Fe  
The number of PEG molecules per iron oxide 
nanoparticle 
NPEG per IO 11740 molecules/particle  
The number of PEG molecules per unit surface area 
 (“hard sphere”) 
NPEG per SA 2.5 molecules/nm2  
 
Table S7. Estimation of the PEG packing Density for the 30 nm core IONP-ML-PDP 
nanoparticles. 
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Section 6: Theoretical Estimation of Hydrodynamic Diameter Using a Scaling Model  
 
The hydrodynamic size of the PEGylated core-shell iron oxide nanoparticles in aqueous 
solution can be theoretically predicted using a starlike scaling model5. PEG chains grafted to the 
surface of spherical particles extend out from the particle surface forming a hydrodynamic layer 
of thickness L. The combined size of the particle’s “hard sphere”, a sphere to which the PEG 
chains are attached, and the thickness of the surface PEG layer provide an estimate of the 
particle hydrodynamic size. The scaling model relates the PEG layer thickness, L, to the radius, 
Rc, of the nanoparticle’s ‘hard sphere’, while accounting for polymer characteristics and the 
number of surface-grafted polymer chains as following: 
 
 
(S5)                    𝐿 = q𝑁rs × 𝑙t u⁄ × wx(yz{)/p{|uny/{ + 𝑅t/uu −	𝑅 
 
Where L is the thickness of the PEG layer, NEO is the number of monomeric ethylene 
oxide (EO= OCH2CH2) units per PEG chain, l is the statistical length of the EO monomer, f is the 
number of PEG chains on the nanoparticle surface, v is the Flory exponent, Rc is the radius of 
the “hard sphere”. 
 
To estimate the PEG thickness layer, L, for the IONP-ML nanoparticles we used the 
parameters summarized in Table S8. Similar to previous studies6, we assumed that the radius 
of the “hard sphere”, Rc, includes the contributions from both the iron oxide core (RIO) and the 
lipid bilayer formed by DSPE, oleic acid and lipidoid (Rs). The radii of both the iron oxide core 
and the lipid bilayer for the IONP-ML were measured by TEM. We assumed that the IONP-ML 
shell observed by TEM represents the tightly packed hydrophobic portion of the coating 
(DSPE/oleic acid/lipidoid), and hence can be used to approximate Rs. The number of PEG 
chains per particle, f, was calculated based on the surface area of the “hard sphere” and the 
PEG grafting density (δPEG): 
 
(S6)    𝑓 = 	𝛿bcd × 4𝜋(𝑅OP + 𝑅)- 
 
Using the size estimates for the hard sphere Rc and the PEG thickness layer L, we 
calculated the hydrodynamic diameter (Dh) of IONP-ML as following: 
 
(S7)                       𝐷 = (𝑅OP + 𝑅 + 𝐿) × 2 
193 
 
Parameter Symbol Value Units Ref. 
Number of monomeric units in PEG2000 𝑵𝐄𝐎 45  5, 6 
Length of a PEG monomer (OCH2CH2) 𝒍 0.39 nm 5, 6 
Flory exponent 𝒗 0.583  5, 6 
Radius of the lipid bilayer Rs 5 nm Measured by TEM 
PEG grafting density δPEG 2.5 molecules/nm2 Table S7 
 
Table S8. Parameters used to estimate the hydrodynamic diameter of IONP-ML 
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Section 7: Characterization of IONP-ML-PDP  
 
Functionalized nanoparticles IONP-ML-PDP with 10 nm and 30 nm core size were 
prepared as described in the Methods using lipid composition of C12-98(5):DSPE-
mPEG(2000):DSPE-PEG(2000)-PDP (77:11.5:11.5 mol %). Replacement of 50% DSPE-
mPEG(2000) with the functionalized lipid DSPE-PEG(2000)-PDP had no significant effect on 
either the stabilization efficiency (10 nm: p = 0.99; 30 nm: p = 0.98) or the hydrodynamic 
diameter (10 nm: p = 0.84; 30 nm: p = 0.99) of the resulting nanoparticles (Figure S4, A and B). 
 
 
Figure S15. Effect of nanoparticle functionalization on the aqueous stabilization efficiency and 
hydrodynamic size. (A) Stabilization efficiency for the original IONP-ML and functionalized 
IONP-ML-PDP nanoparticles with 10 nm and 30nm core size; Data represents mean ± S.D. (n = 
3). (B) Hydrodynamic diameter of the original IONP-ML and functionalized IONP-ML-PDP 
nanoparticles with 10 nm and 30 nm core size; Data represents mean ± S.D. (n = 3) 
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Section 8: Estimation of Biomolecule Loading per Particle: Loading Multivalency and 
Density  
 
Molar biomolecule loading (CBM per Fe) per unit nanoparticle mass (Fe equivalent) was 
determined as described in the Methods. To calculate biomolecule loading per single 
nanoparticle, we estimated the mass of Fe per iron oxide nanocrystal (mFe,IO) as described in 
section S4. The unit conversions to calculate the number of biomolecules per single iron oxide 
nanoparticle (NBM per IO, loading multivalency) and the number of biomolecules per unit 
nanoparticle surface area (NBM per SA, loading density) were performed using the equations S8 
and S9, respectively: 
 
 (S8)                     𝑁	eMf	OP = 𝐶	eMf	LM × 𝑚LM,OP × 𝑁a 
 (S9)     𝑁	eMf	ha = T	lVm	RSn[(/-)p 
Where Dh is the hydrodynamic diameter of the IONP-ML nanoparticle 
 
 
IONP-ML 
Core 
Diameter 
(nm) 
Biomolecule 
IONP-ML 
Hydrodynamic 
Diameter (nm) 
Biomolecule 
loading 
(µmol/g Fe) 
Mass of 
Fe per 
single 
core (g) 
Multivalency 
(Biomolecules 
per Sphere) 
Surface 
Area per 
Sphere 
(nm2) 
Biomolecule 
Surface 
Density 
(molecule/nm2) 
10 CpG ~35 87±8 2 x 10-18 104 ~3630 0.03 
10 Peptide ~35 201±30 2 x 10-18 239 ~3630 0.06 
30 CpG ~54 88±8 5 x 10-17 2824 ~9160 0.3 
30 Peptide ~54 170±52 5 x 10-17 5455 ~9160 0.6 
 
Table S9. Biomolecule Loading per Single Nanoparticle: Multivalency and Density 
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Section 9: Retention of Nanoparticle-Conjugated Biomolecules in Serum  
 
To evaluate the stability of the disulfide linkages selected for conjugation of biomolecules 
to the nanoparticle surface, we analyzed retention of the biomolecules on nanoparticles 
following incubation with serum. CpG-functionalized nanoparticles IONP-ML-CpG with 10 nm 
and 30 nm core size were prepared as described in the Methods. The nanoparticles (0.5 
mgFe/mL) were incubated in serum (50% fetal bovine serum (FBS) in PBS) at 37°C for 1 hour 
under gentle agitation. Subsequently, the nanoparticles were recovered by magnetic 
chromatography and analyzed for the contents of iron oxide and CpG as described in the 
Methods. The CpG loading per particle was calculated as described in Section S7 above. 
Comparison of the CpG loading per particle before and after incubation with serum is presented 
in Figure S5. The CpG contents of the nanoparticles before and after incubation with serum did 
not differ significantly (10 nm: before – 120 ± 37 vs after – 115 ± 41, p=0.89; 30 nm: before – 
3180 ± 430 vs after – 3150 ± 450, p=0.96) confirming stability of the disulfide linkages in serum.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S16. Retention of nanoparticle-conjugated biomolecules in serum. (A) CpG content of 
IONP-ML-CpG nanoparticles with 10 nm core size before and after incubation with serum (50% 
FBS in PBS, 37C for 1 hour); Data represents mean ± S.D. (n = 3). (B) CpG content of IONP-
ML-CpG nanoparticles with 30 nm core size before and after incubation with serum (50% FBS 
in PBS, 37C for 1 hour); Data represents mean ± S.D. (n = 3). 
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Appendix C 
 
Supporting Information in Chapter 4 
 
Experimental Section 
Materials. All reagents were used as obtained from commercial sources without further 
purification. Ovalbumin (OVA) was purchased from MP Biomedical. Succinimidyl 3-(2-
pydridylthio) propionate) (SPDP) was obtained from CovaChem. CpG oligonucleotides with a 3’ 
terminal disulfide bridge modification (3’ Thiol Modifier C3 S-S; 1-propanol-disulfide, 1'-succinyl-
lcaa-CPG) were purchased from IDT DNA Technologies (CpG 1826 (5’) 
TCCATGACGTTCCTGACGTT-(CH2)3-S-S-CH3 (3’)). 2-Nitrophenyl β-D-galactopyranoside 
(ONPG), tris(2-carboxyethyl) phosphine hydrochloride (TCEP-HCl), ammonium persulfate and 
N,N,N’,N’-tetramethylethylenediamine (TEMED) were acquired from Sigma-Aldrich. SYBR Gold 
Nucleic Acid Gel Stain (10,000X) and the microBCA protein assay kit were obtained from 
Thermo Fisher. Macrophage Colony Stimulating Factor (M-CSF) and Anti-CD45.2 APC were 
purchased from eBiosciences. B3Z T-cell hybridoma cells were generously donated by Dr. 
Stephen Schoenberger (La Jolla Institute for Allergy and Immunology). 
Synthesis and purification of Ovalbumin-CpG conjugate (OVA-CpG). OVA-CpG covalent 
conjugates were synthesized using a three-step disulfide coupling chemistry. In the first step, 
OVA was reacted with SPDP to produce functionalized OVA-PDP. The reaction was carried out 
as previously described1 with minor modifications. Briefly, OVA (1 mg/mL in 100 mM PBS 
buffer, pH 7.4) was reacted with a molar excess of SPDP (20 mM SPDP, dimethylsulfoxide 
DMSO) for 12 hours at room temperature. The molar ratios of SPDP to OVA were varied to 
produce conjugates with different degrees of functionalization (5-fold to 15-fold molar excess). 
OVA-PDP was purified sequentially by anion exchange chromatography (HiTrap Q FF, 5 mL) 
and ultrafiltration (10,000 MWCO) to remove unreacted species. Purified OVA-PDP was 
analyzed by microBCA and pyridine-2-thione spectrophotometric assays2 to determine the PDP 
content of the functionalized protein. In the second step, CpG oligonucleotides modified with a 
terminal protected disulfide were reacted with a reducing agent (TCEP-HCL, 100 mM, 
199 
 
overnight) to produce oligonucleotides with a free terminal sulfhydryl group (CpG-SH). CpG-SH 
was purified by anion exchange chromatography (HiTrap Q FF, 1 mL), followed by desalting 
with ultrafiltration (1,000 MWCO). The purified oligonucleotides were quantified by 
spectrophotometric analysis (NanoQuant Plate, Tecan M1000 PRO)3. In the third step, OVA-
CpG covalent conjugates were produced by reacting OVA-PDP (1 mg/mL in 100 mM PBS, pH 
7.4) with CpG-SH (at 1:1 molar ratio of PDP:CpG) at room temperature for 48 hours. To isolate 
OVA-CpG conjugates with defined CpG content, the reaction mixture was fractionated using 
anion exchange chromatography with a stair-step sodium chloride (NaCl) elution gradient (0-2 
M, NaCl). Fractions were desalted and purified of unreacted oligonucleotide species using 
centrifugal filtration (30,000 MWCO, 15 mL).  
Characterization of Ova-CpG conjugates. To confirm isolation of major conjugate species 
from heterogeneous product mixtures, purified species were characterized by anion exchange 
chromatography. Anion exchange chromatography was carried out using quaternary ammonium 
solid phase (HiTrap Q FF, 5 mL) with a stair-step sodium chloride (NaCl) elution gradient (0-2 
M, NaCl). Molecular weights were estimated by SDS polyacrylamide gel electrophoresis (SDS-
PAGE, 10% crosslinking, 75V, 2 hours) visualized with silver staining4.  Migration distances on 
SDS-PAGE electrograms were quantified by Image J and used as a relative measure of the 
molecular weight. Calibration was performed using protein standards of known molecular 
weights (Bio-Rad). The calibration curve was linear (R2 = 0.98) in the range of 28-78 kDa. The 
propensity of proteins to aggregation was determined by gel densitometry image analysis5. 
Image analysis was carried out using Matlab R2016b software. For qualitative analysis, pixel 
densities of individual lanes were averaged axially and the means plotted as a function of 
migration distance. For quantitative analysis, lane densities above the defined threshold for 
aggregation intermediates (77 kDa) were integrated and normalized by total lane density. To 
determine the oligonucleotide content per unit protein in conjugate species, conjugates were 
analyzed using SYBR Gold6, 7 and microBCA assays (Thermo Scientific) to quantify single-
stranded DNA and protein, respectively. 
In vitro cross-presentation assay using B3Z CD8 T cell hybridoma. The ability of OVA-CpG 
conjugates to facilitate antigen cross-presentation was evaluated by an in vitro cross-
presentation assay using the CD8+ T-cell hybridoma B3Z cell line and bone marrow derived 
macrophages (BMDMs). The B3Z T-cell hybridoma is a genetically modified T-cell line that can 
be triggered to produce beta-galactosidase via activation by antigen-presenting cells that 
display the OVA epitope SIINFEKL in the context of a murine Kb MHC Class I molecule8. In this 
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way, the B3Z T-cell hybridoma assay provides a measure of the extent of antigen cross-
presentation and T-cell activation9. Prior to beginning experiments, BMDMs10 were cultured in 
12-well plates seeded at 500,000 cells/well (IMDM, 10% FBS, 10 ng/mL M-CSF). B3Z T-cell 
hybridoma cells were cultured in suspension at a concentration of 5 x 106 cells/100mL (RPMI, 
10% FBS, 1% penicillin/streptomycin, 1mM pyruvate, 2 mM glutamine, 50 µM β-
mercaptoethanol). All cells were maintained at 37°C, 5% CO2/95% air atmosphere and 
approximately 85% relative humidity. The cross-presentation assay was conducted essentially 
according to the protocol of Karttunen et al8 with minor modifications. Briefly, BMDMs (5 x105 
cells/well) were co-cultured with B3Z T-cell hybridoma cells (1 x 106 cells/well) in 12-well plates 
in RPMI complete media (10% FBS). To this co-culture, OVA-CpG conjugates and controls 
were added to a final concentration of 9µM (OVA-equivalent) and incubated for 24 hours (37°C, 
5% CO2 incubator) with gentle agitation. Subsequently, the B3Z cells were recovered and 
processed to extract β-Gal as previously described11. The activity of β-Gal in extracted samples 
was quantified by the ONPG spectrophotometric method (at 420 nm)11, using purified β-Gal 
enzyme with known enzymatic activity for calibration.  
Statistical analysis. Data are expressed as mean ± S.D. Means of multiple groups were 
compared with the one-way ANOVA, followed by post hoc Tukey’s pairwise comparisons. All 
probability values are two-sided, and values of p < 0.05 were considered statistically significant. 
Statistical analyses were carried out using the GraphPad Prism 7 software package. 
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Supplementary Figures 
 
Figure S17. Generation of OVA-PDP species with controlled extent of PDP functionalization. 
The content of PDP functional groups per unit OVA was quantified using the BCA and the 
pyridine-2-thione spectrophotometric assays to determine the contents of protein and the PDP 
functional group, respectively. Data represent mean ± S.D., n = 3 
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Figure S18. SDS polyacrylamide gel electrophoresis (SDS-PAGE) of crude OVA-CpG 
conjugates.  Representative image of SDS-PAGE analysis (10%, 75V, 90 minutes) for OVA 
(lane 1), crude OVA-1-CpG (lane 2) and crude OVA-2-CpG (lane 3) conjugates prior to 
purification by anion exchange chromatography.  Molecular weights were analyzed using the 
ladder of protein standards. 
 
 
 
 
 
 
 
 
 
 
 
203 
 
 
Figure S19. Representative anion exchange chromatogram for crude OVA-3-CpG species. 
Anion exchange chromatography was carried out using quaternary ammonium solid phase with 
a stair-step sodium chloride (NaCl) elution gradient (dashed line).  
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